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AA-EQS  Annual Average Environmental Quality Standard 
ADBI   4-Acetyl-6-tert-butyl-1,1-dimethylindane, Celestolide
®
 
AES   Atomic Emission Spectrometry 
AHMI   6-Acetyl-1,1,2,3,3,5-hexamethylindane, Phantolide
®
 
AHTN   6-Acetyl-1,1,2,4,4,7-hexamethyltetralin, Tonalide
®
 
AITI   5-Acetyl-3-isopropyl-1,1,2,6-tetramethylindane, Traseolide
®
 
AOPs   Advanced Oxidation Processes 
BT   Benzotriazole 
CID   Collission Induced Dissociation 
DEET   N,N’-Diethyltoluamide 
EC   European Commission 
EDCs   Endocrine Disrupting Compounds 
EDTA   Ethylenediaminetetraacetic acid 
EEQ   Estrogen Equivalents 
EHDPP   2-Ethylhexyldiphenylphosphate 
ESI   Electrospray Ionisation 
EU   European Union 
GC    Gas Chromatography 
GIS    Geographical Information System  
HDPE   High Density Polyethylene 
HHCB   1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclopenta(g)-2-benzopyran,  
   Galaxolide
®
 
HPLC   High Performance Liquid Chromatography 
HRMS   High Resolution Mass Spectrometry 
ICP   Inductively Coupled Plasma 
IS    Internal Standard 
Lab.   Laboratory 
LAS   Linear Alkylbenzene Sulfonates 
LC    Liquid Chromatography 
LC-MS-MS
 
Liquid Chromatography (tandem) Triple Quadrupole Mass Spectrometry 
LLE    Liquid-Liquid Extraction 
LOD   Limit of Detection 
LOQ   Limit of Quantification 
MAC-EQS  Maximum Allowable Concentration EQS 
MRM   Multiple Reaction Monitoring 
MS    Mass Spectrometry 
NSAID    Non-Steroidal Anti-inflammatory Drug  
OPEs   Organophosphate Esters 
PAC   Powdered Activated Carbon 
PFASs   Perfluoroalkyl substances 
PFBS   Perfluorobutane sulfonate 
PFHxA   Perfluorohexanoic acid 
PFHpA   Perfluoroheptanoic acid 
PFOA   Perfluorooctanoic acid 
PFOS   Perfluorooctansulfonate 
PNEC    Predicted No-Effect Concentration 
POPs   Persistent Organic Pollutants 
PPCPs    Pharmaceuticals and Personal Care Products 
RP   Reversed-phase 
RSD   Relative Standard Deviation 
SDB   Styrol-divinylbenzene 
SIM   Selected Ion Monitoring 
SPE    Solid-Phase Extraction 
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TBP   Tributylphosphate 
TBEP   Tris(2-butoxyethyl)phosphate 
TCEP   Tris(2-chloroethyl)phosphate 
TCP   Tricresylphosphate 
TCPP   Tris(2-chloroisopropyl)phosphate 
TDCP   Tris(1,3-dichloro-2-propyl)phosphate 
TEHP   Tris(2-ethylhexyl)phosphate 
TEQbio   Dioxin-like toxicity (toxic equivalents) 
TIBP   Tri-iso-butylphosphate 
TIC   Total Ion Current (chromatogram) 
TPP   Triphenylphosphate 
TT   Tolyltriazole 
WFD   Water Framework Directive 
WWTP   Waste Water Treatment Plant 
 8 
 
LIST OF PARTICIPANTS 
The following synopsis lists the participants in the exercise, who actively contributed to 
the project. The names of the persons listed may not be complete as many hands 
supported the project behind the scene. This important contribution is however gratefully 
acknowledged, too. 
Austria 
 Christoph Scheffknecht 
Umweltbundesamt GmbH, Bregenz 
Belgium 
 Eric de Wulf 
 Flemish Environment Agency, Laboratory for Environmental Monitoring and 
 Research, Gent 
Cyprus 
 Irene Michael 
 University of Cyprus, Department of Civil and Environmental Engineering, 
 Nicosia 
Czech Republic 
 L. Bláha, B. Jarošová 
 Masaryk University, Faculty of Science, RECETOX, Brno 
 O. Beneš, R. Hušková, M. Koubová, J. Michalová, K. Vondra 
 Veolia Voda 
 M. Kubát, J. Kyzlink 
 Brněnské vodárny a kanalizace 
Finland 
 Kirsti Kalevi 
 Finnish Environment Institute SYKE, Research Programme for Contaminants and 
 Risks, Helsinki 
France 
 Marina Coquery 





 Jörg Oppermann 
 Bundesministerium für Umwelt, Naturschutz und Reaktorsicherheit, Bremen 
 Adolf Pirchner 
 Landeshauptstadt München, Münchener Stadtentwässerung, Eching/Dietersheim 
 Gundula Hübner 
 Bayerisches Landesamt für Umwelt, Huglfing 
Greece 
 Athanasious Soupilas 
 Thessaloniki Water Supply & Sewerage Co, Thessaloniki 
Hungary 
 Teszárné Nagy Mariann; György Istvan Toth 
 Central Directorate for Environment and Water (VKKI), Budapest 
Ireland 
 Colman Concannon 
 Environmental Protection Agency, McCumiskey House, Dublin 
Italy 
 Camilla Braguglia 
 Instituto di Ricerca sulle Acque (IRSA-CNR), Rome 
Lithuania 
 Nijole Remeikaite-Nikiene 
 Environmental Protection Agency, Department of Marine Research, Klaipeda 
Portugal 
 Maria de Fátima Alpendurada 
 IAREN- Instituto da Água da Região Norte, Matosinho 
 António M. A. Lisboa 




 Viktor Grilc 
 National Institute of Chemistry, Laboratory for Environmental Science and 
 Engineering, Ljubljana 
Spain 
 Carles Ibàñez Martí 
 IRTA, Sant Carles de la Ràpita 
Sweden 
 Ulrika Olofsson, Peter Haglund 
 Umeå University; Department of Chemistry, Umeå 
Switzerland 
 Thomas Kupper 
 Berner Fachhochschule, Schweizerische Hochschule für Landwirtschaft, 
 Zollikofe 
The Netherlands 
 Erik van der Klok 











We would like to thank all participants of this exercise around Europe. 
Manfred Clara (UBA, Vienna, Austria) gave important input on the occurrence and 
concentrations of Diclofenac and Acesulfame K in waste and surface waters. 
Robert Kase (Oekotoxzentrum; Swiss Centre for Applied Ecotoxicology; Eawag/EPFL; 





In the year 2010, effluents from 90 European waste water treatment plants (WWTPs) 
were collected and analysed in total for 160 organic chemicals and 20 inorganic trace 
elements. The analyses were complemented by applying also effect-based monitoring 
approaches aiming at estrogenicity and dioxin-like toxicity analysed by in vitro reporter 
gene bioassays, and yeast and diatom culture acute toxicity optical bioassays. The 
analytical work was performed in six European expert laboratories:  
 Institute of Environment and Sustainability of the European Commission’s Joint 
Research Centre (JRC) in Ispra, Italy 
 IWW Water Centre, Mülheim a.d. Ruhr, Germany 
 UMEȦ University, Umeå, Sweden 
 RECETOX, Masaryk University, Brno, Czech Republik 
 VITO, Mol, Belgium 
 Federal Environmental Agency (Umweltbundesamt; UBA), Vienna, Austria 
 Analyses of organic substances were performed by solid-phase extraction (SPE) or 
liquid-liquid extraction (LLE) followed by liquid chromatography tandem mass 
spectrometry (LC-MS-MS) or gas chromatography high-resolution mass spectrometry 
(GC-HRMS). Inorganic compounds were analysed by inductively coupled plasma – mass 
spectrometry (ICP-MS) or ICP atomic emission spectrometry (ICP-AES).  
 This European-wide monitoring study on the occurrence of micropollutants in 
WWTP effluents represents the largest EU wide monitoring survey on WWTP effluents 
ever performed. It produced a comprehensive data set on many so far only locally 
investigated “emerging” compound classes including pharmaceuticals and personal care 
products (PPCPs), veterinary (antibiotic) drugs, perfluoroalkyl substances (PFASs), 
organophosphate ester flame retardants, pesticides (and some metabolites) or industrial 
chemicals such as benzotriazoles (corrosion inhibitors), polycyclic musk fragrances, x-
ray contrast agents, Gadolinium compounds, and siloxanes. The obtained results show the 
presence of 131 target organic compounds in European wastewater effluents, in 
concentrations ranging from low nanograms to milligrams per liter. These results 
obtained from 90 different European WWTPs allow the calculation of a European median 
level for the chemicals investigated.  
 The most relevant compounds identified in the effluent water samples in terms of 
frecquency of detection, maximum, average and median concentration levels were 
Sucralose, Acesulfame K (artificial sweeteners), PFOA, PFHxA, PFHpA, PFOS 
(perfluoroalkyl substances), N,N’-Diethyltoluamide (DEET; insect repellent), 
Benzotriazoles (corrosion inhibitors), the pharmaceuticals Bisoprolol, Carbamazepine, 
Ciprofloxacine, Citaprolam, Clindamycine, Codeine, Diltiazem, Diphenhydramin, 
Eprosartan, Fexofenadine, Flecainide, Gemfibrozil, Fluconazole, Haloperidol, Ibersartan, 
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Ibuprofen, Ketoprofen, Oxazepam, Risperidone, Sulfamethoxazole, Telmisartan, 
Tramadol, Trimethoprim, Venlafaxin, the organophosphate ester flame retardants Tri-iso-
butylphosphate (TIBP), Tributylphosphate (TBP), Tris(2-chloroethyl)phosphate (TCEP), 
Tris(2-chloroisopropyl)phosphate (TCPP), Tris(2-butoxyethyl)phosphate (TDCP), Tris(2-
butoxyethyl)phosphate (TBEP), Triphenylphosphate (TPP), 2-Ethylhexyldiphenyl-
phosphate (EHDPP), the x-ray contrast media Amidotrizoic acid, Iohexol, Iopromid, 
Iomeprol, Iopamidol, the pesticides Terbutylazine, Terbutylazine-desethyl (metabolite), 
MCPA, Mecoprop, Diuron, Triclosan (antibacterial), and Gadolinium (from magnetic 
resonance imaging contrast media used in hospitals).  
 The toxicity tests applied showed some toxicity. From the total number of 75 WWTP 
effluents analyzed for estrogenicity, 27 sample extracts showed estrogenic activity higher 
than the detection limit > 0.5 ng/l estrogen equivalents (EEQ). Twenty five effluent 
sample extracts we screened for dioxin-like activity, and twenty one out of these 25 
tested sample extracts exceeded the detection limit (0.1 ng/l TEQbiotest) but the maximal 
detected dioxin-like activity was only 0.4 ng/l TEQbiotest. Finally, three out of 13 effluent 
samples tested on acute toxicity revealed themselves harmful for the growth of yeast and 
diatom organisms.  
 Finally, the results were compared with other published local, national, or smaller 
international studies on WWTPs. This comparison showed that lower median effluent 
concentrations were found in our large-scale European-wide study (n=90) compared to 
local studies of single WWTPs. It is difficult to compare results of median concentrations 
of one WWTP (or a small number) with the median of this study (n=90) because many 
different domestic and industrial plants around Europe were included. In contrast, 
maximum and average concentrations are in relatively good agreement to other studies.  
 What is clear is that the elimination of most of the anthrophogenic substances in 
conventional WWTPs with secondary biological treatment is incomplete and 
improvements of wastewater treatment and subsequent treatments of the produced sludge 
are required to prevent the introduction of these micropollutants in the environment. It 
must be considered that today’s conventional waste water treatment technology 
(mechanical and biological steps) is from the 1970s; it was designed to remove nitrogen 
and phosphorus, and some non-polar chemicals which are removed with the sewage 
sludge.  
 It is being discussed in Europe to upgrade WWTPs with additional tertiary or 
advanced treatment steps such as ozonation and/or powdered activated carbon adsorption 
to remove micropollutants from WWTP effluents. In the Swiss “Micropoll Strategy” 
project complementary treatment steps have been evaluated and it has been shown that 
water quality can be significantly improved using processes such as powdered activated 
carbon adsorption or ozonation. Also a further treatment by micro- or nanofiltration or 
reverse osmosis is possible for water reuse strategies.  
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 Under the view of escalating population growth, and increased water stress in many 
regions of the world, reuse of treated water and waste water recycling are becoming more 
important options for water supply. The increasing worldwide contamination of 
freshwater systems with thousands of industrial and natural chemical compounds is one 
of the key environmental problems facing humanity. Although most of these compounds 
are present at low concentrations, many of them raise considerable toxicological 
concerns, particularly when present as components of complex mixtures (Schwarzenbach 




Commission Directive 91/271/EEC (EC, 1991) concerns the collection, treatment and 
discharge of urban wastewater and the treatment and discharge of wastewater from 
certain industrial sectors. Its aim is to protect the environment from any adverse effects 
caused by the discharge of such waters. The increasing extent and level of municipal 
wastewater treatment in Europe in the past decades has significantly improved the quality 
of surface waters, even though obligations set for the European Union are not equally 
fulfilled by all its members (EC, 2004; Reemtsma et al., 2006). However, priority 
substances or other organic compounds are not regulated in waste water treatment plant 
(WWTP) effluents (EC, 1991), but in surface waters under the Water Framework 
Directive (EC, 2000).  
 Whilst household and industrial wastewater treatment has been implemented 
progressively across Europe, and existing treatment technologies produce water that 
meets current legislation on water-quality standards, it has been demonstrated that the 
removal of many emerging contaminants, including pharmaceuticals and personal-care 
products (PPCPs), hormones, and other industrial chemicals is incomplete, with many 
emerging contaminants being detected in treated effluents that are subsequently 
discharged to surface waters. Various studies over recent years have shown that treated 
municipal wastewater contributes significantly to water pollution from micropollutants 
(e.g.: Ashton et al., 2004; Castiglioni et al., 2006; Clara et al., 2005; De la Cruz et al., 
2012; Gabet-Giraud et al., 2010; Gracia-Lor et al., 2010, 2012; Gros et al., 2010; 
Hollender et al., 2009; Jelic et al., 2012; Joss et al., 2005, 2006; Köck-Schulmeyer et al., 
2011; Lindqvist et al., 2005; Martínez Bueno et al., 2012; Micropoll, 2011; 2012; Miège 
et al., 2009; Nakada et al., 2006; Paxéus, 2004; Radjenović et al., 2007a,b; Reemtsma et 
al., 2006; Ternes, 1998; Vieno et al., 2007; Zhang et al., 2008a).  
 Conventional WWTPs are designed to reduce loads of carbon, nitrogen, and 
phosphorus. In addition, non-polar chemical compounds are well removed by sorption. 
The most important removal pathways of organic compounds during wastewater 
treatment are biotransformation / biodegradation, abiotic removal by adsorption onto the 
sludge and stripping by aeration (volatilization) (Radjenović et al., 2007a). Several polar 
compounds, especially those which are poorly degradable, may however be discharged 
with WWTP effluents into receiving waters and then occur in surface waters (Reemtsma 
et al., 2006). Some polar chemical compounds such as Nonylphenol (Yu et al., 2009a; 
Zhang et al., 2008b) or Perfluoroalkyl Substances (PFASs) like Perfluorooctansulfonic 
acid (PFOS) and Perfluorooctanoic acid (PFOA) (Becker et al., 2008) are even formed in 
WWTPs from precursor compounds.  
 It is well established that insufficiently treated WWTP effluents are the main sources 
of PPCPs and other micropollutant residues in the aquatic environment, because many 
micropollutants are not considerably degraded in conventional WWTPs. Treated 
wastewater effluents are the main contributors to PPCPs and industrial chemicals loads in 
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rivers, as WWTP effluents are often major contributors to rivers’ flows (Hollender et al., 
2009; Kasprzyk-Hordern, et al., 2009).  
 Such discharges are near-continuous and hence these substances do not need to be 
persistent in nature to give rise to chronic effects due to long-term exposure (such as 
endocrine disruption) in aquatic ecosystems (EEA, 2011). However, veterinary 
pharmaceuticals residues are discharged also directly into the ecosystem via agricultural 
field run-off. In general, there are several different input pathways of micropollutants into 
surface waters: (1) Input with treated wastewater through WWTPs; (2) input with 
untreated wastewater through sewer overflows if the capacity of the sewer system or the 
wastewater treatment plant is exceeded; (3) input through leaks in the sewer network or 
wrongly connected sewers; (4) input of polluted rainwater from roofs and sealed areas 
through rainwater channels (Micropoll, 2011); and (5) other diffuse sources such as field 
run-off.   
 Moreover, there might be the possibility of contamination of water resources (surface 
and groundwaters) by the application of contaminated sewage sludge (solid waste of the 
wastewater treatment process) to soils or agricultural fields. 
 Mass balance calculations to estimate the fate of contaminants during waste water 
treatment, including sorption to sludge showed that usually less than 2% of the total mass 
load of pharmaceuticals is removed by sorption. For most pharmaceuticals (including 
Carbamazepine, Sulfamethoxazole, and Trimethoprim) adsorption to sludge is negligible. 
Some micropollutants, however, such as selected antibiotics (Ciprofloxacin, Nor-




), Nonylphenol, PFOS, Triclosan, or 
some steroid estrogens partition by a considerable amount onto sludge (Heidler and 
Halden, 2008; Jelic et al., 2012).  
 Water bodies that receive a large amount of WWTP effluents are significantly 
influenced by the influx of micropollutants that pass through WWTPs. Therefore, the 
adverse effect of WWTP effluents on the quality of river water is significant and cannot 
be underestimated. The presence of small concentrations of PPCPs or other 
micropollutants has been associated to chronic toxicity (Carlsson et al., 2009; Gilbert, 
2011; Sanchez et al., 2011; Santos et al., 2010), endocrine disruption (feminization, 
intersex, and lower sperm counts in wild fish populations) (Baynes et al., 2012 and 
references therein; Kidd et al., 2007), and the development of antibiotic pathogen 
resistance (Lubick, 2011). They might also affect water bodies that have an important 
function as drinking water resources, as well as infiltrate into groundwater (Loos et al., 
2010; Stuart et al., 2012), with possible effects on human health.   
 In 2006, Reemtsma and co-workers (2006) published the first EU-wide study on the 
occurrence of polar organic pollutants in WWTP effluents and the receiving surface 
waters. In this study, the effluents of eight municipal WWTPs in Western Europe were 
analyzed by liquid chromatography - mass spectrometry (LC-MS) for the occurrence of 
36 polar pollutants, comprising PPCPs and other household and industrial chemicals. 
 16 
 
Moreover, in a long-term study of the effluents of three WWTPs over 10 months 
Benzotriazoles, Benzothiazole-2-sulfonate, Diclofenac, and Carbamazepine showed 
mean concentrations of 1-10 micrograms per liter (µg/l), followed by some flame 
retardants, Naphthalene disulfonates, and PPCPs in the range of 0.1-1 µg/l. Half of the 
determined compounds were not significantly removed in tertiary wastewater treatment 
with enhanced nutrient removal (Reemtsma et al., 2006).  
 In the last years, several fate studies on the occurrence and behavior of PPCPs, 
endocrine disruptors, illicit drugs, and other industrial chemicals have been performed. 
The efficiency of the removal of PPCPs (and other compounds) was found to be strongly 
dependent on the technology implemented in the WWTP (Hollender et al., 2009; 
Kasprzyk-Hordern, et al., 2009; Vieno et al., 2007). 
 In Switzerland, in 2006 the interdisciplinary research project “Micropoll Strategy” 
was started to develop a strategy for micropollutants removal in municipal wastewater. 
The aim of the project was to upgrade municipal WWTPs with additional treatment steps 
to remove micropollutants for the protection of ecosystems and drinking water resources. 
Complementary treatment steps have been evaluated and it has been shown that water 
quality can be significantly improved using processes such as powdered activated carbon 
(PAC) adsorption or ozonation (Micropoll, 2011; 2012). 
 Currently, tertiary or advanced treatment technologies (e.g. ozonation, chlorine 
dioxide treatment, UV-Fenton, membrane technologies, Ferrate (VI), sand filters, 
activated carbon) of secondary effluents are widely discussed as one of the most 
promising options for the mitigation of micropollutants entering the aqueous environment 
via discharges from municipal WWTPs (Baynes et al., 2012; Gabet-Giraud et al., 2010; 
Göbel et al., 2007; Hollender et al., 2009; Joss et al., 2008; Klamerth et al., 2010; 
Klavarioti et al., 2009; Lee et al., 2008, 2009; Nakada et al., 2007; Nowotny et al., 2007; 
Oller et al., 2011; Radjenović et al., 2007a,b; Stalter et al., 2011). It has already been 
shown that additional treatment of wastewater reduces endocrine disruption in wild fish 
(Baynes et al., 2012; Filby et al., 2010; Lee et al., 2008).  
 The main objective of this research project (“Fate Sees”) was to verify on a 
European-wide scale the occurrence of as many as possible organic and inorganic 
chemical contaminants in WWTP effluents, in order to get a European overview.  
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2. Biological based assays 
The chemical-based monitoring of freshwater sources according to the WFD is faced 
with limitations in the detection of some emerging pollutants as well as in the assessment 
of the potential effects caused by mixtures of pollutants. Complex mixtures are the rule, 
not the exception in environmental samples and they can include additive, antagonistic or 
synergistic interactions of the diverse compounds in a mixture (Kortenkamp et al., 2009). 
Biological-based analysis has been drawing increasing attention by allowing the 
evaluation of the effective toxicity of complex environmental samples, often without pre-
treatment of the sample or chemical extraction.  
 Biological-based assays can analyse mixture effects providing data from molecular 
up to organism level. Special interest is focused on the possibility for fast-screening 
bioassays using model organisms to provide toxicity and endocrine-disrupting potential 
of water samples. 
 The diatom Thalassiosira pseudonana and the yeast Saccharomyces cerevisiae are 
both fully sequenced eukaryotic organisms, with recognized applications in 
ecotoxicology studies. The full genome sequence of the budding yeast Saccharomyces 
cerevisiae has been known since 1996 (Goffeau et al., 1996). Although initially 
established as a model organism for medical studies, yeast has recently become of high 
interest also in the ecotoxicology field. An accepted yeast-based bioassay for endocrine 
disruptors detection has been developed in 1996 (Arnold et al., 1996) and since then, 
several new bioassays for the detection of hormonal activities have been described 
(Balsiger et al., 2010; Nguyen et al., 2011). The development of genomics tools in yeast, 
including yeast disruption and deletion mutants for drug-sensitivity/resistance screening 
have applications in the identification of targeted genes and pathways for small molecules 
or therapeutic drugs (Bharucha and Kumar, 2007). Yeast has also been applied to the 
detection of environmental pollutants-associated molecular pathways, e.g. for cadmium 
(Serero et al., 2008). 
 Diatoms are eukaryotic photosynthetic organisms with a worldwide distribution in 
freshwater and marine environments and they play a dominant role in the global carbon 
cycle (Smetacek, 1999). Although diatoms have been exploited for decades in 
environmental monitoring through the use of diatomic indices, the recent full genome 
sequence of two marine diatoms, the centric Thalassiosira pseudonana (Armbrust et al., 
2004) and the pennate Phaeodactylum tricornutum (Bowler et al., 2008), stirred their 
potential as model organisms in ecotoxicology. Since then, there has been a steadily 
increase in research on diatoms, and the diatom T. pseudonana has already been the 
target of various studies based on “omics” approaches to identify cellular changes at the 
molecular level upon conditions of stress. Thus, changes at the molecular level 
(transcriptome and/or proteome) have been identified linked with nutrient limitation, 
temperature and pH (Mock et al., 2008), exposures to copper and hydrogen peroxide 
(Davis et al., 2006), and to the polycyclic aromatic hydrocarbon benzo(a)pyrene 
(Carvalho et al., 2011a; Carvalho et al., 2011b; Carvalho and Lettieri, 2011).  
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 The full genome of a freshwater diatom species is yet to be completed, which so far 
has hindered the application of diatom-based molecular bioassays for monitoring of 
freshwaters. Despite the fact that T. pseudonana has been initially isolated from a coastal 
zone, T. pseudonana cultures have been progressively adapted in the laboratory to lower 
salinities in order to facilitate toxicity testing of transition and freshwater samples using 
this marine diatom. 
 In these studies, 13 effluent water samples were used to set up the screening bioassay 
based on diatom and yeast growth effects. 
 In vitro bioassays enable estimation of total biological activity of all compounds that 
act through the same mode of action present in extracts of any environmental media 
including waste water. In these studies, presence of toxicants with two important modes 
of action, i.e. activation of aryl hydrocarbon (AhR) and estrogenic receptor (ER), were 
investigated in 25 (AhR) and 75 (ER) waste water extracts.  
 Chemicals that activate aryl hydrocarbon receptor AhR can elicit toxic effects similar 
to that of 2,3,7,8-Tetrachlorodibenzo-p-dioxin and they are known as dioxin-like 
chemicals. Related effects include hepatotoxicity, immunotoxicity, dermal toxicity, 
lethality as well as embryotoxicity, teratogenicity, carcinogenesis or tumor promotion, 
wasting syndrome and others. Compounds with ability to activate estrogenic receptor ER 
have the potential to disrupt normal reproduction or developmental processes which are 
known to lead to adverse health effects such as compromised reproductive capacity, 
breast and testicular cancer, reproductive dysfunction such as feminization or 
demasculanization of males and other adverse effects (Hilscherova at al., 2000). These 
chemicals cause adverse effects at extremely low concentrations (ng/l) and therefore it is 
usually difficult and also expensive to detect them by commonly employed instrumental 
analyses. Reporter gene bioassays utilizing mammalian cells, as used in the present 
studies, are considered one of the most sensitive tools with respect to detection of 
estrogens. Evaluation of these toxic potentials also requires high level of expertise 




3. Description of the campaign and selection of WWTP sampling 
sites 
Annex 1 gives a list of the 91 WWTPs investigated in this study. It contains information 
on the type of discharges treated in the plant (domestic or industrial), the plant capacity 
(m
3
/day), the capacity in population equivalents, and, if applicable, the type of tertiary 
treatment applied.  
 The selection of the WWTPs was done by the participating EU Member States. No 
selection criteria were given by the JRC. Mainly municipal WWTPs were investigated, 
but some plants were dominated by industrial waste waters. Unfortunately, not all 
participants of the campaign (owners of the WWTPs) provided all information requested. 
Sampling was performed by grab sampling or in many cases also with automated systems 
as 24h composite samples. One liter water samples, stored in HDPE plastic bottles, were 
shipped to the JRC by fast courier in thermostated boxes with cooling elements; the 
samples were stored in a fridge at ~4˚C, and further distributed as fast as possible to the 
other expert laboratories. Annex 1 also shows for some samples the storage time (in the 
fridge), which was in most cases between one and two months.  
 Wastewater treatment generally comprises a primary, secondary and sometimes an 
advanced tertiary treatment, employing different physico-chemical and biological 
techniques. During the primary treatment, solids are removed from wastewater entering 
for further processing, typically in a biological secondary activated sludge treatment, 
including nitrification and denitrification, and phosphorus removal.   
 In some WWTPs, effluent is also disinfected before it is released into the 
environment (e.g., chlorination, or ultraviolet radiation). In addition, advanced 
wastewater treatments can be applied to enhance the removal of nitrogen, phosphorus and 
other pollutants. Tertiary treatment comprises processes such as sand filtration, 
chlorination, ozonation, or advanced oxidation processes (AOPs) (Radjenović et al., 
2007a).  
 In general, today most WWTPs use activated sludge processes wherein 
microorganisms are applied to mineralize the pollutants to water and carbon dioxide, or 
degrade them to acceptable forms. Pollutants can also be removed from water by 
stripping into air or by sorption onto sludge that is regularly discharged. Some substances 
may be subject to phototransformation. Therefore, the removal of pharmaceutical 
residues in activated sludge processes includes four mechanisms: biotransformation, air 






4. Selection of the target compounds 
The target compounds analysed in the different laboratories are shown in the following 
tables. For more information, see also the results and discussions part.  
 The annual average Environmental Quality Standards (AA-EQS) for inland waters 
are given for the priority substances (PS) and the newly proposed PS of the WFD.  
Table 1: Polar organic chemicals analysed by LC-MS-MS; Lab: JRC-IES, Ispra, Italy. 90 samples 
analysed; Priority Substances of the WFD in blue. 
Pharmaceuticals Use Perfluoroalkyl Substances 
Diclofenac (EQS: 0.10 g/l) Non-steroidal anti-inflammatory drug PFHxA; perfluorohexanoate 
Ketoprofen Non-steroidal anti-inflammatory drug PFHpA; perfluoroheptanoate 
Naproxen Non-steroidal anti-inflammatory drug PFOA; perfluorooctanoate 
Ibuprofen Non-steroidal anti-inflammatory drug PFNA; perfluorononanoate 
Bezafibrate Drug to lower cholesterol levels PFDA; perfluorodecanoate 
Gemfibrozil Drug to lower lipid levels PFBS; perfluorobutansulfonate 




Sulfamethoxazole Antibiotic PFOS; perfluorooctane 
sulfonate (EQS: 0.65 ng/l) 
Carbamazepine Anti-convulsion drug to treat epilepsy  
  Pesticides 
Personal Care Products  MCPA 
N,N’-Diethyltoluamide (DEET) Insecticide Mecoprop 
Caffeine Stimulant 2,4-D 
Triclosan Antibacterial substance Bentazone 
  Dichlorprop 
Benzotriazoles  2,4,5-T 
1H-Benzotriazole Corrosion inhibitor Diuron (EQS: 0.2 g/l) 
5-Methyl-1H-benzotriazole Corrosion inhibitor Isoproturon (EQS: 0.3 g/l) 
  Atrazine (EQS: 0.6 g/l) 
Sweeteners  Atrazine-desethyl 
Sucralose  Simazine (EQS: 1 g/l) 
Acesulfame K  Terbutylazine 
  Terbutylazine-desethyl 
Nitrophenols  Propazine 
1-Nitrophenol  Carbaryl 
2,4-Dinitrophenol  Diazinon 
  Methabenzthiazuron 
Steroid estrogens  Chlortoluron 
17-Estradiol (EQS: 0.4 ng/l) Natural human estrogen Hexazinone 
Estrone Metabolite Linuron 
17-Ethinylestradiol Synthetic estrogen (contraceptive) Metolachlor 
(EQS: 35 pg/l)  Metoxuron 
  Alachlor (EQS: 0.3 g/l) 
  Molinate 
  Propanil 
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Table 2: Pharmaceuticals analysed by LC-MS-MS; Lab: UMEȦ University, Jerker Fick, Sweden; 
89 samples analysed; for some selected substances the use is given.  
Pharmaceuticals Use Pharmaceuticals Use 
Alfuzosin α1-Receptor antagonist to treat 
benign prostatic hyperplasia 
Fluphenazine  
Alprazolam  Flutamid  
Amitryptiline  Glibenclamide  
Atorvastatin  Glimepiride  
Azelastine  Haloperidol Antipsychotic drug for the 
treatment of schizophrenia 
Biperiden  Hydroxyzine  
Bisoprolol Beta blocker to treat 
cardiovascular diseases 
Ibersartan Angiotensin II receptor antagonist 
for the treatment of hypertension 
Bromocriptin  Loperamide  
Buprenorphin  Maprotilin  
Bupropion Antidepressant and smoking 
cessation aid 
Meclozine  
Chloprothixen  Memantin  
Chlorpromazine  Mianserin  
Cilazapril  Miconazole  
Citaprolam Antidepressant drug Nefazodon  
Clemastine  Orphenadrin Parkinson's Disease drug 
Clomipramine  Oxazepam Treatment of anxiety and insomnia 
Clonazepam  Paroxetin  
Clotrimazol  Perphenazine  
Codeine Analgesic opium alkaloid Pizotifen  
Cyproheptadine  Promethazin  
Dicycloverin  Ranitidine  
Diltiazem Calcium channel blocker to treat 
hypertension, and angina pectoris 
Repaglinide Blood glucose-lowering drugs to 
treat type II diabetes 
Diphenhydramin Sedative to treat allergies and 
insomnia 
Risperidone Antipsychotic drug for the 
treatment of schizophrenia 
Duloxetin  Rosuvastatin  
Eprosartan Angiotensin II receptor antagonist 
to treat high blood pressure 
Sertraline  
Etonogestrel Progestin used in hormonal 
contraceptives 
Tamoxifen  
Fenofibrate  Telmisartan Angiotensin II receptor antagonist 
to treat hypertension 
Fentanyl  Terbutalin  
Fexofenadine Antihistamine drug to treat 
hayfever, allergy symptoms, and 
urticaria 
Tramadol Opioid analgesic used in treating 
severe pain 
Flecainide Antiarrhythmic agent to treat 
tachyarrhythmias (abnormal fast 
rhythms of the heart) 
Trihexyphenidyl Antiparkinsonian agent 
Fluconazole Triazine antifungal drug Venlafaxin Antidepressant drug 
Fluoxetin  Verapamil  
Flupetixol  Zolpidem  
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Table 3: Organophosphate ester flame retardants; Lab: UMEȦ University, Peter Haglund, 
Sweden; 89 samples analysed. 
















Gadolinium from magnetic resonance 
imaging contrast media used in hospitals 
Amidotrizoic acid Gadolinium (Gd) 




Iothalamic acid  
 
Table 5: Veterinary drugs / antibiotics analysed by LC-MS-MS; Lab: VITO, Belgium; 30 samples 
analysed. 
 Pharmaceutical class Active substance 
ANTIBIOTICS Tetracyclines Oxytetracycline 
  Doxycycline 
 Macrolides Tylosin 
  Tilmicosin 
 -lactam antibiotics - Penicillins Penicillin V 
  Penicillin G (benzylpenicillin) 
  Ampicillin 
  Amoxicillin 
 Sulfonamides Sulfamethoxazol 
  Sulfadoxin 
  Sulfadiazin 
 Quinolones Flumequine 
  Enrofloxacine 
  Ciprofloxacine 
 Lincosamides Clindamycine  
  Lincomycine 
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 Other Trimethoprim  
  Florfenicol 
  Tiamulin  
ANTI-PARASITIC Imidazothiazoles Levamisole 
 
Table 6: Siloxanes and musk fragrances; Lab: UBA, Vienna, Austria; 77 samples analysed. 
Siloxanes Musk fragrances 
Decamethylcyclopentasiloxan (D5) Cashmeran 
Decamethyltetrasiloxan (MD2M) Celestolid® (ADBI) 
Dodecamethylcyclohexasiloxan (D6) Galaxolid® (HHCB) 
Dodecamethylpentasiloxan (MD3M) Phantolid® (AHMI) 
Octamethylcyclotetrasiloxan (D4) Tonalid® (AHTN) 
Octamethyltrisiloxan (MDM) Traesolid® (AITI) 
 
Table 7: Trace elements analysed by ICP-AES; Lab: JRC-IES, Ispra, Italy; 90 samples analysed; 
MAC-EQS for mercury.  
Trace elements using ICP-AES 
Hg (EQS: 0.07 g/l) , Ag, Al, As, Ba, Be, Cd (EQS: 0.08-0.25 g/l), Co, Cr, Cu 
Mg, Mn, Mo, Ni (EQS: 4 g/l), Pb (EQS: 1.2 g/l), Sb, Se, Ti, Zn 
 
Table 8: Toxicity analysis by in vitro reporter gene bioassays; Estrogenicity equivalents (EEQ) 
and Dioxin-like toxicity (TEQbio); Lab: RECETOX, Masaryk University, Brno, Czech Republic; 75 
samples (EEQ) and 25 samples (TEQbio) analysed.  
Estrogenicity equivalents (EEQ) Dioxin-like toxicity (TEQbio) 
 
Table 9: Acute toxicity to yeast and diatom cultures measured by optical bioassays; Lab: JRC-
IES, Ispra, Italy; 13 samples analysed. 
Yeast culture bioassay (strain W303.1a) Thalassiosira pseudonana culture bioassay 
(strain CCMP 1335) 
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5. Analytical methods 
5.1. Multi-compound SPE-LC-MS-MS method (JRC-IES) 
5.1.1. Sample preparation / Solid-phase extraction (SPE) 
The water samples were extracted at the JRC by solid-phase extraction (SPE) with Oasis
®
 
HLB (200 mg) cartridges. Most water samples contained particles (suspended particle 
material; SPM) which settled to the bottom of the plastic bottles. The water was not 
filtered, but decanted into a 500 ml glass bottle (Schott-Duran). Thus, only the dissolved 
(liquid) water phase was investigated. Before extraction, the samples (500 ml) were 
spiked with the internal standard (50 l), which contained the labeled substances 2,4-D 








C3, Triclosan d10, 




C3. The spiking 




C5, and PFOS 
13
C4, one 
microgram per liter for Sucralose d6, and 100 ng/l for the other labeled compounds. The 
glass bottles were closed, and then the samples were mixed by shaking for some seconds.   
 The SPE procedure for the clean-up and concentration of water samples was 
performed automatically using an AutoTrace

 SPE workstation (Thermo Scientific). 200 
mg (6 ml) Oasis
®
 HLB columns (Waters, Milford, MA, USA) were used. The cartridges 
were activated and conditioned with 5 ml methanol and 5 ml water at a flow-rate of 5 
ml/min. The water samples (400 ml) were passed through the wet cartridges at a flow-
rate of 5 ml/min, the columns rinsed with 2 ml water (flow 3 ml/min), and the cartridges 
dried for 30 min using nitrogen at 0.6 bars. Elution was performed with 6 ml methanol. 
Evaporation of the extracts with nitrogen to 500 l was performed at a temperature of 
35°C in a water bath using a TurboVap

 II Concentration Workstation (Caliper Life 
Sciences).  













Figure 1: Sampling bottles, water extracts, and SPE cartridges. 
 27 
 
5.1.2. Liquid chromatography tandem mass spectrometry (LC-MS2) 
Analyses were performed by reversed-phase liquid chromatography (RP-LC) followed by 
electrospray ionization (ESI) mass spectrometry (MS) detection using atmospheric-
pressure ionization with a triple-quadrupole MS-MS system. Quantitative LC-MS
2
 
analysis was performed in two separate LC-MS
2
 runs in the multiple reaction monitoring 
(MRM) mode in negative and positive ionization.  
 LC was performed with an Agilent 1100 Series LC systems consisting of a binary 
pump, vacuum degasser, autosampler and a thermostated column compartment. LC 
separations were performed with a Hypersil Gold column (Thermo Electron Corp., 
100 × 2.1 mm, 3m particles). Tandem mass spectrometry was performed on a bench-top 
triple-quadrupole quattro micro MS from Waters-Micromass (Manchester, UK) equipped 
with an electrospray probe and a Z-spray interface.  
 The eluants used for the separations of the target analytes were water and 
acetonitrile. The water phase used was acidified with 0.1% acetic acid (pH 3.5) in the 
negative and positive ionization modes. The flow-rate was 0.25 ml/min. The gradient 
started with 90% water and proceeded to 90% acetonitrile over 25 min, conditions hold 
for 5 min, returned back to the starting conditions over 5 min, and followed by 5 min 
equilibration. The injection volume was 5 µl; injection was performed by the 
autosampler.  
 Instrument control, data acquisition and evaluation (integration and quantification) 
were done with MassLynx software. Nitrogen is used as the nebulizer gas and argon as 
the collision gas. Capillary voltage was operated at 3.2 kV, extractor lens at 1.0 V, and 
RF lens at 0.0 V. The source and desolvation temperatures were set to 120 and 350C 
under chromatographic HPLC conditions. Cone and desolvation gas flows were 50 and 
600 l/h, respectively. The applied analyser parameters for MRM analysis were: LM 1 and 
HM 1 resolution 11.0, ion energy 1 1.0, entrance –1 (negative mode), 2 (positive mode), 
exit 1, LM 2 and HM 2 resolution 11.0, ion energy 2 2.0, multiplier 600 V. The MRM 
inter-channel delay was 0.05 and the inter-scan delay 0.15. 
 Collision-induced dissociation (CID) was carried out using argon at approx. 3.5×10
-3
 
mbar as collision gas at collision energies of 7 - 40 eV. The optimized characteristic 
MRM precursor  product ion pairs monitored for the quantification of the compounds 
are given in Table 10.  
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Table 10: LC-MS2 parameters, retention times, recoveries, LOQs (JRC). MRM = multiple reaction 
monitoring; SPE recovery rates from 400 ml Milli water spiked at 100 ng/l using 200 mg Oasis HLB 
cartridges; LOQ = method detection limits; internal standards are grey-shaded; priority substances of the 
WFD in blue; Carb. = Carbamazepine; second transition in brackets. 








Negative mode       
Acesulfame K 55589-62-3 162 > 82 2.4 10 ± 9 10 Sucralose d6 
Sucralose 56038-13-2 395 > 359 5.5 62 ± 9 100 Sucralose d6 
Sucralose d6  401 > 365 5.5 64 ± 7  Sucralose d6 
Nitrophenol 100-02-7 138 > 108 10.4 58 ± 7 5 2,4-D d3 
2,4-Dinitrophenol 51-28-5 183 > 109 11.8 63 ± 6 5 2,4-D d3 
Bentazone 25057-89-0 239 > 132 13.1 62 ± 8 1 2,4-D d3 
2,4-D 94-75-7 219 > 161 14.9 56 ± 8 1 2,4-D d3 
2,4-D d3  222 > 164  58 ± 7   
MCPA 94-74-6 199 > 141 15.1 63 ± 8 0.5 MCPA d3 
MCPA d3  202 > 144 15.1 63 ± 7   
Ketoprofen 22071-15-4 253 > 209 15.8 71 ± 8 10 MCPA d3 
Naproxen 22204-53-1 229 > 169 16.1 65 ± 8 5 2,4-D d3 
Bezafibrate 41859-67-0 360 > 274 16.4 66 ± 12 1 MCPA d3 
Mecoprop 7085-19-0 213 > 141 16.4 62 ± 8 1 MCPA d3 
Dichlorprop 120-36-5 233 > 161 16.4 64 ± 8 3 MCPA d3 
Clofibric acid 882-09-7 213 > 127 15.5 65 ± 6 2 MCPA d3 
2,4,5-T (Trichlorophenoxyacetic a.) 93-76-5 255 > 197 16.7 71 ± 8 2 MCPA d3 




C3  208 > 163.4 19.1 65 ± 9   
Diclofenac 15307-86-5 294 > 250 18.8 65 ± 6 1 Ibuprofen 
13C3 
Gemfibrozil 25812-30-0 249 > 121 20.7 62 ± 9 1 Ibuprofen 
13C3 




C12  299 > 35 21.6    
Perfluoroalkyl Substances       
PFHxA; perfluorohexanoate 68259-11-0 313 > 269 17.2 61 ± 12 1 PFOA 
13
C4 
PFHpA; perfluoroheptanoate 375-85-9 363 > 319 19.4 81 ± 14 1 PFOA 
13
C4 





C4  417 > 372 22.2 82 ± 9   





C5  467.5 > 422.7 25.0 85 ± 9   
PFBS; perfluorobutansulfonate  298.8 > 79.7 17.7 59 ± 9 1 PFOS 
13
C4 
PFHxS; perfluorohexansulfonate  398.8 > 79.7 24.2 63 ± 8 1 PFOS 
13
C4 





C4  503 > 80 (99) 28.3 66 ± 12   
PFDA; perfluorodecanoate 335-76-2 513 > 469 27.7 76 ± 8 1 PFNA 
13
C5 
Positive mode       
Caffeine 58-08-2 195 > 138 3.2 75 ± 8 5 Carb. d10 
1H-Benzotriazole 95-14-7 120.1 > 64.6 (92) 5.0 56 ± 9 40 Carb. d10 
5-Methyl-1H-benzotriazole 13351-73-0 134.1 > 78.6 (77) 8.8 47 ± 8 40 Carb. d10 
Atrazine-desethyl 6190-65-4 188 > 146 8.2 71 ± 10 1 Simazine 
13C3 
Sulfamethoxazole 723-46-6 254 > 156 9.4 64 ± 9 1 Carb. d10 




Hexazinon 51235-04-2 253 > 171 11.4 70 ± 7 2 Simazine 
13C3 
Terbutylazine-desethyl 30125-63-4 202 > 146 12.5 70 ± 8 1 Simazine 
13C3 




C3  205 > 134 11.4 72 ± 9   
Carbamazepine 298-46-4 237 > 194 13.1 68 ± 11 1 Carb. d10 
Carbamazepine d10  247 > 204 13.1 69 ± 8   
Methabenzthiazuron 18691-97-9 222 > 165 13.5 64 ± 9 3 Simazine 
13C3 
Chlortoluron 15545-48-9 213 > 71.6 13.9 62 ± 8 3 Atrazine 
13
C3 





C3  219 > 177 13.9 73 ± 8   
Carbaryl 63-25-2 202 > 145 14.1 55 ± 7 3 Atrazine 
13
C3 
N,N’-Diethyltoluamide (DEET) 134-62-3 192 > 119 14.4 75 ± 6 1 Atrazine 
13
C3 
Isoproturon 34123-59-6 207 > 72 14.6 72 ± 13 1 Atrazine 
13
C3 
Diuron 330-54-1 233 > 72 14.8 72 ± 12 1 Atrazine 
13
C3 
Terbutylazine 5915-41-3 230 > 174 (132) 16.6 69 ± 8 1 Atrazine 
13
C3 
Linuron 330-55-2 249 > 160 17.1 57 ± 7 5 Atrazine 
13
C3 
Metolachlor 51218-45-2  284 > 252 18.8 64 ± 11 3 Atrazine 
13
C3 
Alachlor 15972-60-8 270 > 238 19.0 58 ± 8 3 Atrazine 
13
C3 
Diazinon 333-41-5 305 > 169 20.7 56 ± 9 1 Atrazine 
13
C3 
5.1.3. Identification, quantification, QA/QC and LOQs 
The first mass transition in Table 10 was used for quantification, and the second (between 
brackets) only for confirmation purposes. For most compounds the second transition was 





C3 and Simazine 
13
C3 were purchased from Cambridge Isotope Laboratories 
(Andover, MA, USA), Carbamazepine d10 from CDN ISOTOPES (Quebec, Canada), 
PFOS, PFOA, and PFNA 
13
C standards from Wellington Laboratories (Guelph, Canada). 
The recoveries were determined with spike experiments in the concentration range of 10 
and 100 ng/l using Milli-Q water (replication n=6); they were in the range of 50-90% (see 
(Loos et al., 2007).   
 The compounds were identified by retention time match and their specific LC-MS
2
 
MRM transitions. Good performance of the developed analytical methods was 
demonstrated by successful participation in several interlaboratory exercises on non-
steroidal anti-inflammatory drugs (NSAIDs) (Farré et al., 2008; Heath et al., 2010), 
perfluoroalkyl substances (PFASs) (van Leeuwen et al., 2009) and nonyl- and 
octylphenol (Loos et al., 2008b). Quantification of the individual compounds was 
performed with similar internal standards (IS).  
 For instance, the first compounds (pesticides, pharmaceuticals) in Table 10 were all 
quantified with the internal standard ibuprofen 
13
C3. All perfluorinated carboxylates were 
quantified with PFOA 
13
C4, and PFOS with PFOS 
13
C4. Sulfamethoxazole, 
Carbamazepine, Caffeine, and the Benzotriazoles were quantified with the IS 





C3. The relative response factors of the compounds in relation to the IS 
were calculated in all cases. Thus, the reported concentrations are corrected with the 
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recoveries of the compounds. A comparative check of internal quantification was always 
performed with external quantification. 
 The compound-dependent method detection limits (MDLs or LODs) for the SPE-
LC-MS
2
 procedure were calculated from the mean concentrations of the blanks of the 
real water samples plus 3 times the standard deviation; 400 ml water was extracted and 
concentrated to 0.5 ml, which results in an enrichment factor of 800.  
5.1.4. Measurement uncertainty 
Measurement uncertainties of analytical methods can be estimated based on the method 
performance criteria obtained from method validation, combined with the outcome of the 
analysis of certified reference materials (CRM), or from the z-scores derived from 
interlaboratory studies. CRMs for polar organics in water samples do not exist. The JRC-
IES laboratory participated in two interlaboratory studies on non-steroidal anti-
inflammatory drugs NSAIDs (Farré et al., 2008; Heath et al., 2010), the 3
rd
 international 
interlaboratory study on  PFASs (van Leeuwen et al., 2009), and a dedicated study on 
Nonyl- and Octylphenol (Loos et al., 2008b). The measurement uncertainty is estimated 
to be around 25-50%; it was shown that typical uncertainties for the analysis of water 
samples by SPE-GC-MS are in the range of 25-50% (Planas et al., 2006).  
5.1.5. Statistical analyses 
Frequency of positive detection (freq) in [%], average, median (med), and percentile 90% 
(Per90), were quantified with excel software (Microsoft).  
5.2. Organophosphate ester flame retardants (UMEȦ) 
5.2.1. Sample preparation and clean-up 
The effluent samples (100 ml) were extracted according to Bester (2005) using liquid-





D-TBP). The organic phase was separated from the aqueous one 
after freezing the samples overnight at -20 °C. The effluent extracts were concentrated to 
approximately 1 ml by rotary evaporation, quantitatively transferred to conical GC vials, 
and further reduced to 100 μl under a gentle stream of nitrogen. 
5.2.2. Instrumental analysis 
The samples were analyzed using a GC-HRMS high-resolution system consisting of an 
Agilent Technologies 6890 GC equipped with a CTC Analytics autosampler and coupled 
to a Micromass AutoSpec-Ultima mass spectrometer tuned to a resolution of 8000. 1 μl 
of each sample was injected into the GC, which was operated in splitless mode (2 mins 
splitless time). The injector temperature was set to 250°C and gas chromatographic 
separation was carried out using a DB-5 fused silica capillary column (length 30 m, i.d. 
0.25 mm, film thickness 0.25 μm) from J&W Scientific (Folsom, CA). The GC oven was 
initially held at 80°C for 4 mins, increased to 190°C at a rate of 15°C/mins, and then at 
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10°C/mins to the final temperature, 310°C, which was maintained for 4 mins. Helium 
was used as a carrier gas at a flow rate of 1.3 ml/mins. The MS was operated in selected 
ion monitoring (SIM) mode with electron ionization at 37 eV. The OPs were identified 
by comparing mass fragment ratios and retention times of sample components and 
reference standards, and quantified using the internal standard technique, which 
automatically corrects the data for losses during sample work-up and analysis. 
5.2.3. Quality control 
The following quality criteria were used to ensure correct identification and 
quantification of the target compound: (a) the retention time should match those of the 
standard compounds within ± 0.05 min, (b) the intensity ratios of the selected ions 
(target- and qualifier-ions) are within ± 15% of expected/theoretical value (c) the signal-
to-noise ratios are greater than 3:1. An analytical method blank was included for each 
sample batch analysed to assess background interferences and possible contamination of 
the samples. The data was blank corrected if the background contributed with less than 
10% of the sample concentration. Internal standard was added to the sample at the start of 
the working-up procedure of the sample. The internal standard has similar chemical and 
physical properties to the compounds to be analyzed. A recovery rate of >70% was 
considered acceptable (but was usually higher). 
5.3. Pharmaceuticals (UMEȦ) 
5.3.1. Sample preparation / Solid-phase extraction (SPE) 
The water samples were extracted by solid-phase extraction (SPE) with Oasis
®
 HLB 
(200 mg) cartridges (Waters, Milford, MA, USA). Before extraction, the samples 
(100 ml) were filtered through a 0.45 µm membrane filter (MF, Millipore, Sundbyberg, 
Sweden) and acidified to pH 3 using sulphuric acid. Five nanograms of each internal 
surrogate standard were added to each sample. The glass bottles were closed, and then the 
samples were mixed by shaking.  
 The cartridges were activated and conditioned with 5 ml methanol and 5 ml water at 
a flow-rate of 5 ml/min. The water samples were passed through the wet cartridges at a 
flow-rate of 5 ml/min, the columns rinsed with 2 ml water (flow 3 ml/min), and the 
cartridges dried for 10 min using air. Elution was performed with 5 ml methanol followed 
by 3 ml ethylacetate. The eluates were evaporated to 20 µl under a gentle air stream, and 
dissolved in 5% acetonitrile in water, with 0.1% formic acid, to a final volume of 1.0 ml. 
5.3.2. LC-MS-MS analyses 
Analyses were performed by reversed-phase liquid chromatography (RP-LC) followed by 
heated electrospray ionization (HESI), in positive and negative mode, mass spectrometry 
(MS) detection with a triple-quadrupole MS-MS system.  
 LC was performed with an Accela LC pump (Thermo Fisher Scientific, San Jose, 
CA, USA) and a PAL HTC autosampler (CTC Analytics AG, Zwingen, Switzerland). 
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Tandem mass spectrometry was performed on a bench-top triple-quadrupole TSQ 
Quantum Ultra EMR (Thermo Fisher Scientific, San Jose, CA, USA).  
 The eluants used for the separations of the target analytes were water, methanol and 
acetonitrile. The water phase used was acidified with 0.1% formic acid. The elution 
conditions were programmed as follows: 200 µl/min of 100% water for 1 min followed 
by a gradient change to 20/20/60 water/ACN/MeOH at a flow of 250 µl/min in 8 min, 
and final gradient change to ACN/MeOH 40/60 at a flow of 300 µl/min in 11 min. These 
parameters were held for 1 min and then changed to starting conditions and retained 4 
min to equilibrate the column for the next run. The injection volume was 20 μl; injection 
was performed by the autosampler. All experiments were performed at 22°C ambient 
temperature.  
 Instrument control, data acquisition and evaluation (integration and quantification) 
were done with Excalibur software (Thermo Fisher Scientific, San Jose, CA, USA). 
Nitrogen is used as the nebulizer gas and argon as the collision gas. Capillary voltage was 
operated at 3.5 kV. Heated electrospray (HESI) in positive or negative ion mode was 
used for ionization. Fused-silica capillary in the spray (standard set up) was replaced with 
metal capillary. The key parameters were set as follows: ionization voltage 3.5 kV; 
sheath gas 50, and auxiliary gas, 35 arbitrary units; vaporizer temperature 200 °C; 
capillary temperature 325°C; and collision gas (argon) flow 1.5 ml/min. Both first and 
third quadrupoles were operated at a resolution of 0.7 FMWH.  
 Collision-induced dissociation (CID) was carried out using argon at approx.1.5 
mTorr as collision gas at collision energies of 10-59 eV. The optimized characteristic 
MRM precursor product ion pairs monitored for the quantification of the compounds are 
given in Table 11. 
Table 11: LC-MS2 parameters, retention times, recoveries, LOQs (UMEȦ). 
Compound MRM transitions Ret.Time 
[min] 
Recovery [%] LOQ 
[ng/l] 
Internal standard 
Negative mode      
Clonazepam 313.9>278 7.84 82 ± 11 5 Tramadol 
Flutamid 275>202 8.72 87 ± 9 5 Amitryptiline 
Glibenclamide 492.1>170 9.57 52 ± 43 5 Oxazepam 
Glimepiride 489.2>225 9.27 52 ± 38 5 Oxazepam 
Positive mode      
Alfuzosin 390.1>156.2 6.85 76 ± 10 0.1 Tramadol 
Alprazolam 309.0>205.1 8.18 68 ± 7 10 Tramadol 
Amitryptiline 278.1>233.2 8.8 97 ± 5 5 Amitryptiline 
Amitryptiline IS 284.1>191.1 8.8    
Atorvastatin 559.2>250.0 9.04 45 ± 21 50 Amitryptiline 
Azelastine 382.1>112.2 8.63 95 ± 14 5 Tramadol 
Biperiden 312.1>294.3 8.78 101 ± 4 0.1 Amitryptiline 
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Bisoprolol 326.1>116.2 7.28 145 ± 6 0.1 Tramadol 
Bromocriptin 654.1>301.0 8.66 70 ± 31 5 Tramadol 
Buprenorphin 468.2>55.4 7.9 64 ± 16 10 Tramadol 
Bupropion 240>131.2 7.21 98 ± 9 0.1 Tramadol 
Chloprothixen 316>231 9.41 79 ± 9 10 Amitryptiline 
Chlorpromazine 319>214 9.23 74 ± 12 5 Amitryptiline 
Cilazapril 418.1>114.2 8.5 139 ± 6 1 Tramadol 
Citaprolam 325.1>109.2 7.9 65 ± 14 5 Tramadol 
Clemastine 344>180 9.65 75 ± 22 0.5 Oxazepam 
Clomipramine 315>242.1 9.33 88 ± 9 0.5 Amitryptiline 
Clotrimazol 277>165.1 8.9 82 ± 8 1 Amitryptiline 
Codeine 300.1>21.15 4.86 90 ± 9 0.5 Tramadol 
Cyproheptadine 288.1>191.1 8.55 102 ± 14 5 Tramadol 
Dicycloverin 310.1>109.2 10.1 112 ± 17 5 Oxazepam 
Diltiazem 415.1>150.1 8.15 101 ± 14 0.5 Tramadol 
Diphenhydramin 256.1>165.1 7.82 85 ± 11 0.05 Tramadol 
Duloxetin 298.1>123.5 8.7 114 ± 16 1 Tramadol 
Eprosartan 425.1>201.1 7.42 106 ± 13 5 Amitryptiline 
Etonogestrel 325.1>91.2 9.62 85 ± 12 0.5 Amitryptiline 
Fenofibrate 361>139 10.23 52 ± 33 0.5 Carbamazepin 
Fentanyl 337.1>105.2 7.6 82 ± 11 50 Fluoxetin 
Fexofenadine 502.2>171.1 8.6 106 ± 8 5 Amitryptiline 
Flecainide 415.1>301.1 7.94 98 ± 9 0.1 Tramadol 
Fluconazole 307.1>238.1 6.06 132 ± 6 0.5 Trimetoprim 
Fluoxetin 310.1>44.3 9 110 ± 7 5 Fluoxetine 
Fluoxetin IS 315.1>44.3 9    
Flupetixol 435.1>265 10.1 59 ± 32 5 Oxazepam 
Fluphenazine 438.1>143.2 9.9 57 ± 30 10 Oxazepam 
Haloperidol 376>123.1 7.81 80 ± 21 0.1 Tramadol 
Hydroxyzine 375.1>166.1 8.7 106 ± 4 0.5 Amitryptiline 
Ibersartan 429.2>180.1 8.39 102 ± 5 0.5 Amitryptiline 
Loperamide 477.2>210.2 9.23 68 ± 17 0.5 Amitryptiline 
Maprotilin 278.1>219.2 8.8 97 ± 6 5 Amitryptiline 
Meclozine 391.1>200.1 10.03 48 ± 41 5 Oxazepam 
Memantin 180.1>107.2 7.87 119 ± 8 0.5 Tramadol 
Mianserin 265>118.2 7.9 95 ± 12 1 Tramadol 
Miconazole 414.9>159 10.7 60 ± 31 5 Tramadol 
Nefazodon 470.1>246.2 9.06 72 ± 17 0.5 Amitryptiline 
Orphenadrin 270.1>165.1 8.35 94 ± 6 0.1 Amitryptiline 
Oxazepam 287>241.1 7.98 104 ± 13 5 Oxazepam 
Oxazepam IS 292>246.1 7.98    
Paroxetin 330>192.1 8.6 87 ± 8 10 Amitryptiline 
Perphenazine 404.1>143.2 9.6 71 ± 30 10 Oxazepam 
Pizotifen 296>199.1 8.6 92 ± 5 0.5 Amitryptiline 
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Promethazin 285.1>86.3 8.4 81 ± 6 10 Amitryptiline 
Promethazin IS 292.1>89.3 8.4    
Ranitidine 315>176.1 4.62 58 ± 21 0.5 Amitryptiline 
Repaglinide 453.2>162.2 8.76 104 ± 3 0.5 Amitryptiline 
Risperidone 411.1>110.2 7.2 96 ± 3 0.1 Risperidone 
Risperidone IS 415.1>195.1 7.2    
Rosuvastatin 482.1>258.1 8.21 102 ± 12 10 Tramadol 
Sertraline 306>19 9.55 84 ± 13 10 Amitryptiline 
Tamoxifen 372.2>129.1 10.9 122 ± 10 5 Tamoxifen 
Tamoxifen IS 375.2>75.2 10.9    
Telmisartan 515.2>26.17 9.13 79 ± 18 50 Amitryptiline 
Terbutalin 226.1>107.2 4.37 27 ± 10 0.5 Tramadol 
Tramadol 264.1>246.2 6.37 101 ± 11 0.5 Tramadol 
Tramadol IS 268.1>58.4 6.37    
Trihexyphenidyl 302.2>70.3 8.7 97 ± 6 0.1 Amitryptiline 
Venlavafaxin 278.1>121.3 7.4 101 ± 7 0.5 Tramadol 
Verapamil 455.2>165.1 8.26 116 ± 13 10 Tramadol 
Zolpidem 308.1>235.2 6.89 103 ± 7 0.5 Tramadol 
5.3.3. Identification, quantification, QA/QC and LOQs  
The first mass transition in Table 11 was used for quantification, and the second only for 



















Aldrich, Steinheim, Germany); which surrogate standards used for which analyte is 
presented in Table 11. 
 Absolute recoveries were determined with spike experiments in the concentration 
range of 1000 and 2500 ng/l using sewage effluent (replication n = 20); they were in the 
range of 27-145% (average 88%) (Table 11).  
 The compounds were identified by retention time match and their specific LC-MS
2
 
MRM transitions. The relative response factors of the compounds in relation to the IS 
were calculated in all cases. Thus, the reported concentrations are corrected with the 
recoveries of the compounds. A comparative check of internal quantification was always 
performed with external quantification.  
 The compound-dependent limits of quantifications (LOQs) for the SPE-LC-MS
2
 
procedure were calculated based on the second point in the calibration curves. 100 ml 




5.4. Antibiotics (VITO) 
5.4.1. Compound selection 
This study on the occurrence of veterinary active substances in the aquatic environment 
focused on those pharmaceuticals that are administered to cattle, pigs, horses and poultry. 
The use of many of these pharmaceuticals are not restricted to veterinary applications but 
are also used in human medicine. Data on use in Belgium indicate that anti-infectious and 
anti-parasitic active substances are the most applied. These groups of substances include 
a variety of different chemical classes, which necessitated a further selection of 
compounds based on frequency of use. Table 5 (section 3) gives an overview of the 
compounds of interest that were included in this study.  
5.4.2. Chemicals and reagents 
High purity (> 95%) analytical standards of the selected pharmaceuticals were purchased 
from Sigma-Aldrich (Sigma-Aldrich Laborchemikalien GmbH, Seelze, Germany). The 
individual stock standard solutions were prepared in methanol (MeOH) at a concentration 
of 500 µg/ml. The working standard solutions in a concentration range from 1 µg/l to 
1000 µg/l were prepared by dilution with MilliQ water. All solutions were preserved at 
4°C. Certain active substances like quinolones are light sensitive. Therefore, all solutions 
were prepared in amber bottles. 
5.4.3. Sample pre-treatment 
The analytical method was optimised in order to cope with the diverse physico-chemical 
properties of the analytes of interest. Therefore, extractions of sample aliquot were 
performed at either pH 3 or pH 6.  Tetracyclines and sulfonamides tend to form stable 
complexes with divalent metallic ions like calcium and magnesium. To prevent this 
complexation, the chelating agent Na2EDTA2H2O was added (Díaz-Cruz and Barceló, 
2006; Gros et al., 2006). For a limited set of analytes that were determined at pH 6 the 
chelating agent was not used. Table 12 shows the various method parameters. 
 Each pH-adjusted extraction was performed on 250 ml of sample using Oasis HLB 
SPE cartridges (Waters, Milford, MA, USA). Sample pretreatment was performed as 
follows. For each effluent sample, 1 aliquot was acidified to pH 3 and 2 aliquots to pH 6 
using 6 N HCl. After addition of 250 mg of Na2EDTA2H2O the solution was shaken and 
stored for 2h. For extractions at pH 3, the Oasis
®
 HLB SPE cartridges were conditioned 
with consecutively 20 ml of MeOH, 6 ml of MilliQ water and 6 ml of acidified water 
(pH 2). For the extraction of the effluent samples at pH 6 with and without addition of 
Na2EDTA2H2O, the cartridges were conditioned with 20 ml of MeOH and 12 ml of 
Milli-Q water. 
 The effluent sample was loaded on the SPE cartridge, which was washed with 10 ml 
of MilliQ water to remove residual EDTA and was consecutively dried under reduced 
atmospheric pressure. The compounds of interest were eluted with 20 ml of MeOH.  The 




 The optimal conditions for the extraction of the pharmaceutical compounds were 
determined by the analysis of spiked mineral water. The fortification level of the 
compounds of interest was 250 ng/l. The recovery was calculated as the ratio between the 
experimentally obtained concentration and the nominal concentration. For the majority of 
the compounds (65%), the extraction at acidic conditions (pH 3) resulted in the highest 
recoveries. 
 By applying the extraction conditions as listed in Table 12, a recovery above 80% 
was obtained for the majority of the compounds. On the contrary, amoxicillin and 
ampicillin are determined with a slightly lower recovery. The recovery of these -lactam 
antibiotics varied between 40% and 50%.  
Table 12: Extraction parameters of targeted analytes. 
pH EDTA Analyte 
3 Yes Amoxicillin, ampicillin, penicillin G, penicillin V, 
sulfadiazine, sulfamethoxazole, sulfadoxin, trimethoprim, 
oxytetracycline, doxycycline, flumequine, tylosin, tiamulin 
6 Yes Levamisole, ciprofloxacine, enrofloxacine 
6 No Lincomycine, clindamycine, florfenicol, tilmicosin 
5.4.4. LC-MS-MS analysis 
The instrumental analysis was performed using a Waters Acquity UPLC system 
consisting of an Acquity binary solvent manager, an Acquity sample manager and an 
Acquity column heater manager. The compounds of interest were separated on an 
Acquity BEH C18 column (2.1 mm × 150 mm, 1.7 µm). The column temperature was 
kept at 40°C. A gradient elution programme with water: formic acid (0.1%) (solvent A) 
and acetonitrile: formic acid (0.1%) (solvent B) was used. Chromatographic details are 
given in Table 13. The flow rate of the mobile phase was 0.4 ml/min. An aliquot of 10 µl 
of the final extract was injected into the LC system. 
Table 13: Gradient elution programme for the LC-MS-MS analysis of antibiotic substances. 
Time (min) Solvent A (%) Solvent B (%) 
Initial 95 5 
0.30 95 5 
7.00 5 95 
8.00 5 95 
8.30 95 5 
 
 The UPLC system was coupled to a triple quadrupole MS detector (Micromass 
Quattro Premier XE, Waters), which was operated in positive electrospray ionisation 
mode (ESI+). A capillary voltage of 3 kV was used for all compounds.  For each 
compound the cone voltage and the collision energy were optimized, the mass spectrum 
was recorded and the most abundant ions in the spectrum were subjected to further MS
n
 
fragmentations. Out of these results, characteristic precursor and product ions were 
selected for detection in the multiple reaction monitoring (MRM) mode. These 
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characteristic precursor and product ions, with the corresponding collision energy (eV) 
and cone voltage (V) are listed in Table 14. 








Oxytetracycline 461 426 23 20 
Doxycycline 445 428 23 23 
Tylosin 917 174 56 41 
Tilmicosin 870 174 55 40 
Penicillin V 383 160 26 11 
Penicillin G  367 160 23 26 
Ampicillin 350 106 17 20 
Amoxicillin 349 114 20 20 
Sulfamethoxazol 254 92 26 29 
Sulfadoxin 311 156 35 17 
Sulfadiazin 251 156 17 14 
Flumequine 262 244 26 20 
Enrofloxacine 360 316 32 17 
Ciprofloxacine 332 231 29 35 
Clindamycine  427 126 26 29 
Lincomycine 407 126 35 29 
Trimethoprim  291 230 38 23 
Florfenicol 377 243 17 20 
Tiamulin  495 192 14 20 
Levamisole 205 178 11 20 
 
5.4.5. Method performance 
The linearity of the method was determined for each veterinary active substance by 
injecting standard solutions in the concentration range 1-1000 µg/l. Based on the 
concentration in the standard solution and the area of the chromatographic peak, the 
response factor was calculated as the peak area divided by the concentration.  Within the 
working range, the calibration curve fulfilled the requirements for a linear fit. For the 
selected concentration range, calibration curves were constructed and the squared 
regression coefficients (R²) were calculated (Table 15). These regression coefficients 
were higher than 0.99 for all compounds. 
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Table 15: Concentration range and corresponding linear regression coefficient (R²) for the 
selected veterinary active substances. 
Compound Concentration range R² 
Oxytetracycline 1-1200 µg/l 0.99972 
Doxycycline 1-1100 µg/l 0.99994 
Tylosin 60-1300 µg/l 0.99760 
Tilmicosin 15-1100 µg/l 0.99940 
Penicillin V 1-1100 µg/l 0.99167 
Penicillin G 5-1100 µg/l 0.99902 
Ampicillin 5-1100 µg/l 0.99988 
Amoxicillin 1-1100 µg/l 0.99990 
Sulfamethoxazol 6-1200 µg/l 0.99752 
Sulfadoxin 5-1100 µg/l 0.99781 
Sulfadiazin 1-1100 µg/l 0.99944 
Flumequine 8-1700 µg/l 0.99552 
Enrofloxacine 50-1000 µg/l 0.99951 
Ciprofloxacine 65-1400 µg/l 0.99157 
Clindamycine 14-1100 µg/l 0.99967 
Lincomycine 1-600 µg/l 0.99658 
Trimethoprim 1-1000 µg/l 0.99922 
Florfenicol 1-120 µg/l 0.99918 
Tiamulin  6-140 µg/l 0.99525 
Levamisole 2-145 µg/l 0.99668 
 
Performance characteristics for the analysis in effluents were determined by the duplicate 
analysis of five samples. The samples were fortified with the pharmaceutical compounds 
at two concentration levels, i.e. 50 and 250 ng/l. A significant reduction of the recoveries 
of the pharmaceutical compounds was observed due to matrix suppression (Table 16). 
This reduction amounted to 20-30% for most compounds. Furthermore, for tilmicosin 
and tylosin the recovery decreased by more than 50%. Thus matrix effects play an 
important role in the determination of pharmaceutical compounds in water and suitable 
countermeasures are necessary to acertain valid and qualitative results. 
 As can be seen from the data in Table 15, the analysis of the selected veterinary 
active substances is characterised by a good precision, despite sometimes a low recovery. 
With a few exceptions, the relative standard deviation (% RSD) was lower than 15%. 
 The limit of detection (LOD) and limit of quantification (LOQ) were calculated as 
three times and six times the standard deviation SR of the duplicate analyses. These values 
were compared with the LOQ values determined as concentrations that would give a 
signal-to-noise ratio of 6 from the chromatograms of both the surface water samples 
(spiked at low concentration level) and a standard solution (1-2 µg/l). Of these two 
approaches, the highest LOQ was used for reporting. The resulting LOQ values are listed 
in Table 16 for the different pharmaceutical compounds. All LOQ values are based on the 
standard deviation of the duplicate analysis of five surface water samples, with exception 
of those from amoxicilline, florfenicol and tilmicosine. The LOQ value of these latter 
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compounds was higher due to the observed signal-to-noise ratio in either the surface 
water samples or the standard solution. 
Table 16: Recovery, reproducibility and limit of quantification (LOQ) of the selected 
pharmaceuticals in surface water, using the optimal extraction conditions.  
Compound 
Recovery, % (RSD) 
LOQ 
(ng/l) Spiking level  
50 ng/l 
Spiking level  
250 ng/l 
pH 3 with addition of EDTA    
Amoxicillin 6 (58) 5 (52) 25 
Ampicillin 19 (18) 7 (46) 25 
Penicillin G 85 (13) 104 (8) 50 
Penicillin V 75 (21) 85 (12) 50 
Sulfadiazin 62 (15) 73 (12) 30 
Sulfadoxin 79 (14) 98 (7) 50 
Sulfamethoxazole 42 (12) 49 (7) 20 
Trimethoprim 66 (5) 75 (5) 10 
Oxytetracycline 22 (41) 41 (10) 30 
Doxycycline  25 (51) 50 (10) 50 
Flumequine  96 (4) 117 (4) 20 
Tylosin 122 (11) 103 (11) 50 
Tiamuline  49 (7) 44 (17) 20 
    
pH 6 with addition of EDTA    
Levamisole 35 (13) 69 (6) 15 
Ciprofloxacine 40 (8) 33 (7) 15 
Enrofloxacine 58 (9) 73 (5) 20 
    
pH 6 without addition of EDTA    
Lincomycine 88 (4) 76 (19) 15 
Clindamycine  76 (1) 69 (3) 10 
Florfenicol  < 10%* < 10%* 100 
Tilmicosin  39 (4) 22 (6) 50 
* % RSD values are not mentioned.  The standard deviation SR is comparable with the values of the other compounds.  
However, due to the very low recovery, very high % RSD values are obtained. 
 
 Due to the occurrence of matrix suppression that leads to a strong reduction of 
recovery the standard addition approach was used. Standard addition means a procedure 
in which the test sample is divided in three (or more) test portions. One portion is 
analysed as such, and known amounts of the compound of interest are added to the other 
test portions. The unknown concentration of the analyte in the sample is derived by 
extrapolation. Thus a linear response in the appropriate concentration range is essential 
for achieving accurate results. 
 Applying the standard addition approach, the MeOH extract (20 ml) was divided into 
4 equivalent test portions. One portion was used as such, while the other 3 portions were 
spiked with an increasing concentration of the compounds of interest: 25 µg/l, 62.5 µg/l 
and 150 µg/l. Consecutively, the 4 test portions of each sample were concentrated to 0.5 
ml, followed by LC-MS-MS analysis. 
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5.5. X-ray contrast agents (IWW Water Centre) 
5.5.1. Reagents, standard substances and stock solutions 
Acetonitrile (MS-grade) purchased from LGC-Standards (Wesel, Germany) and water 
(MS-grade) purchased from Biosolve (the Netherlands) were used as mobile phase for 
high performance liquid chromatography (HPLC). Water and methanol (both residual 
grade) used for SPE conditioning, extraction and elution were from LGC Standards 
(Wesel, Germany). Stock solutions containing 6 x-ray contrast agents of interest 
dissolved in a mixture of water/methanol (95/5) at six concentration levels (0.01 µg/mL 
to 0.40 µg/ml) were used as reference solutions. The following x-ray contrast agents 
listed with their chemical purity (in brackets) were purchased from different suppliers: 
amidotrizoic acid (97.1%) from Sigma Aldrich (Germany), iohexol (> 95%), iopromide 
(97.9%) and iothalamic acid (> 95%) from U.S. Pharmacopeia (USA), iomeprol (> 95%) 
from Bracco (Germany) and iopamidol (97.5%) from Dr. Ehrenstorfer GmbH 
(Germany). Labeled x-ray contrast agents of high purity were used as internal standards. 
Amidotrizoic acid-d6 (96%, isotopic purity: 98.5%) was purchased from LGC-Standards 
(Wesel, Germany) and iopromide-d3 (98%, isotopic purity: 98%) from Campro Scientific 
(Germany). All stock solutions of x-ray contrast agents with different concentration 
levels were prepared by volumetric dilution using appropriate solvents and were stored at 
4°C in the refrigerator. For spiking of samples these solutions were prepared in 
water/methanol (95/5).  
5.5.2. Sample preparation using solid-phase extraction (SPE) 
Non filtered samples (1 liter each) were acidified at pH 3 using HCl (12.5%). Prior to 
extraction, samples were spiked with labeled internal standard substances (100 µl) to a 
spiking level of 5 ng/l (amidotrizoic acid-d6) and 20 ng/l (iopromide-d3) respectively. 
Sample processing was done by a manually operated SPE vacuum device “BAKER spe-
10” (Mallinckrodt Baker, Griesheim, Germany) using 3-ml SPE-cartridges filled with 
200 mg embedded reversed phase Isolute ENV+ adsorbent (Biotage, Sweden). The 
cartridges were activated and conditioned with 2 × 3 ml methanol/acetonitrile (50/50) and 
2 × 3 ml blank water (pH 3) ensuring that the adsorbent does not run dry. Water samples 
were passed through the wet cartridges at a flow-rate of 5 ml/min, thereafter the columns 
were rinsed with 2 × 3 ml water (pH 7), and the cartridges dried for 60 min under reduced 
pressure using an air stream. Elution was performed with 5 × 2 ml methanol/acetonitrile 
(50/50). Concentration of extract was performed with a TurboVap® LV Evaporation 
System from Caliper Life Sciences (Hopkinton, MA, USA) using a gentle stream of 
nitrogen. The temperature of the eluate during concentration was kept at 40°C by using a 
water bath. The final solvent volume was adjusted to 1 ml methanol/water (5/95). An 
aliquot was used for the LC-MS determination.  
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5.5.3. HPLC-MS-MS  
HPLC analyses were performed by using a reversed-phase liquid chromatography (LC) 
column of the type Gemini C18 (150 mm × 2 mm, 3 µm) from Phenomenex (Torrance, 
CA, USA) followed by positive electrospray ionization (ESI) mass spectrometry (MS) 
detection using atmospheric-pressure ionization (API) with a triple-quadrupole tandem 
mass spectrometric system (Waters TQD-MS-MS, Milford, USA). Quantitative LC-
MS/MS analysis was performed in the multiple reaction monitoring (MRM) mode. The 
m/z values of the precursor ions, product ions, and the collision-induced dissociation 
(CID) energy for all used transitions within the quantification process are listed in 
Table 17. 
Table 17: X-ray contrast agents. Precursor ions and product ions used for identification and 
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Amidotrizoic acid  117-96-4 614.69 360.74 232.94 38 42 
Iohexol 66108-95-0 821.85 626.50 448.37 40 40 
Iomeprol 78649-41-9 777.84 404.80 287.82 59 42 
Iopamidol 60166-93-0 777.80 558.64 386.78 40 42 
Iopromide 73334-07-3 791.86 572.59 299.69 60 48 
Iothalamic acid 2276-90-6 644.88 428.89 176.88 47 38 
Amidotrizoic acid-d6 NA 620.73 366.80 239.00 45 36 
Iopromide-d3 NA 795.11 575.95 299.94 68 56 
5.6. Analysis of Gadolinium anomaly as a measure of Gd-based 
contrasting agents (IWW Water Centre) 
Analyses of Gd and 20 isotopes of other rare earth elements (REE) were carried out by 
Inductively Coupled Plasma – Mass Spectrometry (ICP-MS) with quantitation limits of 
about 1 ng/l for each of the REE.  
 The procedure to quantify anthropogenic Gd is the calculation of a so-called Gd 
anomaly. This procedure is based on the (linear or polynomic) interpolation of the 
expected Gd concentration from the neighbouring REE after shale normalisation. The Gd 
anomaly is calculated as the ratio of the measured Gd (after normalisation) to the 
expected (geogenic) Gd (after normalisation). This approach has been described in the 
geochemical literature (e.g. by Bau & Dulski, 1996; Möller et al., 2003). It is based on 
the observation that the REE distribution of geologic materials and of water (that is not 
anthropogenically influenced) follows a consistent pattern similar to a linear or 
exponential function if shale-normalised concentrations are plotted against the atomic 
number of the elements. By using mathematical interpolation methods, the expected 
value of the (geogenic) normalised Gd can be calculated from the normalized results of 
the neighbouring REE, and the ratio of measured to expected normalised Gd can be 
calculated (the general approach is visualised Figure 2. Post-Archaean Australian shale 
(PAAS) was used for normalisation (McLennan, 1989).  
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 The fraction of anthropogenic Gd is calculated from the Gd anomaly and the 












   (1) 
 
This can also be converted to a percentage of the total Gd measured. 
 
Figure 2: Calculating a Gd anomaly from shell-normalised REE data (from Schwesig & 
Bergmann, 2011). 
5.7. Biological methods (RECETOX) 
5.7.1. Sample preparation / Solid-phase extraction (SPE)  
Similarly to the chemical methods the water samples were extracted by solid-phase 
extraction (SPE) with Oasis
®
 HLB cartridges with only a few differences. A half liter of 
each water sample with suspended particle material was manually shaken to simulate 
turbulent conditions of waste water effluent and filtered through glass fiber filter (2 µm, 
Fisher Scientific, CZ). Consequently, the samples were applied to the Oasis
®
 HLB SPE 
columns (500 mg, 6 ml). Each column was activated by 6 ml of MeOH and equilibrated 
by 8 ml of distilled water without applying vacuum. Maximal pressure used for draining 













































samples passed through the solid phase, the columns were left to dry for about 10 min, 
and consequently were gravimetrically eluted by 6 ml of MeOH without use of any 
pressure. Finally, the eluates were concentrated under a gentle nitrogen stream at 
laboratory temperature to final volumes which corresponded to 1200-times concentrated 
original effluents. This aliquot was chosen a as maximum concentration which was 
mostly not cytotoxic to the cells in our previous studies, and enabled detecting estrogenic 
activity with limits of detection for estrogenicity 0.5 ng/l EEQ (estrogen equivalents) or 
dioxin-like activity 0.1 ng/l TEQbio (dioxin toxic equivalents determined with the biotest). 
Sample extracts were stored at -18°C until analyses. 
5.7.2. In vitro bioassays 
Two individual bioassays were used to determine estrogenic and dioxin-like potentials of 
the water extracts. The results were expressed as estrogenic (EEQ) or dioxin-like 
equivalents (TEQbio) with respect to standard estrogen (17β-estradiol (E2)), or dioxin 
(2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)).  
 To determine estrogenity of the sample extracts, MVLN (human breast carcinoma) 
cells stably transfected with luciferase gene under the control of estrogen receptor were 
used (Novak et al., 2009). Cells were grown in DMEM-F12 without phenol red (Sigma 
Aldrich, USA) containing 10% fetal calf serum at 5% CO2 and 37°C.  Once the cells 
reached about 80% confluence they were trypsinized and seeded into a sterile 96-well 
plate at a density of 25.000 cells/well. For experiments, cells were grown in medium 
containing foetal calf serum treated with dextran-coated charcoal (strongly reduces 
concentrations of natural steroids in the serum). After 24 h, the cells were exposed to the 
dilution series of the tested samples (at least 5 different concentrations of each sample 
were tested), to the calibration of the reference estrogen - 17β-estradiol (dilution series 1– 
500 pM E2) and blank and solvent controls (0.5% v/v methanol). Exposures were 
conducted in three replicates for 24 h at 37°C. After the exposure, intensity of the 
luminescence was measured using Promega Steady Glo Kit (Promega, Mannheim, 
Germany).  
 The H4IIE-luc, rat hepato-carcinoma cells stably transfected with the luciferase gene 
under control of the Arylhydrocarbon receptor (AhR) were used for analysis of dioxin-
like activity of the samples (Novak et al. 2009). The used procedure was similar to 
MVLN bioassay method described above with few differences: H4IIE-luc were plated in 
DMEM-F12 with phenol red (Sigma Aldrich, USA) containing 10% foetal calf serum 
with a cell density of 15.000 per well. 
5.7.3. Estrogenic and dioxin-like potential quantification 
After subtraction of the solvent control response, detected induction of luminescence was 
related to the maximal response of standard ligand (E2max for estrogenicity, TCCDmax 
for dioxin-like compounds) and converted into percentages of E2max or TCDDmax 
respectively. The maximal induction as well as the shape of the curve differed among 
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samples, thus equal efficacy or parallelism of the dose-response curves could not be 
assumed (Villeneuve et al., 2000). We have used a EEQ25/TEQbio25 estimate (based on 
the 25% E2/TCDDmax response) to avoid any predictions beyond the measured 
responses with all samples. EEQ/TEQ25 values were based on relating the amount of 
E2/TCDD causing 25% of the E2/TCDDmax response (EC25) to the amount of sample 
causing the same level of response. Values were determined from the nonlinear 
logarithmic regression of dose-response curve of calibration standard and samples in 
Graph Pad Prism (GraphPad Software, San Diego, USA).  
5.8. Biological based assays (JRC-IES) 
5.8.1. Effluent sample preparation 
To perform exposure tests of yeast and diatom cultures to undiluted samples (100% 
exposure), the effluents were filtrated using a 0.2 µm filter and concentrated to half the 
volume on falcon tubes by spin vacuum centrifugation at 4C. Upon exposure, the 
concentrated effluent was diluted 1:1 (yeast, diatom) and 1:2 (yeast) using concentrated 
media. This procedure assured that no growth limitation occurred due to lack of nutrient 
availability in the effluent-exposed cultures as compared to the untreated control yeast 
cultures. 
A total of 13 effluent water samples of WWTPs were tested (Table 18). 










Sample code Country Location 
#148 Czech Republic Veslarska 
#150 Belgium TWZ Evergem (2406) 
#164 Belgium WWTP Ronse 
#165 Belgium WWTP Waregem 
#166 Belgium WWTP Deurne 
#167 Belgium WWTP Hasselt 
#168 Belgium WWTP Geel 
#195 Ireland Dublin 
#196 Ireland Oberstown 
#202 Austria AWV Hall i. Tirol-Fritzens 
#209 Spain Ulldecona 
#210 Spain Godall 
#257 NL WWTP Leek (Noorderzijlvest) 
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5.8.2. Yeast culture 
The yeast strain W303.1a was selected for the test because of its increased sensitivity to 
oxidative stress. W303.1a is a haploid strain with genotype MATa (leu2-3,112 trp1-1 
can1-100 ura3-1 ade2-1 his3-11,15), carrier of a ybp1-1 mutation that increase peroxide 
sensitivity (Veal et al., 2003). A small scale bioassay performed in broth (Hasenbrink et 
al., 2006) was optimized and adapted to a 96-well microtiter plate for fast-screening of 
multiple samples. The culture was grown in minimal media (YNB, Sigma) to prevent any 
interference from protein binding to chemicals, with addition of limiting nutrients 
(Tryptophan, Uracil, Adenine, Histidine and Leucine) for 48 hours before exposure. The 
cell cultures were added to each test mix (effluent in culture media) and to the control 
(just media) at the desired starting cell density (corresponding to an Abs600 nm ≈ 0.3) as 
measured on a spectrophotometer. The cultures were then distributed, in triplicates of 
200 µl, in a 96-well plate (Sarstedt). The measured cell densities were corrected by 
removing the optical density contribution of each effluent diluted in the media at the 
same concentration as in the cultures.  
 The optical density was measured immediately after addition of the cells to the 
effluent mixture (time zero), and after 2, 4, 6, 8, 10, 24, 30 and 48h of exposure. 
 Three replicates were performed using the same starting culture for all control and 
effluent exposure conditions in each experiment replicate.  
5.8.3. Diatom culture 
T. pseudonana (strain CCMP 1335) was obtained as axenic culture from the Provasoli-
Guillard National Center for Culture of Marine Phytoplankton (CCMP, West Boothbay 
Harbour, Maine, USA). Diatoms were maintained at around 14°C under a diurnal light 
cycle of 13 h light and 11 h darkness. The culture medium was f/2-medium, based on 
artificial sea water with a salt concentration of 32 g/l Sodiumchloride (NaCl) (ASW, 





 cells/ml. Fresh cultures for maintenance were inoculated every 7 
days. Cell densities were determined by measuring the absorption at 450 nm using a 
microplate spectrophotometer (Biorad, Hercules, CA, USA) and used to calculate growth 
rates, as previously described (Bopp and Lettieri, 2007). T. pseudonana cultures were 
progressively adapted to decreasing salinities weekly, i.e. 24, 16 and 8 g/l, and let grown 
at the final salinity for at least one month prior to the tests.  
 The culture protocol was adapted to a 96-well plate and exposure to the effluents (at 
the original concentration) was followed by measuring the cell density immediately after 
addition of the effluent (time zero), and after 24, 48 and 72h of exposure. Prolonged 




 For those effluents eliciting growth inhibition, a serial dilution of the effluent was 
performed and exposed to the diatom cultures at the different salinities, to find the lowest 




6. Results and discussion 
6.1. SPE-LC-MS2 analysis of the target compounds (JRC-IES) 
The SPE-LC-MS
2
 procedure for the analysis of selected polar organic chemicals was 
developed and optimized before (Loos et al., 2007, 2008, 2009). Figure 3 shows an LC-
MS
2
 chromatogram of a standard solution in the negative ionization mode, and Figure 4 












































Figure 3: LC-MS2 chromatogram of a standard mixture (negative ionization). 
 
 
Figure 4: LC-MS2 chromatogram of a standard mixture (positive ionization). 
 48 
 
 The analytical parameters MRM transitions, retention times, recoveries, LOQs, and 
the internal standards used for the quantification are given in Table 10.  
 In comparison to the analysis of surface and ground water (Loos et al., 2009a, 2010), 
the LOQs for the analysis of waste water were a bit higher, due to higher matrix 
interferences and lower recoveries.  
6.2. Chemical compounds identified 
Table 19 summarizes the analytical results for the polar organic compounds which were 
measured in the WWTP effluents across Europe and all single analytical results are given 
in Annex 2-10. In total 90 effluent samples were analysed (by JRC-IES). The UMEȦ 
University (Sweden) analysed 89 samples, UBA (Austria) 77 samples, IWW (Germany) 
and Masaryk University 73 samples, and VITO (Belgium) 30 samples. The compounds 
are sorted according to their frequency of detection (Freq. in %); “Max.” is the maximum 
concentration found, “Med.” the median concentration, and “Per90” the 90th percentile.  
Table 19: Summary of analytical results for chemicals in EU WWTP effluents (Fate Sees). 
Chemical LOQ 
[ng/l] 
Freq. [%] Max. [ng/l] Average 
[ng/l] 
Med. [ng/l] Per90 
[ng/l] 
TBEP, Tris(2-butoxyethyl)phosphate 1 100 43 g/l 2220,3 190,0 7580,0 
TCPP, Tris(2-chloroisopropyl)-
phosphate 1 100 21 g/l 1231,2 620,0 2100,0 
Irbesartan 0,5 100 17.9 g/l 479,5 85,4 859,9 
DEET, N,N’-Diethyltoluamide 1 100 15.8 g/l 678,1 195,8 1091,3 
TCEP Tris(2-chloroethyl)phosphate 1 100 2400,0 130,9 71,0 246,0 
TBP, Tributylphosphate 1 100 1700,0 259,8 160,0 574,0 
Tramadol 0,5 100 1165,7 255,8 218,4 503,5 
TIBP, Tri-iso-butylphosphate 1 100 870,0 133,2 110,0 244,0 
TDCP, Tris(1,3-dichloro-2-
propyl)phosphate 1 100 860,0 176,2 110,0 480,0 
Gadolinium 1,9 100 789,4 115,0 58,4 236,4 
TPP, Triphenylphosphate 1 100 610,0 35,6 17,0 71,8 
Risperidone 0,1 100 85,8 6,9 3,3 15,6 
Trihexyphenidyl 0,1 100 1,7 0,2 0,0 0,4 
Methylbenzotriazole 40 100 24,3 g/l 2,9 g/l 2,1 g/l 4,7 g/l 
PFOA, Perfluorooctanoic acid 1 99 15.9 g/l 255,0 12,9 60,9 
Venlafaxin 0,5 99 548,3 118,9 97,0 242,6 
Codeine 0,5 98 826,4 70,6 20,9 167,0 
Fluconazole 0,5 98 598,1 108,2 67,5 286,7 
Diphenhydramin 0,05 98 141,5 11,7 4,9 26,0 
Repaglinide 0,5 98 12,3 3,1 2,1 6,6 
1H-Benzotriazole 40 97 221 g/l 6,3 g/l 2,7 g/l 10,9 g/l 
Flecainide 0,1 97 552,6 45,5 10,8 108,6 
Bisoprolol 0,1 97 423,4 41,6 15,7 135,6 
EHDPP, 2-Ethylhexyldiphenyl-
phosphate 1 94 5400,0 92,7 6,5 42,2 
PFHpA, Perfluoroheptanoic acid 1 94 2962,3 82,9 5,1 20,3 
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PFOS, Perfluorooctansulfonate 0,5 93 2100,9 62,5 12,2 94,1 
Trimethoprim 10 93 799,8 229,0 178,3 552,4 
Acesulfame K 10 93 2.5 mg/l 76 g/l 14.3 g/l 61 g/l 
Caffeine 5 93 3002,0 191,1 34,6 400,0 
Alfuzosin 0,1 91 20,5 2,8 1,5 8,3 
Bupropion 0,1 91 4,9 1,0 0,6 2,7 
Ciprofloxacine 15 90 264,5 96,3 82,1 197,1 
Oxazepam 5 90 1765,8 161,7 64,3 429,0 
Carbamazepine 1 90 4608,8 832,3 751,9 1556,4 
Diclofenac*
1
 1 89 174,3 49,5 43,3 102,8 
PFNA, Perfluorononanoic acid 0,5 89 2734,5 35,1 2,3 7,9 
Sucralose 100 88 12,9 g/l 2,6 g/l 1,7 g/l 6,1 g/l 
Orphenadrin 0,1 85 46,7 3,9 0,5 6,8 
Sulfamethoxazole (VITO) 20 83 1690,5 280,2 164,1 617,7 
Haloperidol 0,1 83 2691,5 32,2 0,3 1,2 
Citaprolam 5 83 188,6 33,8 21,1 74,6 
PFDA, Perfluorodecanoic acid 1 81 1687,0 23,9 2,9 7,7 
Sulfamethoxazole (JRC) 1 81 1147,4 142,3 67,5 398,7 
Fexofenadine 5 80 1287,1 165,0 58,8 431,3 
MCPA 0,5 80 2403,9 149,9 22,1 499,0 
Diltiazem 0,5 79 64,4 10,7 6,4 25,7 
Fluoxetine 5 78 21,5 2,1 0,0 7,8 
Diuron 1 77 1425,8 61,7 11,6 83,7 
Terbutalin 0,5 76 4,7 1,1 0,9 2,6 
Clindamycine 10 73 277,2 70,4 45,9 150,9 
PFHxA 1 72 23866,5 303,7 5,7 18,2 
2,4-D 1 72 356,7 27,1 11,9 72,2 
Mecoprop 1 72 2208,6 127,4 17,2 251,7 
Diazinon 1 71 391,0 21,4 4,1 30,1 
PFHxS, Perfluorohexansulfonate 1 71 921,9 48,6 3,4 34,8 
Terbutylazine 1 67 2411,4 90,6 4,7 96,9 
Atrazine 1 68 36,6 4,2 2,2 11,0 
Naproxen 5 66 957,6 26,7 8,2 33,1 
Telmisartan 50 63 4344,8 367,5 120,1 888,6 
Bezafibrate 1 63 343,5 25,4 3,5 81,9 
Eprosartan 5 62 6810,2 226,8 13,7 432,5 
Gemfibrozil 1 60 3618,5 137,7 4,9 300,4 
Zolpidem 0,5 58 42,6 1,5 0,6 1,7 
Ibuprofen 2 57 2128,5 80,5 7,0 134,2 
Hydroxyzine 0,5 51 9,6 1,1 0,5 3,0 
Terbutylazine-desethyl 3 51 1530,8 68,8 4,7 131,1 
Isoproturon 1 49 270,4 10,1 0,4 19,5 
Ketoprofen 10 49 1653,1 86,0 0,0 179,7 
Bentazone 1 48 220,0 9,6 0,0 20,6 
Amidotrizoic acid 50 47 8,4 g/l 619 0,0 1,7 g/l 
Ranitidine 5 42 43,6 6,8 0,0 21,5 
Nitrophenol 5 42 1300,8 49,4 0,0 84,6 
Triclosan*
2
 4 41 4258,6 74,8 0,0 100,5 
Levamisol 15 37 339,9 40,6 0,0 116,0 
Lincomycine 15 37 317,1 31,2 0,0 106,5 
Rosuvastatin 10 36 978,9 31,0 0,0 41,6 
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Iopromid 50 36 150 g/l 2,7 g/l 0,0 1,3 g/l 
Biperiden 0,1 35 2,4 0,1 0,0 0,3 
Penicilline V 50 33 122,0 28,7 0,0 97,3 
Clotrimazol 1 33 5,3 0,6 0,0 2,0 
Metolachlor 3 29 288,9 12,4 0,0 38,0 
Dichlorprop 3 29 186,3 9,6 0,0 19,2 
Mianserin 1 28 62,3 1,5 0,0 3,8 
Simazine 5 28 689,3 26,3 0,0 67,1 
Clofibric Acid 2 26 127,0 5,3 0,0 12,1 
Dinitrophenol 5 26 473,5 18,8 0,0 58,0 
Atrazine-desethyl 3 24 155,4 13,8 0,0 54,6 
Iomeprol 50 22 12,0 g/l 376 0,0 378 
Clomipramine 0,5 20 3,0 0,3 0,0 1,0 
Iohexol 50 18 7,7 g/l 158 0,0 258 
Iopamidol 50 15 6,1 g/l 144 0,0 158 
Memantin 0,5 12 1312,1 22,8 3,7 23,1 
Sertraline 10 12 37,5 2,1 0,0 11,1 
Tiamuline 20 10 44,5 3,3 0,0 2,4 
Clonazepam 5 9 43,7 1,6 0,0 0,0 
Chlortoluron 3 9 183,7 3,2 0,0 0,0 
Carbaryl 3 9 81,4 1,6 0,0 0,0 
Hexazinon 2 9 42,0 0,8 0,0 0,0 
Loperamide 0,5 8 2409,1 29,3 0,0 0,0 
Alprazolam 10 8 33,0 1,3 0,0 0,0 
Pizotifen 0,5 8 1,9 0,1 0,0 0,0 
Fenofibrate 10 7 25,7 1,1 0,0 0,0 
Nefazodon 0,5 7 2,4 0,1 0,0 0,0 
Linuron 5 7 3264,8 40,1 0,0 0,0 
Buprenorphin 10 6 259,1 3,9 0,0 0,0 
Fentanyl 0,5 6 1,6 0,1 0,0 0,0 
Methabenzthiazuron 3 6 17,8 0,5 0,0 0,0 
Cilazapril 1 4 2,2 0,1 0,0 0,0 
Maprotilin 5 3 16,5 0,4 0,0 0,0 
Sulfadiazine 30 3 105,4 3,5 0,0 0,0 
Tilmicosine 50 3 93,2 3,1 0,0 0,0 
Flumequine 20 3 25,7 0,9 0,0 0,0 
2,4,5-T 2 3 10,2 0,3 0,0 0,0 
Cyproheptadine 5 2 325,1 3,9 0,0 0,0 
Glibenclamide 10 2 28,0 0,4 0,0 0,0 
Amitryptiline 5 2 14,6 0,3 0,0 0,0 
Tamoxifen 5 2 12,6 0,3 0,0 0,0 
Duloxetin 1 2 6,3 0,1 0,0 0,0 
TCP, Tricresylphosphate 1 2 1,3 0,0 0,0 0,0 
Atorvastatin 59 1 72,9 0,8 0,0 0,0 
Verapamil 10 1 16,5 0,2 0,0 0,0 
Miconazole 5 1 14,8 0,2 0,0 0,0 
Chlorpromazine 5 1 10,4 0,1 0,0 0,0 
Flupetixol 5 1 7,9 0,1 0,0 0,0 




Substances not found: Azelastine, Bromocriptin, Chloprothixen, Clemastine, Dicycloverin, Etonogestrel, Fluphenazine, 
Glimepiride, Meclozine, Paroxetin, Perphenazine, Promethazin, TEHP, Oxytetracycline, Doxycycline, Penicilline G, 
Amoxilline, Ampicilline, Florfenicol, Tylosine, Sulfadoxine, Enrofloxacine, Fenbendazole, Decamethyltetrasiloxan (MD2M), 
Dodecamethylpentasiloxan (MD3M), Octamethyltrisiloxan (MDM), Celestolid, Phantolid, and Traesolid.  
*
1
Diclofenac: It might be possible that the levels for Diclofenac are higher than reported here (see section 6.3.3.) 
*
2
Triclosan levels are probably the double of the reported concentrations because the used HDPE bottles are not 
recommended for use when sampling for this compound (due to adsorption) (Vanderford et al., 2012, chapter 2, page 19).  
6.2.1. Frequency of detection 
The high overall frequency of detection (above the LOQ) is shown by the percentile 
frequency (freq.) of detection for the compounds. The average frequency of detection for 
all 161 compounds was 43%.  
 The most frequently detected compounds were DEET, Methylbenzotriazole, 
Irbesartan, Risperidone, Tramadol, Trihexyphenidyl, TIBP, TBP, TCEP, TCPP, TDCP, 
TBEP, TPP, Gadolinium (all 100% frequency), PFOA, Venlafaxin (99%), Codeine, 
Diphenhydramin, Fluconazole, Repaglinide (98%),  Benzotriazole, Bisoprolol, Flecainide 
(97%), EHDPP, PFHpA (94%), PFOS, Trimethoprim, Acesulfame K, Caffeine (93%), 
Alfuzosin, Bupropion (91%), Ciprofloxacine, Oxazepam, Carbamazepine (90%), 
Diclofenac, PFNA  (89%), Sucralose (88%), Orphenadrin (85%), Citaprolam, 
Haloperidol (83%), PFDA, Sulfamethoxazole (81%), Fexofenadine, MCPA (80%), 




















































































































































































































































Figure 5: Most frequently detected compounds. 
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 Twenty eight compounds (out of 161) were not detected in any of the samples. These 
substances were: Azelastine, Bromocriptin, Chloprothixen, Clemastine, Dicycloverin, 
Etonogestrel, Fluphenazine, Glimepiride, Meclozine, Paroxetin, Perphenazine, 
Promethazin, TEHP, Oxytetracycline, Doxycycline, Penicilline G, Amoxilline, 
Ampicilline, Florfenicol, Tylosine, Sulfadoxine, Enrofloxacine, Fenbendazole, Deca-
methyltetrasiloxan (MD2M), Dodecamethylpentasiloxan (MD3M), Octamethyltrisiloxan 
(MDM), Celestolid, Phantolid, and Traesolid.  
 It must be noted that also 17-Estradiol, 17-Ethinylestradiol, and Estrone were 
analysed within the multi-compound screening method (negative ESI method) in all 
samples (by JRC-IES), but these estradiol hormones were not detected in any of the 
samples above the LOQ of ~ 10 ng/l.  
 Other substances with a low frequency of detection (<10%) were Verapamil, 
Miconazole, Flutamid, Flupetixol, Chlorpromazine, Atorvastatin, Tonalid, Octamethyl-
cyclotetrasiloxan (D4), Dodecamethylcyclohexasiloxan (D6), Decamethylcyclo-
pentasiloxan (D5), 2,4,5-T, TCP, Tamoxifen, Glibenclamide, Duloxetin, Cyproheptadine, 
Amitryptiline, Flumequine, Sulfadiazine, Tilmicosine, Maprotilin, Cilazapril, Metha-
benzthiazuron, Fentanyl, Buprenorphin, Linuron, Nefazodon, Fenofibrate, Pizotifen, 
Loperamide, Alprazolam, Chlortoluron, Hexazinon, Carbaryl, and Clonazepam (see 
Table 19).  
 These chemicals have a relatively low relevance for occurrence in the effluents of 
WWTPs.  
6.2.2. Maximum concentrations 
The highest maximum concentrations were found for the chemicals Acesulfame K (2.5 
mg/l), 1H-Benzotriazole (221 µg/l), Iopromid (150 µg/l), TBEP 43 µg/l), 
Methylbenzotriazole (24 µg/l), PFHxA (23.9 µg/l), TCPP (21 µg/l), Irbesartan 
(17.9 µg/l), PFOA (15.9 µg/l), DEET (15.8 µg/l), Sucralose (12.9 µg/l), Iomeprol 
(12.0 µg/l), Amidotrizoic acid (8.4 µg/l), Iohexol (7.7 µg/l), Eprosartan (6.8 µg/l), 
Iopamidol (6.1 µg/l), EHDPP (5.4 µg/l), Carbamazepine (4.6 µg/l), Telmisartan 
(4.3 µg/l),  Triclosan (4.3 µg/l), Gemfibrozil (3.6 µg/l), Linuron (3.2 µg/l), Caffeine 
(3.0 µg/l), PFHpA (3.0 µg/l), PFNA (2.7 µg/l), Haloperidol (2.7 µg/l), Terbutylazine 
(2.4 µg/l), Loperamide (2.4 µg/l), MCPA (2.4 µg/l), TCEP (2.4 µg/l), Mecoprop 
(2.2 µg/l), Ibuprofen (2.1 µg/l), PFOS (2.1 µg/l), Oxazepam (1.8 µg/l), TBP (1.7 µg/l), 
Sulfamethoxazole (1.7 µg/l), PFDA (1.7 µg/l), Ketoprofen (1.7 µg/l), Terbutylazine-






























Figure 6: Chemicals found at the highest concentrations. Excluded are Acesulfame K (2.5 mg/l), 1H-
Benzotriazole (221 g/l), Iopromid (150 g/l), and TBEP (43 g/l). 
6.2.3. Median concentrations 
Table 19 shows also the median (med.) concentration levels for the substances studied. 
The highest median concentrations were measured for Acesulfame K (14.3 µg/l), 1H-
Benzotriazole (2.7 µg/l), Tolyltriazole (2.1 µg/l), Sucralose (1.7 µg/l), Carbamazepine 
(752 ng/l), TCPP (620 ng/l), Tramadol (218 ng/l), DEET (196 ng/l), TBEP (190 ng/l), 
Trimethoprim (178 ng/l), TBP (160 ng/l), Telmisartan (120 ng/l), TIBP (110 ng/l), TDCP 
(110 ng/l), Venlafaxin (97 ng/l), Irbesartan (85 ng/l), Ciprofloxacine (82 ng/l), TCEP (71 
ng/l), Fluconazole (68 ng/l), Sulfamethoxazole (68 ng/l), Oxazepam (64 ng/l), 
Fexofenadine (59 ng/l), Gadolinium (58 ng/l), Clindamycine (46 ng/l), Caffeine (35 ng/l), 
MCPA (22 ng/l), Citaprolam (21 ng/l), and Codeine (21 ng/l). These results show the 










































































































































































































































Figure 7: Median concentrations of the target compounds (90 samples). 
6.3. Comparison with other WWTP studies (Interpretation) 
In the EU-wide WWTP study performed by Reemtsma and co-workers (2006) (see 
introduction), EDTA (Ethylenediaminetetraacetic acid), a complexing agent, (which was 
not analysed in Fate Sees) was the substance with by far the highest median 
concentrations (60 µg/l). Moreover, very high concentrations (median: 57 µg/l) were 
found in this study for sulfophenyl carboxylates, a group of biodegradation intermediates 
of the anionic surfactants LAS (linear alkylbenzene sulfonates). In our study (Fate Sees), 
the highest median concentration was found for Acesulfame K (14.3 µg/l), followed by 
the Benzotriazoles. The median concentration found for 1H-Benzotriazole (2.7 µg/l) 
corresponds very well to the study by Reemtsma et al. (2006), who found a median of 
2.9 µg/l.  
 Other compounds determined by Reemtsma et al. (2006) at relatively high levels 
(µg/l range) were Benzothiazoles, Naphthalenedisulfonates, and Nonylphenolethoxy-
carboxylates (NPECs), the predominant biodegradation intermediates of NPEO 
(Nonylphenolethoxylates) surfactants (not analysed in Fate Sees). For many 
pharmaceuticals (Diclofenac, Ibuprofen, Ketoprofen, Naproxen, Bezafibrate, 
Carbamazepine, Clofibric acid, and Sulfmethoxazole) median concentrations in the range 




 In the Swiss “Micropoll Strategy” project (Micropoll, 2011; 2012), 47 Swiss-specific 
micropollutants were identified out of 250 candidate substances (using a prioritization 
procedure), representative for the contamination caused through micropollutants from 
municipal wastewater. Table 20 shows the average effluent concentrations for these 
substances in comparison to the Fate Sees results; they are discussed in the following 
parts.  
Table 20: Comparison of the Fate Sees data with data from the Swiss Micropoll project; 
average effluent concentrations in ng/l; n = number of measurements; n.a. = not analysed.  
 Micropoll Project (CH) Fate Sees (Europe) 
 Average n  pos. n Average n Freq.(%) 
Amidotrizoic acid (contrast agent) 598 7 10 619 73 57 
Iomeprol (contrast agent) 380 9 19 376 73 37 
Iopamidol (contrast agent) 377 15 19 144 73 31 
Iopromid (contrast agent) 876 13 19 2680 73 48 
Acesulfame K 22500 4 4 76100 90 93 
Sucralose 4600 6 6 2600 90 87 
Benzotriazole 12881 41 41 6300 90 97 
Methyl-benzotriazole 1140 30 30 2900 90 99 
Bezafibrate 139 12 15 25 90 62 
Carbamazepine 482 78 78 832 90 89 
Diclofenac 647 54 54 50 90 90 
Ibuprofen 394 54 54 81 90 56 
Naproxen 462 38 39 27 90 64 
Sulfamethoxazole 238 34 34 142 90 81 
Trimethoprim 100 42 45 229 30 93 
Triclosan 116 6 6 75 90 41 
PFOS 114 7 7 63 90 93 
2,4-D  13 4 6 27 90 71 
Diazinon (insecticide) 173 40 84 21 90 71 
DEET (insect repellent) 593 11 55 678 90 100 
Diuron 1379 13 34 62 90 77 
Isoproturon (herbicide) 12 11 14 10 90 53 
MCPA 25 6 6 150 90 79 
Mecoprop 424 26 29 127 90 69 
Carbamazepine-10,11-dihydro-10,11-dihydroxy 1551 6 6 n.a.   
Atenolol (betablocker) 843 18 18 n.a.   
Metoprolol (betablocker) 166 17 17 n.a.   
Sotalol (betablocker) 435 21 21 n.a.   
Azithromycin (antibiotic) 175 18 19 n.a.   
Clarithromycin (antibiotic) 276 32 32 n.a.   
Erythromycin (antibiotic) 42 17 17 n.a.   
Mefenamic acid (analgetic) 870 10 10 n.a.   
Metformin (antidiabetikum) 10347 6 6 n.a.   
Irgarol (herbicide) 30 9 29 n.a.   
Carbendazim (fungicide) 81 17 30 n.a.   
Bisphenol A 331 22 25 n.a.   
Estradiol (hormone) 3 18 28 < 5   
Ethinylestradiol (hormone) 2 6 27 < 5   
 56 
 
Nonylphenol 267 7 7 n.a.   
Benzothiazol (additive) 494 6 6 n.a.   
EDTA (complexing agent) 20930 10 10 n.a.   
NTA (complexing agent) 5370 10 10 n.a.   
6.3.1. Perfluoroalkyl Substances (PFASs) 
Polyfluorinated compounds (PFCs) are useful anthropogenic chemicals that have been 
incorporated into a wide range of products for the past six decades. The products in 
which they are utilized include protective coatings for food contact packaging, textiles, 
carpets, paper, coats, fabrics, leather, non-stick cooking material, commercial and 
industrial surfactants (e.g. fire-fighting foams, electroplating baths), and insecticides. 
This class of compounds includes thousands of chemicals, but is best known for the 
perfluorosulfonates (PFSAs) such as perfluorooctane sulfonate (PFOS), and the 
perfluorocarboxylic acids (PFCAs) which include perfluorooctanoic acid (PFOA). 
Concerns about these compounds have developed as many satisfy the defining 
characteristics of persistent organic pollutants (POPs): they are toxic, extremely resistant 
to degradation, bioaccumulate in food chains, are transported over large distances, and 
can have long half-lives in humans. They are ubiquitous present in the environment and 
wildlife, and further have been found in human blood serum worldwide (Lindstrom et al., 
2011).  
 The discharge of municipal waste waters is one of the principal routes of entry of 
PFOA and PFOS into the aquatic environment (Becker et al., 2008; Guo et al., 2010; 
Huset et al., 2008; Loganathan et al., 2007; Ma and Shih, 2010; Schultz et al., 2006a,b; 
Sinclair and Kannan, 2006). Often PFAS concentrations increase in WWTPs as a result 
of biodegradation of precursors during the activated sludge process. In Bayreuth, 
Germany, it was found that PFOA is fully discharged into the river, while about half of 
PFOS is retained in the sewage sludge (Becker et al., 2010). Despite the voluntary 
phasing out of the production of perfluorooctane sulfonyl-based chemicals in 2002 (by 
the main producers), the detection of PFOS in WWTPs indicates that products containing 
PFASs are still releasing these substances into the environment.  
 The most frequent PFAS found in the Fate Sees study was PFOA (detection 
frequency of 99%), followed by PFOS (93%), PFHpA (C7; 94%), PFNA (C9; 89%), 
PFDA (C10; 81%), PFHxA (C6; 71%), and PFHxS (C6; 70%). PFOA was also detected 
at the highest median concentration levels (12.9 ng/l), followed by PFOS (12.2 ng/l), 
PFHxA (5.7 ng/l), PFHpA (5.1 ng/l), PFHxS (3.4 ng/l), PFDA (2.9 ng/l), and PFNA (2.3 
ng/l). The highest (single) maximum concentrations were found for PFHxA (23.9 µg/l), 
and PFOA (15.9 µg/l), followed by PFHpA (3.0 µg/l), PFNA (2.7 µg/l), PFOS (2.1 µg/l), 
PFDA (1.7 µg/l), and PFHxS (922 ng/l).  
 Similar PFAS levels are reported in the literature (Table 21). Highest maximum 
levels were found in the Fate-Sees study in industrial WWTPs. In WWTPs in Bayreuth 
(Germany), PFOA was found in all treated waste water samples in concentrations ranging 
from 9 to 93 ng/l, and PFOS at levels from 12–336 ng/l (Becker et al. 2008; 2010). In 
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Denmark, levels in 11 WWTPs were for PFOA <2-115.4 ng/l (median: 16.9 ng/l), and for 
PFOS <1-1115 ng/l (median: 4.3 ng/l) (Bossi et al., 2008). In six WWTPs in New York 
(USA) PFOS effluent concentrations ranged between 3-68 ng/l, and between 58-1050 
ng/l for PFOA (Sinclair and Kannan, 2006). Guo and co-workers (Guo et al., 2010) 
investigated the fate of PFASs in WWTPs in Korea. Ten PFASs were analyzed in 
influent and effluent wastewater and sludge samples in 15 municipal, 4 livestock and 3 
industrial WWTPs. The observed distribution pattern of PFASs differed between the 
wastewater and sludge samples. PFOS was dominant in the sludge samples with a 
concentration ranging from 3.3-54 ng/g, whereas PFOA was dominant in wastewater and 
ranged from 2.3 to 615 ng/l and 3.4 to 591 ng/l in influent and effluent wastewater, 
respectively. PFOS was the second dominant compound in the wastewater with the level 
of not detected (n.d.)-68 ng/l and n.d.-8.9 ng/l in the influent and effluent, respectively. 
Concentrations of PFOS in the effluent were 4- to 70-fold lower than those of WWTPs 
(42-635 ng/l) in Japan (Murakami et al., 2009), but similar to those of WWTPs in 
Kentucky and Georgia, USA (1.8-28 ng/l) (Loganathan et al., 2007). Very high PFOA 
effluent concentrations were reported from China in industrial WWTPs (Chen et al., 
2012a).  
Table 21: Overview of PFOA and PFOS concentrations (ng/l) in WWTP effluents. 
 
Number of 
WWTPs PFOA PFOS 
Reference 






USA 1 8.2-15 15-34 Schultz et al. (2006b) 
USA (New York) 6 58-1050 3-68 Sinclair and Kannan (2006) 






Bossi et al. (2008) 
Switzerland 4 12-35 16-303 Huset et al. (2008) 
Germany 9 12-78 0.06-82 Ahrens et al. (2009) 
Japan 5 10-68 42-635 Murakami et al. (2009) 
Singapore 13 16-1057 7.3-462 Yu et al. (2009b) 
Germany (Bayreuth) 4 9-93 12-336 Becker et al. (2008, 2010) 
Korea 22 3.4-591 n.d.-8.9 Guo et al. (2010) 
Hong Kong 4 n.d.-4.1 19-50 Ma and Shih (2010) 
China (Taiwan) 2 19-25 163-265 Lin et al. (2010) 
China 
12 Domestic: 3-191 
Ind.: 160-280 µg/l 
1-75 Chen et al. (2012a) 
6.3.2. Benzotriazoles 
1H-Benzotriazole (BT) and Methyl-Benzotriazoles (=Tolyltriazole, TT, used as a 
technical mixture of 4- and 5-TT) are a class of high production volume chemicals which 
find broad applications in various industrial processes as well as in households. They 
show metal complexing properties and are used as anticorrosive additives and flame 
retardants in aircraft de-icers and anti-ice fluids, in cooling and hydraulic fluids and for 
silver protection in dishwashing agents (Janna et al., 2011; Reemtsma et al., 2010; Weiss 
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et al., 2006). Benzotriazoles are compounds with high water solubility and a high 
polarity. Moreover, they are quite persistent against biological and photochemical 
degradation processes in the aquatic environment (Hart et al., 2004). Acute toxicity to 
aquatic organisms is in the low to moderate mg/l range, but there is a lack of a complete 
set of good quality eco-toxicological data on possible chronic effects of these high use 
chemicals (Janna et al., 2011). 
 Benzotriazoles were for the first time analysed in Berlin (Germany) and Switzerland. 
In Switzerland, BT and TT were found in the μg/l range in all samples of primary and 
secondary effluents from 24 municipal WWTPs. The BT concentrations were always by 
a factor of 10 to 100 higher than the corresponding TT values. The median values for BT 
concentrations in primary and secondary effluents were 18 and 10 μg/l, respectively 
(Voutsa et al., 2006). Four WWTPs in Berlin, treating municipal wastewater as a mix of 
household and industrial wastewater were investigated for the occurrence and removal of 
benzotriazoles over a six month period. Mean influent concentrations for the four plants 
ranged from 17-44 µg/l for BT and from 1.1-4.9 µg/l for each of the TT-isomers. Of the 
three benzotriazoles, none was eliminated completely during wastewater treatment. 
Generally, relative removal was best for 5-TT, but highly variable between the plants; it 
ranged from 19 to 69%. BT showed moderate removal (29–58%), whereas for 4-TT only 
one plant showed a significant but still limited removal (34%). Owing to the incomplete 
removal, BT median values of 7–18 µg/l were found for the effluents of the four WWTP 
(Reemtsma et al., 2010). In a previous study on WWTPs in Berlin 12 µg/l for BT and 1.3 
µg/l for 5-TT and 2.1 µg/l for 4-TT were reported as the two-year average (Weiss et al., 
2006). Concentrations of 1H-Benzotriazole in eight UK sewage effluents ranged from 
840 to 3605 ng/l, and were consistently less than those of TT (2685 to 5700 ng/l; in 
contrary to Germany and Switzerland). There was no relationship between effluent 
concentrations and treatment type, which were either activated sludge or biological filters 
with or without tertiary treatment (Janna et al., 2011). It is clear that the occurrence of 
Benzotriazoles in municipal wastewaters is caused by its application as an anticorrosive 
additive in dishwasher products, but there are also many industrial applications.  
 In our Fate-Sees study median concentrations were 2.7 µg/l for BT, and 2.1 µg/l for 
5-TT, with maximum values found up to 221 µg/l and 24.3 µg/l for BT and 5-TT, 
respectively. These levels are in relatively good agreement with the other studies cited 




Table 22: Comparison of the Fate Sees data for Benzotriazoles with other studies; WWTP 
effluent concentrations in (µg/l).  
Location Reference (µg/l) 










10 WWTPs (CH) 
Voutsa et al. (2006) 
1H-Benzotriazole: 
Median: 10 
WWTPs (Berlin, Germany) 
(two years average) 







WWTPs in western Europe 





4 WWTPs (Berlin, Germany) 
Reemtsma et al. (2010) 
1H-Benzotriazole: 
Median: 7-18 
WWTP Vidy Lausanne (CH) 






The removal of pharmaceuticals (or PPCPs) and other micropollutants in WWTPs has 
been investigated in several excellent studies before. State of the art biological treatment 
schemes for municipal wastewater are not efficient in degrading many pharmaceutical 
compounds; they are only poorly removed in conventional WWTPs.   
 For example, Joss and coworkers (2005) studied the removal of seven 
pharmaceuticals and two fragrances in the biological units of various full-scale municipal 
WWTPs. The observed removal of pharmaceuticals was mainly due to biological 
transformation and varied from insignificant (<10% for Carbamazepine and 
Sulfamethoxazole) to >90% (Ibuprofen). Ibuprofen is considered to be readily 
biodegradable, and removal rates reported in the literature are in the range of 80-100%. 
Stronger fluctuations were observed for other substances (e.g. Bezafibrate) (Clara et al., 
2005; Lindqvist et al., 2005; Hollender et al., 2009; Quintana et al., 2005; Radjenović et 
al., 2007a). Naproxen also showed significant removal (50–80%), and partial or 
contradictory removal was seen for Diclofenac (10–70%) (Joss et al, 2005; Radjenović et 
al., 2007a). In a subsequent study, Joss and coworkers studied a heterogeneous group of 
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35 compounds, and found that only 4 out of 35 compounds were degraded by more than 
90% while 17 compounds were removed by less than 50% (Joss et al, 2006).  
 Carbamazepine and Diclofenac are the most frequently detected pharmaceutical 
residues in water bodies thus far, since they are poorly removed in WWTPs (Zhang et al., 
2008). Investigations found that Carbamazepine is persistent and its removal efficiencies 
by the WWTPs are mostly below 10%, because it is resistant to biodegradation at low 
concentrations, and it is hardly attached onto sludge. The removal efficiencies of 
Diclofenac by WWTPs vary, ranging from 0 up to 80%, but mainly in the scope of 20–
40%. It has a relatively low biodegradation potential, but biodegradation is possible under 
some conditions. In any case, Diclofenac is less persistent than Carbamazepine, and the 
sorption behavior onto sludge is similar to that of Carbamazepine. Phototransformation of 
Diclofenac, however, is much faster than for Carbamazepine (Zhang et al., 2008).  
 Lindqvist and coworkers (2005) studied the five acidic pharmaceuticals Ibuprofen, 
Naproxen, Ketoprofen, Diclofenac and Bezafibrate in seven different WWTPs in Finland. 
In the treatment processes, the highest removal rate was observed for Ibuprofen and the 
lowest for Diclofenac, 92% and 26%, respectively. Nakada and coworkers (2006) 
confirm the good removal efficiency of Ibuprofen (>90%), and the lower efficiency 
(<50%) for Ketoprofen and Naproxen.   
 In contrast, Caffeine is efficiently removed in well functioning WWTPs (>99%). 
Nevertheless, it is ubiquitously present in the aqueous environment, due to its extensive 
use (Buerge et al., 2003). It degrades relatively slowly by direct photolysis (>170 h in 
artificial sunlight), but enhanced photodegradation was observed in waters containing 
fulvic acids (Jacobs et al., 2012). 
 Hollender and co-workers (2009) studied in a typical Swiss municipal WWTP 
(Wüeri in Regensdorf) the removal efficiency for 220 micropollutants by conventional 
secondary treatment, and upgraded with post-ozonation followed by sand filtration. The 
secondary treatment was very effective for easily biodegradable compounds such as 
Ibuprofen (eliminations 85%). Compounds known to be moderately persistent such as 
Diclofenac, Naproxen, Bezafibrate, sulfonamide and macrolide antibiotics, several beta 
blockers, and the anticorrosive agents Benzotriazole and 5-Methylbenzotriazole showed 
eliminations between 20 and 80%. As expected, Carbamazepine and a few triazine 
derivatives almost completely persisted during activated sludge treatment. The 
comparison of the Fate Sees data with the secondary effluent concentrations of Hollender 
et al. (2009) shows a relatively good agreement (average concentration levels; Table 23) 
(see also for pesticides under 6.3.4).  
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Table 23: Comparison of the Fate Sees data with the WWTP Regensdorf (Switzerland); 
secondary effluent concentrations in ng/l (Hollender et al., 2009).  
 WWTP Regensdorf (CH) Fate Sees 
 Average levels Average levels 
Bezafibrate 55-67 25 
Clindamycine 18-64 70 
Clofibric acid n.d.-44 5 
Fluconazole n.d.-58 108 
Ketoprofen 98-160 86 
Trimethoprim 76-111 229 
Venlafaxine 150-270 119 
 Gracia-Lor and co-workers (2010) analysed the 20 most consumed pharmaceuticals 
of different therapeutic classes in Spain in urban wastewater and surface water samples. 
The optimized method was applied to the analysis of 42 urban WWTP influent and 42 
effluent water samples (Castellón province), with the result that 17 out of 20 investigated 
compounds were detected in the samples. Analgesics and anti-inflamatories (NSAIDs), 
cholesterol lowering drugs and lipid regulators were the major groups found, with 
Diclofenac, Ketoprofen, Naproxen, 4-Aminoantipyrine, Bezafibrate, Gemfibrozil and 
Venlafaxine being the most frequently detected. The highest concentrations in influents 
were found for Acetaminophen, Salicylic acid and Ibuprofen. Diclofenac, Naproxen, 
Ketoprofen, Gemfibrozil, Bezafibrate, and 4-Aminoantipyrine were present in all influent 
and effluent samples analyzed at concentration levels normally in the range of high ng/l 
or low µg/l. Table 24 compares the maximum and median levels found in WWTPs in the 
Castellón province (Spain) with the Fate Sees data, and shows that the results for the 
maximum levels agree relatively well (with the exception of Ibuprofen, and some 
antibiotics). The median concentrations of Fate Sees are however in most cases much 
lower than in the study by Gracia-Lor et al. (2010, 2012). In a second monitoring 
campaign additional compounds including many antibiotics were analysed (Gracia-Lor et 
al., 2012). This comparison shows that it is difficult to compare results of median 
concentrations of one WWTP (or a small number) with the median of Fates Sees (n=90).  
Table 24: Comparison of the Fate Sees data with three urban WWTPs in the Castellón province 
(Spain); effluent concentrations in (µg/l); 84 samples analysed (Gracia-Lor et al., 2010, 2012).  
 Castellón province (Spain) Fate Sees 
 Maximum levels Median conc. Maximum levels Median conc. 
Diclofenac 0.74 0.33 0.17 0.043 
Ibuprofen n.d. n.d. 2.13 0.007 
Ketoprofen 0.62 0.30 1.65 0.000 
Naproxen 0.72 0.17 0.96 0.008 
Atorvastatin 0.16 0.02 0.073 0.000 
Bezafibrate 0.39 0.07 0.39 0.004 
Gemfibrozil 1.24 0.54 3.62 0.005 
Paroxetin n.d. n.d. n.d. 0.000 
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Venlafaxin 0.30 0.14 0.55 0.097 
Risperidone n.d. n.d. 0.086 0.003 
Alprazolam n.d. n.d. 0.033 0.000 
Ciprofloxacin 1.08 0.70 0.264 0.082 
Enrofloxacin n.d. n.d. n.d. n.d. 
Flumequine n.d. n.d. 0.026 n.d. 
Sulfamethoxazole 0.06 0.05 1.147 0.068 
Sulfadiazine n.d. n.d. 0.105 n.d. 
Lincomycine 0.16 0.01 0.317 0.000 
Clindamycine 0.02 0.02 0.277 0.046 
Trimethoprim 0.10 0.09 0.800 0.178 
 In a long term study by Gros and co-workers (2010), which covered 4 sampling 
periods over three years, a total number of 84 samples, specifically 28 influents, 
effluents, from seven WWTPs located in the main cities along the Ebro river Basin 
(North East of Spain), as well as receiving river waters, were analyzed to assess the 
occurrence of 73 pharmaceuticals covering several medicinal classes. The maximum 
effluent concentrations are compared in Table 25 with the results of Fate Sees. There is a 
relatively good agreement for most compounds, with the exception of Diclofenac, 
Carbamazepine, and Ranitidine.  
Table 25: Comparison of the Fate Sees data with 7 WWTPs located in the main cities along the 
Ebro river basin (Spain); maximum effluent and river water concentrations in (ng/l) (Gros et al., 2010).  
Compounds WWTP effluents River waters Fate Sees 
Naproxen 1740 165 958 
Diclofenac 1090 120 174 
Ibuprofen 2400 185 2128 
Ketoprofen 2980 < LOQ 1653 
Codeine 825 213 826 
Bezafibrate 454 16 344 
Clofibric acid 30 104 127 
Gemfibrozil 520 97 3619 
Atorvastatin 155 34 73 
Fluoxetine 21 410 22 
Paroxetine 14 2 n.d. 
Carbamazepine 366 98 4609 
Ciprofloxacin 313 109 265 
Sulfamethoxazole 620 36 1147 
Trimethoprim 463 114 800 
Ranitidine 1452 115 44 
 The occurrence and degradation of 32 emergent contaminants by AOPs in the 
municipal WWTP of Vidy at the city of Lausanne was investigated by De la Cruz et al. 
(2012). This WWTP treats water of 180,000 inhabitants and several hospitals, employing 
a treatment based on biological activated sludge. Table 26 gives the concentrations of the 
contaminants after the secondary treatment. The comparison to the Fate Sees data shows 
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a relatively good agreement for most of the substances, with the exception of only 
Bezafibrate, and Diclofenac.  
Table 26: Comparison of the Fate Sees data with the WWTP Vidy at the city of Lausanne 
(Switzerland); effluent concentrations of secondary treatment in ng/l (De la Cruz et al., 2012).  
 WWTP Lausanne (CH) Fate Sees 
 Average levels Average levels 
Bezafibrate 426 25 
Gemfibrozil 25 138 
Carbamazepine 263 832 
Diclofenac 518 50 
Ibuprofen 112 81 
Ketoprofen 123 86 
Naproxen 178 27 
Ciprofloxacin 129 96 
Sulfamethoxazole 578 142 
Trimethoprim 131 229 
 Rosal et al. (2010) performed a one-year survey of the WWTP of Alcalá de Henares 
(Madrid), which treats a mixture of domestic and industrial wastewater, and studied the 
occurrence and fate of 84 pollutants (mainly PPCPs). This plant is a “conventional” 
activated sludge WWTP with a biological nutrient removal process aimed to the 
elimination of phosphorous and nitrogen. The following Table 27 compares the 
maximum and average concentration levels of the effluent with the Fate Sees data. This 
comparison shows that the maximum concentrations of the Fate Sees data are for most 
compounds similar to the data of Rosal et al. (2010) (exceptions: Carbamazepine, 
Ciprofloxacin, Diuron, Fluoxetin, Galaxolid, Ranitidine). The average levels however are 
in the same range only for Bezafibrate, Codeine, Diclofenac, Diuron, Ibuprofen, 
Ketoprofen, Sulfamethoxazole, Triclosan, and Trimethoprim.  
Table 27: Comparison of the Fate Sees data with a WWTP from Spain (effluents); concentrations 
in (ng/l) (Rosal et al., 2010).  
 WWTP Alcalá de Henares (Spain) Fate Sees 
(ng/l) Maximum Average 
Removal 
efficiency (%) Maximum Average 
Bezafibrate 280 128 9 344 25 
Caffeine 1589 1176 95 3002 191 
Carbamazepine 173 117 10 4609 832 
Ciprofloxacin 5692 2378 57 265 96 
Codeine 319 160 69 826 71 
Diclofenac 431 220 5 174 50 
Diuron 81 42 62 1426 62 
Fluoxetin 929 223 62 22 2 
Gemfibrozil 5233 845 76 3619 138 
Ibuprofen 653 135 95 2129 81 
Ketoprofen 539 392 11 1653 86 
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Naproxen 2208 923 61 958 27 
Ranitidine 942 360 31 44 7 
Sulfamethoxazole 370 231 17 1147 142 
Trimethoprim 148 99 5 800 229 
 A five-month monitoring program was undertaken in South Wales in the UK to 
determine the fate of 55 PPCPs, endocrine disruptors and illicit drugs in two contrasting 
wastewater plants utilizing two different wastewater treatment technologies: activated 
sludge and trickling filter beds (Kasprzyk-Hordern et al., 2009). The efficiency of the 
removal of PPCPs was found to be strongly dependent on the technology implemented in 
the WWTP. In general, the WWTP utilizing trickling filter beds resulted in, on average, 
less than 70% removal of all 55 PPCPs studied, while the WWTP utilizing activated 
sludge treatment gave a much higher removal efficiency of over 85%. Also here a 
comparison shows that the median concentrations of Fate Sees are in most cases much 
lower (Table 28). Exceptions are Diclofenac, Carbamazepine, and Sulfamethoxazole. The 
maximum concentrations, however, are relatively similar for several pharmaceuticals 
(Trimethoprim, Ibuprofen, Diclofenac, Naproxen, Carbamazepine, Clofibric acid, and 
Bezafibrate).  
Table 28: Comparison of the Fate Sees data with two English WWTPs (effluents); concentrations 
in (ng/l) (Kasprzyk-Hordern et al., 2009).  
 South Wales (UK) Fate Sees 
(ng/l) Range Median Range Median 
Trimethoprim 625-3052 1152 11-800 178 
(WWTP 2) 385-1218 876   
Ibuprofen 131-424  263 0-2128 7 
(WWTP 2) 65-491 143   
Diclofenac 33-142  98 0-174 43 
(WWTP 2) 6-496 179   
Ketoprofen <3-33 16 0-1653 0 
(WWTP 2) 7-37 18   
Naproxen 234-703 370 0-958 8 
(WWTP 2) <2-269 170   
Codeine 2940-15593 5271 0-826 21 
(WWTP 2) 1457-4178 2716   
Tramadol 24132-97616 43813 0-1166 218 
(WWTP 2) 12779-56810 28147   
Carbamazepine 644-4596 2499 0-4609 752 
(WWTP 2) 152-2324 826   
Sulfamethoxazole <3-23 10 0-1147 68 
(WWTP 2) 4-44 19   
Clofibric acid <1-75 15 0-127 0 
(WWTP 2) <1-48 6   
Bezafibrate <85-667 231 0-344 3,5 
(WWTP 2) <94-393 177   
Ranitidine <9-455 224 0-44 0 
(WWTP 2) 15-783 425   
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Diltiazem 95-642 267 0-64 6,4 
(WWTP 2) 108-1156 357   
 Martínez Bueno et al. (2012) carried out an almost two-years monitoring program in 
five municipal WWTPs located in the north, centre and south-east of Spain. The study 
evaluated the occurrence and persistence of a group of 100 organic compounds belonging 
to several chemical groups (PPCPs, pesticides and metabolites). The average removal 
efficiencies of the WWTPs varied from 20% (Erythromycin) to 99% (Acetaminophen). 
Mean concentrations detected for the analytes identified ranged from 7 ng/l to 59 µg/l in 
influent samples and from 5 ng/l to 32 µg/l in effluents. Given this wide range of 
concentrations, it is noteworthy that a group of only 20 compounds was responsible for 
83% of the total load of pollutants in the effluent. This group included 13 
pharmaceuticals, mainly analgesics/anti-inflammatories (Diclofenac, Codeine, Naproxen, 
Ibuprofen), antibiotics (Ofloxacin, Ciprofloxacin, Erythromycin), diuretics (Furosemide, 
Hydrochlorothiazide), lipid regulators (Gemfibrozil), b-blockers (Atenolol), ulcer 
healings (Ranitidine) and the stimulant Caffeine. It is also remarkable the presence at 
very high concentrations of a group of metabolites such as Fenofibric acid (metabolite of 
Fenofibrate), Paraxanthine (metabolite of Caffeine) and four of the main metabolites of 
the antipyretic drug Dypirone (Martínez Bueno et al., 2012). These results are listed in 
Table 29 together with the Fate Sees data. The average levels are in good agreement to 
the results of Fate Sees only for about 50% of the pharmaceuticals (Citalopram, Codeine, 
Ibuprofen, Ketoprofen, Lincomycin, Sulfadiazine, Sulfamethoxazole, Trimethoprim, and 
Venlafaxine).  
Table 29: Comparison of the Fate Sees data (average) with 5 Spanish WWTPs; mean 
concentrations of an almost two years monitoring study; samples were taken monthly; effluent 
concentrations in (ng/l) (Martínez Bueno et al., 2012).  
 Alemeria Cantabria Madrid 1 Madrid 2 Barcelona Average Median Fate Sees 
 (n=15) (n=8) (n=22) (n=12) (n=9)   (average) 
Bezafibrate 174 217 156 300 258 221 217 25 
Caffeine 5521 1531 882 577 215 1745 882 191 
Carbamazepine 274 85 115 154 254 176 154 832 
Ciprofloxacin 712 94 1918 1526 309 912 712 96 
Citalopram  176 51 53 0 151 86 53 34 
Clofibric acid 95 0 238 14 102 90 95 5 
Codeine 180 0 133 107 18 88 107 71 
Diclofenac 249 76 5703 13814 0 3968 249 50 
Fluoxetine 230 0 259 208 14 142 208 2 
Gemfibrozil 6805 4015 1029 2191 5475 3903 4015 138 
Ibuprofen 1181 0 54 0 0 247 0 81 
Ketoprofen 12 68 50 0 62 38 50 86 
Lincomycin 140 0 14 0 96 50 14 31 
Naproxen 5433 498 1118 1046 84 1636 1046 27 
Paroxetine 381 0 30 0 0 82 0 0 
Ranitidine 873 222 614 903 543 631 614 7 
Sulfadiazine 0 0 0 0 19 4 0 4 
Sulfamethoxazole 548 246 208 257 328 317 257 280 
Trimethoprim 371 129 118 196 193 201 193 229 
Venlafaxine 324 273 189 0 448 247 273 119 
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 Miége et al. (2009) collected data on PPCPs in WWTPs from 117 scientific 
publications in a data-base. A comparison with the Fate Sees data is shown in Table 30. 
Miége and co-workers report much higher median (and maximum) values for Diclofenac, 
Ibuprofen, Ketoprofen, Naproxen, Bezafibrate, Gemfibrozil, Clofibric acid, Bisopropol, 
and Triclosan. In contrary, relatively similar concentrations are found for the substances 
Sulfamethoxazole, Trimethoprim, Carbamazepine, and Ciprofloxacin (and the maximum 
for Ketoprofen). A reason for the lower median pharmaceutical concentrations of the Fate 
Sees study might be that also several industrial WWTPs were included in the study.   
Table 30: Comparison of the Fate Sees data with WWTP effluent data from a literature data 
base; concentrations in (µg/l) (Miége  et al., 2009).  
(µg/l) Miége  et al. (2009) Fate Sees 
 Median Max. n Freq.(%) Median Max. n Freq.(%) 
Diclofenac 0,42 1,95 101 85 0,043 0,17 90 90 
Ibuprofen 0,80 24,6 109 93 0,007 2,13 90 56 
Ketoprofen 0,21 1,62 53 73 0,000 1,65 90 71 
Naproxen 0,88 33,9 53 87 0,008 0,96 90 64 
Bezafibrate 0,25 4,80 21 78 0,004 0,34 90 62 
Gemfibrozil 0,60 1,34 21 70 0,005 3,62 90 59 
Clofibric acid 0,15 0,23 24 55 0,000 0,13 90 26 
Sulfamethoxazole 0,07 0,32 11 73 0,068 1,15 90 81 
Trimethoprim 0,06 0,55 27 93 0,178 0,80 30 93 
Carbamazepine 0,52 2,30 63 100 0,752 4,60 90 89 
Clotrimazole 0,01 0,03 3 100 0,000 0,01 90 33 
Tamoxifen 0,20 0,37 3 19 0,000 0,01 90 2 
Bisopropol 0,64 1,43 18 100 0,016 0,42 90 97 
Triclosan 0,13 0,43 19 100 0,000 4,26 90 41 
Ciprofloxacin 0,07 0,14 29 91 0,082 0,27 30 90 
 Moreover, a good one-year WWTP monitoring study to evaluate the occurrence, 
persistence and fate of a group of 14 organic compounds in a WWTP located in the south 
of Spain was published by Gómez and co-workers (2007). Diclofenac concentrations 
ranged between 0.14-2.2 µg/l with a median of 0.9 µg/l. Table 31 shows that a 
comparison of these data from one WWTP with the Fate Sees data is very difficult.  
Table 31: Comparison of the Fate Sees data with a one-year WWTP study (effluent) in south 
Spain; concentrations in (µg/l) (Gómez et al., 2007).  
 South Spain Fate Sees 
 Range Median Range Median 
Ibuprofen 0.24-28 7.1 0-2.1 0.007 
Caffeine 1.4-44 12 0-3.0 0.035 
Triclosan 0.08-0.40 0.2 0-4.3 0.000 
Diclofenac 0.14-2.2 0.9 0-0.174 0.043 
Carbamazepine 0.11-0.23 0.13 0-4.6 0.752 
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Codeine 0.9-8.1 3.7 0-0.826 0.021 
 Clara and co-workers (2005) investigated several Austrian WWTPs for the 
occurrence and removal of PPCPs and endocrine disrupting compounds. Table 32 reports 
the range of concentration levels found in the effluents of these WWTPs. Also here, it is 
obvious that a comparison of median concentrations with the Fate Sees data is difficult; 
however, for Carbamazepine and Sulfamethoxazole, the agreement is good.  
Table 32: Comparison of the Fate Sees data with Austrian WWTPs; effluent concentrations of 
secondary treatment in (ng/l) (Clara et al., 2005).  
 WWTPs in Austria Fate Sees 
 Mean levels Median levels 
Diclofenac 780-1680 43 
Ibuprofen 20-2400 7 
Bezafibrate n.d.-4800 4 
Carbamazepine 465-1594 752 
Sulfamethoxazole n.d.-91 68 
 Vieno and coworkers (2007) studied twelve WWTPs in Finland, where the 
fluoroquinolone antibiotics Ciprofloxacin, Norfloxacin, and Ofloxacin were eliminated 
by >80%, and the -blockers Acebutolol, Atenolol, Metoprolol and Sotalol in average by 
less than 65%; the elimination varied greatly between the treatment plants. The 
concentrations for Carbamazepine and Ciprofloxacin are in good agreement to Fate Sees 
data (Table 33).  
Table 33: Comparison of the Fate Sees data with WWTP effluents from Finland (ng/l); (Vieno 
et al., 2007). 
 WWTPs in Finland Fate Sees 
 Median Maximum Median Maximum 
Carbamazepine 500 2440 752 4609 
Ciprofloxacin 70 130 82 265 
Diclofenac 
Zhang and co-workers (2008) review the world-wide occurrence of Diclofenac (and 
Carbamazepine) in WWTP effluents. Concentrations for Diclofenac range from ca. 100-
1500 ng/l with an approximate median value of 300 ng/l. Moreover, some information on 
Diclofenac in WWTP influents and effluents is available from the KNAPPE project 
(Knappe, 2008), presented in Table 34. 
Table 34: Concentrations of Diclofenac in WWTP effluents (µg/l). Data from the Knappe Project.   
 Median Maximum Number of samples 
Germany 1.34 10.0 382 
France 0.31 0.92 46 
Spain 0.31 2.20 47 
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UK 0.34 2.30 15 
Austria 1.84 3.00 7 
Greece 0.07 0.89 6 
Italy 0.68 5.45 8 
Average 1.29 4.59  
Table 35 summarizes in comparison to Fate Sees some monitoring data on Diclofenac.  
Table 35: Concentrations of Diclofenac in WWTP effluents (µg/l).    
Country City or Region Concentration Reference 
Europe 






 percentile: 1.60 Ternes (1998) 
EU median 5 countries Median: 0.29 Paxéus (2004) 
Spain South Median: 0.90 Gómez et al. (2007) 
EU median 
 Median: 0.42 
Max.: 1.95 
Miége  et al. (2009) 
UK South Wales Median: 0.14 Kasprzyk-Hordern et al. (2009) 
Switzerland 
Regensdorf Average: 0.69 
(influent: 1.45) 
Singer et al. (2010) 
Spain 
Castellón Median: 0.33 
Max.: 0.74 
Gracia-Lor et al. (2010,2012) 
Spain Ebro river region Max.: 1.09 Gros et al. (2010) 
Spain 
Alcalá de Henares Max.: 0.43 
Average: 0.22 
Rosal et al. (2010) 
Switzerland Lausanne Average: 0.52 De la Cruz et al. (2012) 
 In comparison to the effluents data for Diclofenac from the literature presented in the 
Table 34 and Table 35, in our EU-wide survey (Fate Sees) lower Diclofenac 
concentrations were found (with the exception of Kasprzyk-Hordern et al. (2009) 
(median: 0.14 ng/l), and Rosal et al. (2010) (average: 0.22 ng/l). The maximum 
concentration of Fate Sees was 174 ng/l, median 43 ng/l, average 50 ng/l, and 90
th
 
percentile 103 ng/l. Therefore, the quantification of Diclofenac with the help of the 
internal standard Ibuprofen 
13
C3 was double-checked, but no quantification error could be 
found. Chromatograms for Diclofenac are shown in the Annex. The reason for these 
relatively low Diclofenac concentrations found in the Fate Sees study remains therefore 
unresolved. The JRC-IES laboratory participated in two interlaboratory studies on non-
steroidal anti-inflamatory drugs (NSAIDs) (Farré et al., 2008; Heath et al., 2010). Also 
here, relatively high deviations were observed for the laboratories, and the JRC-IES 
laboratory results were below the median. It must be concluded that the concentrations 
found for Diclofenac in WWTP effluents in Fate Sees are lower than in other studies. A 
reason might be problems with different analytical standards, as noticed during the 
interlaboratory studies. However, also for other substances a comparison with other 
studies is difficult. There is also a great discrepancy in literature data for the removal of 
Diclofenac in WWTPs (i.e., 0–69%) (Ternes, 1998; Radjenović et al., 2007; 2009; 




Triclosan (2,4,4’-trichloro-2’hydroxydiphenylether) is currently used as an antimicrobial 
agent in toothpaste, mouthwash, liquid soap and in functional clothing such as functional 
shoes and underwear, as a stabilizing agent in a multitude of detergents and cosmetics 
and as an antimicrobial agent in polymeric food cutting boards. The primary emission 
route for Triclosan after usage is through wastewater. In WWTPs ~90% of the incoming 
Triclosan is removed from the water (also by adsorption to sludge) (Bester, 2003; Heidler 
and Halden, 2008; Singer et al., 2002), which is a high but not complete removal. As a 
result, it has been found in WWTP effluents as well as in surface water and ground water 
(and sewage sludge) in many countries (Chen et al., 2012b).  
 Table 36 gives some examples of European WWTP effluent concentrations for 
Triclosan, which agree well with Fate Sees. In the Fate Sees study a quite high maximum 
concentration level of 4.3 µg/l was found. It must be noted that the real Triclosan levels 
of Fate Sees are probably the double of the reported concentrations because the used 
HDPE bottles are not recommended for use when sampling for this compound (due to 
adsorption) (Vanderford et al., 2012, chapter 2, page 19).  
Table 36: Comparison of the Fate Sees data for Triclosan with other studies; WWTP effluent 
concentrations in (ng/l).  
Location (ng/l) Reference 
Fate Sees (Europe; n=90) Max.: 4259 
Average: 75 This report 
WWTPs around Lake Greifensee (CH) Range: 42-213 Singer et al. (2002) 
WWTPs (CH) Range: 70-650 Lindström et al. (2002) 
WWTP Dortmund (Germany) Range: 43-59 Bester (2003) 
WWTP in south Spain Range: 80-400 
Median: 200 Gómez et al. (2007) 
WWTPs in Europe (n=19) Max.: 430 
Median: 130 Miége  et al. (2009) 
WWTP Alcalá de Henares (Spain) Max.: 512 
Average: 219 Rosal et al. (2010) 
WWTP Vidy Lausanne (CH) Average: 135 De la Cruz et al. (2012) 
5 WWTPs (Spain) Max.: 3678 
Average: 301 Martínez Bueno et al. (2012) 
6.3.4. Pesticides 
In comparison to PPCPs, less information is available on the occurrence of pesticides in 
WWTPs, because direct inputs via agricultural field run-off might be more important for 
pesticides exposure. The average DEET concentration found in Fate Sees (678 ng/l) is in 
very good agreement to the Swiss Micropoll Project (593 ng/l) (see before) (Micropoll, 
2011; 2012). Clara and co-workers (2012) monitored over a one-year period several 
priority compounds of the WFD (including the pesticide Diuron) in nine Austrian 
WWTPs. The median concentration of 60 measurements was 40 ng/l, slightly higher than 
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the Fate Sees median of 12 ng/l. Table 37 shows also good match for most other 
pesticides (for the average levels).  
Table 37: Comparison of the Fate Sees data for some pesticides with other studies; WWTP 
effluent average concentrations in (ng/l). 
Country CH CH CH Spain Austria Europe 













Clara et al. 
(2012) 
Fate Sees 
Atrazine  30 9 64  4 
Diuron n.d.-70 40 57 259 40 62 
DEET 360-600     678 
Desethylatrazine 36-50 30    14 
Diazinon 59-492 40    21 
Isoproturon 38-159 30 < 10 127  10 
Linuron 21-110     40 
MCPA n.d.-22     150 
Mecoprop 163-3488 1010 34   127 
Simazine    44  26 
Terbutylazine  10    91 
Sulfamethoxazole  140    142 
6.3.5. Sweeteners Acesulfame K and Sucralose 
Artificial low-calorie sweeteners are consumed in considerable quantities with food and 
beverages. After ingestion, some sweeteners pass through the human metabolism largely 
unaffected, are quantitatively excreted via urine and feces, and thus reach the 
environment associated with domestic wastewater. Acesulfame K and Sucralose were 
recently identified as ubiquitous (emerging) environmental contaminants. They were 
detected in untreated and treated wastewater (Buerge et al., 2009; Ferrer and Thurman, 
2010; Scheurer et al., 2009), in surface waters (Buerge et al., 2009; Ferrer and Thurman, 
2010; Loos et al., 2009b; Scheurer et al., 2009), groundwater (Buerge et al., 2009; Ferrer 
and Thurman, 2010), ocean waters (Mead et al., 2009), and even in tap and drinking 
water samples (up to 2.6 µg/l for Acesulfame K and 2.4 µg/l for sucralose) (Buerge et al., 
2009; Mawhinney et al., 2011).  
 Concentrations of Acesulfame K and Sucralose in WWTP influents and effluents are 
quite similar; in Switzerland between 12-46 µg/l for Acesulfame K and between 2-9 µg/l 
for Sucralose were found (Hollender et al., 2009; Scheurer et al., 2009). These sweeteners 
are not eliminated in WWTPs and are quite persistent in surface waters, and in soil 
aquifer treatment. Due to these properties, Acesulfame K and Sucralose are ideal markers 
for the detection of domestic wastewater in natural waters, particularly groundwater 
(Buerge et al., 2009; Oppenheimer et al., 2011; Scheurer et al., 2009; 2010).  
 In our EU-wide study we found maximum concentration levels of around 2.5 mg/l 
Acesulfame K and 13 µg/l Sucralose, respectively. The median levels were (in good 
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agreement to literature data; see above) 14.3 µg/l and 1.7 µg/l for Acesulfame K and 
Sucralose, respectively. These sweeteners were not detected in all WWTPs because also 
some industrial plants were included in our study. Hence, Acesulfame K was the 
substance with the highest overall concentrations found in the Fate Sees study.  
 Note that for the quantification of Acesulfame K a recovery correction factor of 10 
was applied, because it had a very low SPE recovery of only around 10 %.  
6.3.6. Organophosphate ester flame retardants 
Organophosphate esters are high-production-volume chemicals used as flame retardants 
and plasticizers to protect or to enhance the properties of plastics, textiles, furniture and 
many other materials. The widespread usage, which may even increase due to the 
increasing global ban of brominated diphenylethers as flame retardants, and the diffusion 
from host materials result in continuous release of Organophosphate esters and their 
distribution through water, especially wastewater, and air, particularly associated with 
airborne particulate matter (Reemtsma, et al., 2008). 
 Nowadays, TCPP is more prominent in effluents than TCEP, reflecting the phasing 
out of the latter. Chlorinated organophosphate esters flame retardants are hardly removed 
in WWTPs. Of a series of 29 polar trace pollutants, TCPP was among the 10 with no 
significant elimination in WWTP, whereas TCEP showed slight removal (only 20%) 
(Reemtsma, et al., 2006). This European WWTP survey by Reemtsma and co-workers 
confirmed that TCEP and TCPP are routinely detected in WWTP effluents, typically at 
concentrations of a few hundred ng/l. TCPP and TCEP were determined with mean 
concentrations of 0.6 and 0.2 µg/l, respectively. These results were confirmed in effluents 
of 16 WWTPs in Austria, were median concentrations for TCPP, TCEP, and TBEP were 
580 ng/l, 74 ng/l, and 130 ng/l, respectively (Martínez-Carballo et al., 2007).  
 These values are in good agreement to the Fate Sees study were median levels were: 
TCPP 620 ng/l, TCEP 71 ng/l, and TBEP 190 ng/l.  
6.3.7. Fragrances / musk compounds 
Synthetic polycyclic musks are extensively used as fragrance ingredients in a number of 
consumer and personal care products, such as in laundry detergents, fabric softeners, 
cleaning agents, perfumes, shampoos, soaps, deodorants, detergents, body lotions, etc. 
Their lipophilic characteristics and degradation rates are similar to some well known 
hydrophobic and semi-volatile organic pollutants. They have been detected in various 
environmental samples worldwide, including in air, freshwater, sewage sludge, 
sediments, aquatic biota, and even in human adipose tissue, breast milk and blood 
samples. Tonalide
®
 (AHTN) and Galaxolide
® 
(HHCB) are the two largest volume 
products in the group of polycyclic musks, representing about 95% of the EU market. 
Major sources of polycyclic musks are households. In WWTPs overall removal 
efficiencies between approx. 50% and more than 95% are observed during biological 
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wastewater treatment and are mainly removed by sorption onto sludge (Clara et al., 2011; 
Joss et al, 2005; Kupper et al., 2006; Wu and Ding, 2010). 
 Reemtsma and co-workers (2006) investigated four musk components in their 
WWTP study (Galaxolide® (HHCB), Tonalide® (AHTN), Muskketone and Muskxylene); 
a median total concentration of 0.55 µg/l was found, and Galaxolide® (HHCB) and 
Tonalide® (AHTN) prevailed, whereas Muskketone and Muskxylene were hardly 





 were not detected frequently (detection frequency: 22 % and 1 %, 
respectively). Cashmeran
®







 were 260 ng/l, 77 ng/l, and 480 ng/l, 
respectively. Table 38 compares the Fate Sees data of HHCB and AHTN with other 
WWTP studies. Much higher concentrations were found in other studies.  
Table 38: Comparison of the Fate Sees data for HHCB and AHTN in WWTP effluents (ng/l). 




Median: 0,000  




(detection freq. <50%) 
Fate Sees 
WWTPs in Austria Mean: 451-870 Mean: 144-170 Clara et al. (2005) 
WWTP Mittleres Emmental, 
Hasle (CH) Mean: 770 Mean: 320 
Kupper et al. (2006) 
Literature data base 
(worldwide) 
Max.: 1080 
Median: 600 (n=9) 
Max.: 200 
Median: 160 (n=8) 
Miége  et al. (2009) 




Removal efficiency: 88% 
Max.: 315 
Average: 146 
Removal efficiency: 85% 
Rosal et al. (2010) 
WWTPs in Spain 
Max.: 25.9 µg/l 
Average: 4125 
Median: 3365 
Max.: 2.1 µg/l 
Average: 524 
Median: 337 





6.3.8. X-ray contrast agents  
X-ray contrast agents are only found in some WWTP effluents (detection frequency 
between 15-47 %), because they are mainly coming from hospital effluents. Very high 
single maximum concentrations were found in Fate Sees (e.g.: 150 µg/l for Iopromid in a 
WWTP from Portugal).  
Table 39 compares the Fate sees data with literature results. Average concentrations of 
Fate Sees are in very good agreement to the Micropoll Project in Switzerland (Micropoll, 
2011; 2012).  
Table 39: Comparison of the Fate Sees data for x-ray contrast agents with literature data; 






















Switzerland Average:598 Average: 380 Average: 377 Average: 876  Micropoll, 2011 
Regensdorf 
(CH)   
Average:31  Average:31 Hollender et al., 
2009 
Lausanne 
(CH)   
Average:1716 Average:  
< 600 
 De la Cruz et al., 
2012 
Austria   
 Mean: n.d.-
5060 
 Clara et al., 
2005 
 
6.3.9. Trace elements measured by ICP-AES (JRC-IES) 
The trace elements Hg (EQS: 0.05 µg/l), Ag, Al, As, Ba, Be, Cd (EQS: 0.08-0.25 µg/l), 
Co, Cr, Cu, Mg, Mn, Mo, Ni (EQS: 2 µg/l), Pb (EQS: 1.2 µg/l), Sb, Se, Ti, and Zn were 
measured in all 90 effluent samples by ICP-AES (Annex 10).  
 Magnesium (Mg), Manganese (Mn), and Zinc (Zn) were regularly detected in the 
microgram to milligram per liter concentration range. The priority substances of the 
WFD Mercury (Hg), and Cadmium (Cd) were in all cases below the LOD of 1 µg/l. The 
EQS value for Nickel (2 µg/l) was exceeded in three water samples (50-420 µg/l) 
(samples 150, 151, 152).  
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6.4. Bioanalytical results 
6.4.1. Estrogenity 
From the total number of 75 analyzed WWTP effluents, 27 sample extracts showed 
estrogenic activity higher than the detection limit > 0.5 ng/l EEQ (estrogen equivalents) 
(see Annex 9). Estrogenic activity expressed as estradiol equivalents varied (in positive 
samples) from 0.53 to 17.9 ng/l EEQ. Median and arithmetic mean of all tested samples 
were < 0.5 ng/l and 0.9 ng/l EEQ, respectively (Table 40).  
 The levels of detected EEQs are well comparable to the results of previous studies 
evaluating estrogenic activity of European WWTP effluent samples by different in vitro 
bioassays. For example, Svenson et al. (2003) used human estrogen receptor, hosted in a 
yeast strain, to quantify estrogenity in samples of effluents from 20 Swedish municipal 
WWTPs. The treatment plants were selected to represent different treatment processes 
regarding chemical precipitation (coagulation and precipitation by Al or Fe to remove 
phosphorus and coagulate dissolved organic material) and microbial procedures. The 
discharge from Swedish domestic WWTPs contained estrogenic compounds at levels 
ranging < 0.1 - 15 ng/l EEQ (Table 40). The other larger studies evaluating estrogenity of 
European WWTPs effluents were for example those performed by Korner et al. (2001), 
Vethaak et al. (2005), Aerni et al. (2004) or Cargouet et al. (2004). After the exclusion of 
one outlying value reported by Aerni et al. (2004), the levels of measured EEQ in all 
these studies varied from less than 0.03 to 24 ng/l, which is also in good agreement with 
the results present in this report. However, all these studies reported higher frequency of 
detection of positive samples in comparison to our study. Several reasons could be 
considered. First, to provide reliable results for relatively large number of samples 
investigated in the present study, we have done no further concentrations of the initially 
negative samples. This is the reason why our detection limit was higher in comparison to 
previously reported studies, and resulted in decreased frequency of positive "estrogenic" 
samples. Second, higher levels of EEQ in previously published studies were often 
detected at municipal WWTPs with other treatment steps then activated sludge with 
nitrification (e.g. Svenson et al., 2003) while this type of WWTP was the most frequent 
in our study. Finally, 9 out of the 75 sample extracts were either highly cytotoxic or 
elicited anti-estrogenic effects, which might mask effects of estrogens in complex 
mixtures (see Table 40).  
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EU wide study M, I 
Different treatment 
steps but  mostly  
activated sludge with 





steps, only 2 WWTP 
activated sludge with 






steps but  mostly  
activated sludge with 










Activated sludge with 
(de)nitrification 2.1 -5.3 n.a. 53,0 n.a. 5 90 
Aerni et al., 
2004 
France 
Paris area M 
Activated sludge, 
activated sludge with 
(de)nitrification, 








Germany I  
Activated sludge with 
(de)nitrification, 
tricling filter 
<0.03-   -
0.65 0,325 0,7 0,03 2 50 
Korner et 
al., 2001 
M – Municipal (mainly domestic waste waters, industrial waters may contribute only partially)  
I – Industrial 
n.a. – information was not available in the referenced paper 
6.4.2. Dioxin-like activity 
To evaluate approximate levels of dioxin-like activity, we studied 25 WWTP effluent 
sample extracts. Evaluated samples were those that were first delivered to our 
laboratories at RECETOX, Masaryk University, Brno; no other selection criteria were 
used. Twenty one out of the 25 tested sample extracts exceeded the detection limit 
(0.10 ng/l TEQbio) but the maximum detected dioxin-like activity was relatively low 
reaching only 0.44 ng/l TEQbio with median around 0.15 ng/l TEQbio (Table 41).  
 To our knowledge, only a limited number of papers reported about dioxin-like 
activity in dissolved water phase. Most of the known ligands for aryl hydrocarbon 
receptor, which is responsible for dioxin-like effects, are fairly hydrophobic compounds, 
and their presence in other matrices (e.g. particulate matter) is more likely. Nevertheless, 
dioxin-like activity has been reported also in water samples in some previous studies. For 
example Reungoat et al. (2010) tested dioxin-like activity of final effluent of Australian 
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reclamation WWTP by the CAFLUX bioassay. They found levels of TEQbio in the range 
from 0.26 to 0.36 ng/l (24h CAFLUX exposure). These results are in good comparison to 
those observed in the present study (Table 41). In another study, Dagnino et al. (2010) 
detected much higher dioxin-like activity in effluents of 3 French municipal WWTPs 
(2.1–43.7 ng/l TEQbio). These values were based on relatively short and unusual 8h 
exposures, and the authors observed decrease of the activity during the prolonged 
exposure time. This is important to mention as our results were based on more commonly 
used 24h exposure. In another study Ma et al. (2005) did not find levels higher than 
14 pg/l TEQbio in influents or effluents from Chinese municipal WWTPs using 72h 
exposure time. Taken together, it is apparent that WWTP effluents contain detectable 
amounts of AhR ligands but more research is needed to understand the role of dioxin-like 
compounds in dissolved phase of environmental mixtures in general. 




















study 24 0.14 0.14 0.44 0.10 25 84 
FATE 
SEES 
France 8 17.1 18.6 43.7 2 (LOQ) 3 100 
Dagnino et 
al., 2010 
Australia 24 0.31 n.a. 0.36 n.a. 1 100 
Reungoat et 
al., 2010 
China 72 <LOD <LOD <LOD 0.001 1 0 
Ma et al., 
2005 
n.a. – information was not available in the referenced paper 
 
6.4.3. Acute toxicity to yeast and diatoms 
The progressive adaptation of Thalassiosira pseudonana cultures to lower salinities was 
successfully achieved and the growth rates at 24 and 16 g/l Sodiumchloride (NaCl) after 
several weeks were comparable to those at 32 g/l, while a reduced growth rate was visible 
for 8 g/l, even after one month kept at lower salinity. The cultures at lower salinity had 
however corresponding higher sensitivity to additional stress and were able to identify 
toxicants at lower concentrations than the cultures at normal salinity. Additionally, the 
down-scale of both the yeast and diatom cultures to 96-well plate allowed fast screening 
of multiple samples simultaneously, greatly reducing the time and cost of the bioassay. 
 The effect elicited by the different effluents was quite comparable between yeast and 
diatom cultures. Most of the effluents were not harmful to any of the organisms. Some 
effluents even induced an increase in the growth of the cultures, more evidenced in the 













Figure 8: Effect of effluent exposure to culture growth of yeast Saccharomyces cerevisiae and 
diatom Thalassiosira pseudonana. The graphs show the relative cell density of the organisms 
monitored during exposure to 13 different effluent samples from waste water treatment plants. S. 
cerevisiae, W303.1a strain, was exposed to 1:1 (purple line) and 1:2 (green line) dilutions of effluent 
samples (left column), and T. pseudonana, growing at diverse salinities (32 g/l, blue; 24 g/l, purple; 16 g/l, 
green and 8 g/l, orange), were exposed to a 1:1 dilution of effluent samples (right column). The untreated 
yeast W303.1a strain cultures were used as control, while for diatom the untreated cultures grown at 
standard salinity (32 g/l; dashed blue line) was chosen as reference to all the treatments. Bars represent 
the standard deviation of the mean. In red the samples showing the growth inhibition effects. 
 The higher growth upon exposure to these effluents may indicate an abnormal 
enrichment in nutrients, which is particularly relevant to autotrophic organisms like 
diatom, and may be an indication of the eutrophication potential of the effluent water. 
 From the 13 effluent waters tested, only three revealed themselves harmful for the 
growth of both organisms, i.e. effluents #148, 195 and 209 (Figure 8, text in red). Both 
systems identified #195 as the most toxic effluent of those tested. While the effect of 
these effluents induced a growth inhibition of yeast cultures in a dose-response manner, 
they were lethal to diatom cultures of all salinities already after 24 hours exposure 
(Figure 8). When a dose-response was performed with these effluent samples on diatom 
cultures at different salinities, it was clear that sample #195 was the most toxic of all 
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samples. Thus, for the cultures at 32 g/l salinity, already at a 1:10 dilution, the #195 
effluent induced a decrease in the growth rate by half, while at a dilution of 1:5 and lower 
it was lethal. For the effluents #148 and 209, the lethality was induced only at lower 
dilutions (1:3) of the effluent. The lower salinity cultures of this marine diatom, revealed 
themselves more sensitive to the effluents and the dose-response of the effluents 
performed at lower salinities confirmed the data obtained at normal salinity. At 24 g/l, 
effluents #148 and 209 were lethal for dilutions lower than 1:5 and almost completely 
eliminated the diatom growth for the dilution 1:10, while effluent #195 was lethal in all 
dilutions tested (Figure 9). For the lower salinities (16 and 8 g/l) the effluents were lethal 
in all dilutions tested (not shown). 
 Two additional effluents, while harmless to diatom, caused alterations in yeast 
growth, i.e. effluent #150 caused growth inhibition and #164 caused a delay in the lag-
phase that rescued completely after 24h. In these cases, it is possible that the presence of 




Figure 9: Determination of the lowest effluent dilution with harmful effect on the growth of T. 
pseudonana. Graphs show the relative cell density of diatom cultures growing at two different salinities, 
32 g/l (left column) and 24 g/l (right column), upon exposure to the three toxic effluent samples.  Five 
dilutions of the effluents were tested and compared to the untreated diatom cultures grown at the same 




7. Conclusions and outlook 
This European-wide monitoring study on the occurrence of micropollutants in waste 
water treatment plant (WWTP) effluents was the largest WWTP survey ever performed 
in Europe. The influent waters of the WWTPs were not analysed, therefore, no 
elimination rates for the chemicals were determined. What is clear, however, is that the 
elimination of most of the substances in conventional WWTPs with secondary biological 
treatment is incomplete and improvements of the wastewater treatment and subsequent 
treatments of the produced sludge are required to prevent the introduction of these 
micropollutants in the environment. It must be kept in mind that today’s conventional 
waste water treatment technology (mechanical and biological steps) dates back to the 
1970s, and that it was designed to remove nitrogen and phosphorus. Small polar organic 
molecules are poorly removed, many of the non-polar chemicals can however be 
removed with the sewage sludge.  
 Under the view of escalating population growth, and increased water stress in many 
regions of the world, reuse of treated water and waste water recycling are becoming more 
important options for water supply. It is being discussed in Europe to upgrade WWTPs 
with additional tertiary treatment steps such as ozonation and/or powdered activated 
carbon adsorption to remove micropollutants from WWTP effluents. In the Swiss 
“Micropoll Strategy” project complementary treatment steps have been evaluated and it 
has been shown that water quality can be significantly improved using processes such as 
powdered activated carbon adsorption or ozonation. A further treatment even to drinking 
water quality is possible by micro- and nanofiltration or reverse osmosis.  
 In the future, participation of even more laboratories and the analysis of additional 
chemicals in similar monitoring campaigns would be desirable. This report gives a good 
overview on important anthropogenic chemical substances relevant in WWTPs or surface 
waters. Large scale multi-compound analytical screening techniques are being developed, 
and LC-high-resolution-MS allows a general unknown screening in water samples. LC-
MS libraries are necessary for the identification of unknown chemicals.  
 More detailed information on the single WWTPs would help in understanding also 
fate and behavior of the substances. Mass loads of the substances could be calculated if 
the effluent flows of the WWTPs were known. In addition, it is clear that better strategies 
are needed to integrate chemical and biological testing methods (such as biomarkers). 
Moreover, there is a need for more interlaboratory studies for the comparison of 
analytical method performances and QA/QC (e.g. for Diclofenac). 
 Biological-based tools, using acute and chronic toxicity testing of simple model 
organisms in the laboratory can provide fast and valuable information on the toxicity 
potential of the unprocessed water samples and infer possible effects onto endogenous 
species in the environment. In the report, we describe a fast, sensitive and easy method 
for fast screening of water samples based on acute toxicity using yeast or diatom. These 
bioassays however are not able to identify the specific chemical source of the effect. For 
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this purpose, posterior assessment of harmful water samples by chemical or molecular 
tools based on the mode of action of specific classes of pollutants could provide the link 
between the ecological effect and the class of compounds responsible for that effect.  
 The increasing worldwide contamination of freshwater systems with thousands of 
industrial and natural chemical compounds is one of the key environmental problems 
facing humanity. Although most of these compounds are present at low concentrations, 
many of them raise considerable toxicological concerns, particularly when present as 
components of complex mixtures (Schwarzenbach et al., 2006).  
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9. Annex  
Annex 1: European WWTP effluent water samples. Dom. = Domestic; Ind. = Industrial; Tert. = Tertiary Treatment. 














1 Fate Sees_136 Cyprus Larnaka 
12.05.2010 02.07.2010 
Domestic (Dom.) 6000 27500 
Tert. with sand filtration; 
chlorination 
2 Fate Sees_137 Cyprus Limassol 
04.05.2010 01.07.2010 
Dom.; Ind. 15000 70000 
Tert. with sand filtration; 
chlorination 
3 Fate Sees_138 France Evieu (CA 6)  23.02.2011     
4 Fate Sees_139 France Andancette (CA2)  23.02.2011     
5 Fate Sees_140 France   23.02.2011   13000  
6 Fate Sees_141 France   23.02.2011     
7 Fate Sees_142 France Givors (CA5)  23.02.2011     
8 Fate Sees_143 Czech Republic Not disclosed 10.05.2010 29.06.2010 Dom.; Ind.; no rain 700 5000  
9 Fate Sees_144 Czech Republic Not disclosed 10.05.2010 28.06.2010 Dom.; Ind.; no rain 300 2500  
10 Fate Sees_145 Czech Republic Not disclosed 09.05.2010 28.06.2010 Dom.; rain 3000 15000  
11 Fate Sees_146 Czech Republic Not disclosed 09.05.2010 28.06.2010 Dom.; rain 19000 75000  
12 Fate Sees_147 Czech Republic Not disclosed 11.05.2010 01.07.2010 Dom.; Ind.; rain > 100000 >500000  
13 Fate Sees_148 Czech Republic Not disclosed 09.05.2010 28.06.2010 Dom.; Ind.; rain 52000 170000  
14 Fate Sees_149 Czech Republic Not disclosed 10.05.2010 28.06.2010 Dom.; Ind.; rain > 200000 >500000  
15 Fate Sees_150 Belgium Tankreiniging, Evergem (2406) 19.06.2010 15.07.2010 Industrial    
16 Fate Sees_151 Belgium Shanks Vlaanderen, Lokeren 16.06.2010 14.07.2010 Industrial    
17 Fate Sees_152 Belgium Truck-en Tankcleaning Tack, Oostrozebeke 23.06.2010 16.07.2010 Industrial    
18 Fate Sees_153 Belgium Colortex, Sint-Niklaas 16.06.2010 16.07.2010 Industrial    
19 Fate Sees_155 Belgium EOC Belgium, Oudenaarde 15.06.2010 15.07.2010 Industrial    
20 Fate Sees_156 Belgium 3M Belgium, Zwijndrecht 28.06.2010 14.07.2010 Industrial    
21 Fate Sees_157 Belgium Taminco Gent (69471) 16.06.2010 14.07.2010 Industrial    
22 Fate Sees_158 Belgium Ajjinomoto Omnichem, Wetteren 23.06.2010 16.07.2010 Industrial    
23 Fate Sees_159 Belgium Bayer Antwerpen, Zandvliet 30.06.2010 16.07.2010 Industrial    
24 Fate Sees_160 Belgium Janssen Pharmaceutica, Geel 16.06.2010 15.07.2010 Industrial    
25 Fate Sees_161 Belgium Claerebout Potatoes, Heuvelland 17.06.2010 15.07.2010 Food industry    
26 Fate Sees_162 Belgium Ardo, Ardooie (Expl. 84) 23.06.2010 15.07.2010 Food industry    
27 Fate Sees_163 Belgium Agristo, Hulste (Expl. 369) 21.06.2010 09.07.2010 Food industry    
28 Fate Sees_164 Belgium RWZI Ronse 17.06.2010 16.07.2010 Domestic    
29 Fate Sees_165 Belgium RWZI Waregem 23.06.2010 14.07.2010 Domestic    
30 Fate Sees_166 Belgium RWZI Deurne, Antwerpen 22.06.2010 14.07.2010 Domestic    
31 Fate Sees_167 Belgium RWZI Hasselt, Kuringen 22.06.2010 15.07.2010 Domestic 11700 65000  
32 Fate Sees_168 Belgium RWZI Geel 23.06.2010 14.07.2010 Domestic    
33 Fate Sees_169 Slovenia Ljubljana 15.04.2010 01.07.2010 Dom. (62%); Ind. (11%); rain (21%) 103000 360000  
34 Fate Sees_170 Finland Nummi-Pusula  05.07.2010     
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35 Fate Sees_171 Finland Lohja  05.07.2010     
36 Fate Sees_175 Hungary Alattyán Municipal WWTP 08.07.2010 23.02.2011  250   
37 Fate Sees_177 Hungary Martfû 08.07.2010 24.02.2011  1000   
38 Fate Sees_179 Finland Vihti  05.07.2010     
39 Fate Sees_180 Finland Mäntsälä  09.07.2010     
40 Fate Sees_181 Finland Helsinki  06.07.2010     
41 Fate Sees_182 Finland Espoo  08.07.2010     
42 Fate Sees_183 Greece Thessaloniki (WWTP - EELTH)  06.07.2010     
43 Fate Sees_184 Greece 
Thessaloniki  (WWTP - EEL 
AINEIA) 
 07.07.2010     
44 Fate Sees_189 Switzerland Wenslingen  09.07.2010     
45 Fate Sees_190 Switzerland Seuzach 17.05.2010 08.07.2010  3940   
46 Fate Sees_191 Switzerland Konolfingen 04.06.2010 08.07.2010     
47 Fate Sees_193 Switzerland Affoltern a.A.  09.07.2010     
48 Fate Sees_194 Switzerland Zürich Werdhölzli  01.07.2010     
49 Fate Sees_195 Ireland Dublin 24.05.2010 01.07.2010  400000 1900000 Tert. UV Light Treatment 
50 Fate Sees_196 Ireland Osberstown 24.05.2010 02.07.2010     
51 Fate Sees_198 Austria WV Hofsteig 08.06.2010 07.07.2010 Metal, food, landfill, textile, laundry 138150   
52 Fate Sees_199 Austria AWV Region Feldkirch 08.06.2010 06.07.2010 Paper industry, food, metal, textile 380000   
53 Fate Sees_202 Austria AWV Hall i.Tirol-Fritzens 08.06.2010 08.07.2010  16000 120000  
54 Fate Sees_203 Austria Eisenstadt 18.05.2010 29.06.2010   42000  
55 Fate Sees_204 Austria AWV Wiener Neustadt - Sud 
24.05.2010 28.06.2010 Domestic (90%); Paper 
Ind. 
 260000  
56 Fate Sees_205 Austria Feldkirchen 19.05.2010 29.06.2010  6640 50000  
57 Fate Sees_208 Spain Tortosa 14.04.2010 29.06.2010  10296 46847  
58 Fate Sees_209 Spain Ulldecona 14.04.2010 29.06.2010  1620 13500  
59 Fate Sees_210 Spain Godall 14.04.2010 29.06.2010  150 875  
60 Fate Sees_211 Sweden Ryaverket 
 24.02.2011 Dom.;Ind.; hospital; laundries; food 
ind. 
119000000 680000  
61 Fate Sees_214 Sweden Henriksdal 
 24.02.2011 Dom.;Ind.; hospital; laundries; food 
ind. 
88000000 900000  
62 Fate Sees_226 Italy WWTP Roma nord ACEA 25.05.2010 02.07.2010  354240 780000 Final disinfection step 
63 Fate Sees_227 Lithuania WWTP Klaipedo vanduo 19.05.2010 05.07.2010 Domestic    
64 Fate Sees_228 Lithuania Kaunas 18.05.2010 02.07.2010  82000   
65 Fate Sees_229 Lithuania Panevezys regional 19.05.2010 01.07.2010  70000   
66 Fate Sees_233 NL WWTP Harnaschpolder 09.06.2010 06.07.2010  150000 1400000  
67 Fate Sees_235 NL WWTP Zaandam Oost 
03.06.2010  Dom.; urban runoff; Ind.; craft 
industry 
   
68 Fate Sees_236 NL Rotterdam Dokhaven 19.05.2010 02.07.2010 Mainly Domestic 117808 500000  
69 Fate Sees_239 NL WWTP Venlo 22.06.2010 07.07.2010     
70 Fate Sees_242 NL WWTP Winterswijk  05.07.2010 Dom.; Ind. (30-40%); hospital  83500  
71 Fate Sees_243 NL WWTP Nieuwgraaf  07.07.2010 Dom.; Ind. (30-40%); hospital  395000  
72 Fate Sees_245 NL WWTP Simpelveld  24.02.2011 Dom.; health care unit  20500  
73 Fate Sees_247 NL WWTP Amstelveen 14.06.2010 07.07.2010 Domestic  125000  
74 Fate Sees_248 NL Almere 18.05.2010 02.07.2010 Domestic; hospital; no rain  330000  
75 Fate Sees_250 Germany Klaranlage Seehausen, Bremen 17.06.2010 05.07.2010  94246 1000000  
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76 Fate Sees_252 Germany 
Klärwerk Gut Marienhof 
(Muenchen) 
      
77 Fate Sees_253 Italy 
Depuratore 'Jugendwerk 
Brebbia' 
 07.07.2010     
78 Fate Sees_254 Portugal WWTP Parada  24.02.2011     
79 Fate Sees_256 Germany AZV Hungerbachtal 28.06.2010 09.07.2010     
80 Fate Sees_257 NL WWTP Leek (Noorderzijlvest)  06.07.2010 Domestic  34000  
81 Fate Sees_258 NL 
WWTP Garmerwold 
(Noorderzijlvest) 
 06.07.2010 Domestic  300000  
82 Fate Sees_259 Portugal WWTP Viana do Castelo 25.06.2010 08.07.2010     
83 Fate Sees_260 Sweden Umeå  24.02.2011 Dom.; Ind.; hospital; dairy 35342 116000  
84 Fate Sees_261 Sweden Nolhaga  24.02.2011 Dom.; Ind.; laundry 8767 60000  
85 Fate Sees_262 Sweden Gasslosa 
 24.02.2011 Dom.; Ind.; hospital; food;; laundry; 
craft ind. 
3452 110000  
86 Fate Sees_263 Sweden Ellinge 
 24.02.2011 Dom.; Ind.; food; crop; laundry; 
craft ind. 
10137 330000  
87 Fate Sees_264 Sweden Borlange  24.02.2011 Dom.; Ind.; hospital; paper mill 15342 60000  
88 Fate Sees_265 Sweden Bollebygd  24.02.2011 Dom.; Ind.; fluggers process water 658 6000  
89 Fate Sees_266 Sweden Bergkvara  25.02.2011 Dom. 1644 6500  
90 Fate Sees_267 Sweden Framby 
 25.02.2011 Dom.; Ind.; hospital; laundry; craft 
ind. 
18904 50000  
91 Fate Sees_268 Sweden  
 25.02.2011 Dom.; Ind. Ironworks; paper mill; 
hospital, laundry, slaughterhouse; 
craft ind. 







Annex 2: Analytical results for the European WWTP effluent water samples in [ng/l]. Lab: JRC-IES. “Higher” concentrations are in red; clean, 























































































































LOQ [ng/l] 0.1 g/l 0.01 g/l 1 1 1 0.5 1 1 1 0.5 1 0.5 1 1 10 5 2 
Fate Sees_136 1,33 1,89 0,0 4,5 11,8 3,8 3,0 0,0 0,0 6,2 21,6 0,0 119,4 8,0 56,7 18,0 163,0 
Fate Sees_137 6,07 15,63 13,9 3,9 12,1 1,8 2,4 0,0 4,5 4,7 57,0 0,0 0,0 13,7 36,0 267,4 117,9 
Fate Sees_138 2,05 96,21 0,0 9,3 24,3 4,9 3,4 6 2,4 30,6 3,5 3,2 0,0 1,8 171,4 0,0 0,0 
Fate Sees_139 0,93 44,81 8,1 3,9 5,3 1,2 1,1 0,0 2,6 7,5 12,2 0,0 0,0 0,0 65,5 46,9 0,0 
Fate Sees_140 2,65 68,04 31,8 17,4 31,5 9,3 7,6 0,0 8,8 22,3 69,5 6,9 31,7 44,5 190,3 5,2 0,0 
Fate Sees_141 1,68 54,88 8,5 8,4 17,0 6,4 5,3 0,0 4,7 28,9 50,0 1,8 17,6 28,0 724,7 68,8 2128,5 
Fate Sees_142 4,17 184,7 92,2 37,6 60,8 7,9 8,4 28 180,2 527,7 48,7 28,5 111,4 41,7 63,3 17,2 45,1 
Fate Sees_143 1,60 18,24 7,4 5,1 10,7 1,8 2,5 60 0,0 8,9 85,7 35,7 15,8 43,3 21,6 22,4 89,5 
Fate Sees_144 4,52 88,22 7,6 3,6 14,8 0,0 0,0 65 0,0 0,7 80,4 394,5 0,0 21,4 30,7 5,4 0,0 
Fate Sees_145 2,34 94,77 8,3 4,4 12,6 1,9 0,6 127 0,0 1,4 88,1 217,7 14,4 27,4 63,2 14,8 0,0 
Fate Sees_146 1,46 73,74 14,8 6,1 10,7 0,7 2,0 37 0,0 18,1 89,4 30,9 28,5 37,7 104,0 9,8 7,2 
Fate Sees_147 1,42 14,31 8,4 4,3 35,0 2,4 10,6 26 0,0 12,4 67,9 50,1 25,4 29,7 118,9 24,8 0,0 
Fate Sees_148 1,71 39,48 14,9 11,0 12,2 2,1 0,0 84 16,5 25,3 49,8 55,8 2208,6 22,4 1653,1 0,0 43,6 
Fate Sees_149 2,77 61,17 6,2 8,5 8,7 1,7 3,1 25 2,7 25,2 74,9 25,5 182,0 30,5 32,5 24,7 124,7 
Fate Sees_150 3,78 0,00 1257,0 1926,3 1185,2 99,0 4,3 7476 921,9 113,9 84,0 256,5 1126,5 356,7 0,0 0,0 164,8 
Fate Sees_151 0,00 0,41 1102,9 293,8 153,9 3,6 1,9 5087 459,4 78,3 0,0 14,7 65,5 11,8 0,0 0,0 0,0 
Fate Sees_152 0,68 1,71 180,7 219,6 1307,1 11,0 5,9 9120 332,0 77,1 23,0 33,3 106,8 25,0 0,0 0,0 0,0 
Fate Sees_153 0,00 0,00 0,0 1,1 11,1 0,0 0,0 0,0 0,0 0,0 4,8 0,0 0,0 106,5 0,0 0,0 18,1 
Fate Sees_155 0,00 0,30 0,0 0,0 119,9 0,0 0,0 0,0 0,0 0,0 0,0 41,5 0,0 0,0 0,0 0,0 5,6 
Fate Sees_156 0,00 0,16 23866,5 2962,3 226,9 0,8 0,0 3200000 868,5 139,9 0,0 0,0 0,0 0,0 0,0 0,0 4,4 
Fate Sees_157 0,00 0,00 0,0 0,0 13,0 5,6 2,7 0,0 15,9 21,4 1,9 181,1 101,6 74,4 0,0 0,0 7,9 
Fate Sees_158 0,00 0,11 0,0 22,7 12,3 5,2 0,0 0,0 13,3 0,0 0,9 53,8 0,0 0,0 0,0 0,0 29,3 
Fate Sees_159 0,00 0,00 0,0 6,3 10,9 0,0 0,0 23 0,0 33,4 0,0 0,0 635,7 0,0 0,0 22,3 25,1 
Fate Sees_160 0,00 4,56 16,1 4,4 12,8 0,9 2,3 41 206,7 147,8 0,0 0,0 0,0 136,4 0,0 0,0 0,0 
Fate Sees_161 0,00 0,00 0,0 4,6 3,1 0,0 4,1 0,0 0,0 3,3 0,0 7,7 4,6 0,0 425,3 0,0 0,0 
Fate Sees_162 0,00 0,37 4,0 0,0 3,9 1,2 0,0 56 0,0 8,3 0,0 0,0 0,0 3,9 0,0 0,0 0,0 
Fate Sees_163 0,00 0,00 0,0 2,2 3,8 8,5 0,0 0,0 1,2 2,6 3,3 16,7 0,0 0,0 154,1 0,0 0,0 
Fate Sees_164 1,48 0,88 0,0 40,8 242,2 63,6 132,3 0,0 0,0 91,9 82,0 462,7 211,7 80,2 0,0 69,9 225,6 
Fate Sees_165 2,18 13,69 116,0 1079,6 2534,0 2734,5 1687,0 34 0,0 11,9 33,8 90,1 180,7 42,9 0,0 9,1 0,0 
Fate Sees_166 2,81 10,03 231,4 425,0 15939,7 22,4 39,4 24 30,9 39,4 56,9 18,5 190,3 24,2 122,6 6,3 0,0 
Fate Sees_167 3,27 17,93 3,3 2,8 12,3 2,2 3,6 27 4,2 4,3 79,6 749,7 79,5 58,0 0,0 17,9 0,0 
Fate Sees_168 1,44 10,96 0,0 8,1 27,6 2,8 0,0 2529 137,6 2100,9 39,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_169 1,83 6,39 5,4 4,0 13,3 0,7 3,3 33 3,0 28,4 68,3 0,0 74,3 11,4 0,0 2,6 0,0 
Fate Sees_170 4,98 11,07 0,0 4,0 4,9 3,4 0,0 0,0 0,0 2,4 133,8 12,7 16,7 0,0 443,2 957,6 70,5 
Fate Sees_171 1,56 9,02 0,0 5,1 7,3 0,8 0,0 28 31,6 9,9 43,0 0,0 11,8 0,0 94,3 54,7 21,4 
Fate Sees_175 0,20 2299 11,1 0,0 1,7 1,4 2,7 0,0 3,6 1,8 2,0 1,0 0,0 27,5 168,4 7,2 19,7 
Fate Sees_177 0,44 2482 8,9 3,0 5,4 0,0 0,0 0,0 2,4 4,4 10,8 0,7 7,0 19,3 64,3 0,0 78,3 
Fate Sees_179 6,24 33,26 4,9 6,4 15,9 5,4 5,5 41 0,0 0,0 78,2 6,9 8,6 0,0 0,0 0,0 4,6 
Fate Sees_180 3,06 29,33 4,8 6,1 19,1 2,8 1,8 70 19,7 15,9 35,7 218,3 120,7 0,0 0,0 5,5 0,0 
Fate Sees_181 4,99 32,69 5,4 6,4 14,7 4,3 4,8 0,0 10,9 240,6 46,3 25,7 44,5 9,4 149,1 28,7 16,4 
Fate Sees_182 4,50 22,01 9,2 8,3 21,5 2,1 2,6 43 7,2 12,4 44,7 25,3 103,4 10,1 138,4 15,7 0,0 
Fate Sees_183 2,53 9,28 0,0 4,5 14,7 2,8 4,2 0,0 0,0 10,8 107,1 0,0 0,0 4,9 0,0 15,4 0,0 
Fate Sees_184 2,92 6,54 5,7 3,1 12,1 0,0 2,0 0,0 2,7 7,2 0,0 0,0 0,0 0,0 0,0 0,0 8,5 
Fate Sees_189 1,72 12,78 3,9 1,8 7,9 8,0 3,6 20 6,3 13,5 66,7 546,5 78,4 6,9 0,0 16,9 0,0 
Fate Sees_190 2,42 11,71 3,6 5,1 24,5 3,1 8,1 47 0,0 19,6 81,1 12,2 0,0 20,1 0,0 9,1 0,0 
Fate Sees_191 1,66 11,37 0,0 2,3 8,0 3,8 4,5 29 5,3 11,4 59,4 11,2 130,5 0,0 0,0 26,0 0,0 
Fate Sees_193 1,74 10,40 0,0 4,8 15,2 1,9 4,5 48 8,9 11,4 68,2 16,6 78,0 9,2 0,0 20,7 0,0 
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Fate Sees_194 3,07 13,11 7,1 6,4 12,9 2,0 8,9 19 7,8 0,0 92,1 5,8 126,9 15,8 72,8 40,0 18,3 
Fate Sees_195 7,13 12,41 4,3 6,4 18,5 2,3 5,5 0,0 3,7 6,6 80,3 58,8 193,4 62,0 0,0 30,1 77,2 
Fate Sees_196 9,70 21,02 7,9 4,3 14,8 2,4 2,7 62 9,1 11,6 144,3 81,9 250,6 30,6 90,7 0,0 208,7 
Fate Sees_198 1,09 5,80 11,2 11,2 24,6 3,8 0,0 76 14,2 32,2 106,2 35,8 229,6 27,4 0,0 0,0 8,4 
Fate Sees_199 0,75 4,87 6,2 7,3 17,2 4,0 5,0 96 16,2 154,2 69,0 33,8 126,9 57,9 0,0 0,0 28,9 
Fate Sees_202 1,96 8,47 3,7 2,7 7,8 2,5 3,3 2371 0,0 45,0 50,1 71,2 16,1 6,1 0,0 0,0 0,0 
Fate Sees_203 0,49 7,22 4,6 5,3 0,0 3,6 3,2 34 7,5 9,7 76,7 536,3 129,9 31,9 73,5 25,5 16,3 
Fate Sees_204 0,42 22,84 5,2 9,7 18,4 3,8 6,9 709 2,5 11,3 89,6 643,3 215,5 29,3 69,9 32,3 183,8 
Fate Sees_205 2,28 14,33 7,1 5,4 10,2 2,5 2,6 41 8,1 155,2 174,3 5,5 7,4 0,0 178,5 0,0 0,0 
Fate Sees_208 4,85 16,56 8,6 6,0 16,6 1,7 2,3 55 0,0 4,6 46,9 735,5 34,4 102,5 29,3 8,8 0,0 
Fate Sees_209 3,74 12,40 6,8 3,7 7,5 2,3 3,1 11 0,0 1,8 29,9 1179,5 6,3 21,0 0,0 20,5 94,7 
Fate Sees_210 2,08 4,04 0,0 4,3 7,0 1,9 0,0 14 0,0 2,3 42,3 2403,9 0,0 71,9 112,2 29,2 0,0 
Fate Sees_211 0,94 43,35 2,7 5,8 9,7 1,1 1,1 0,0 3,0 14,4 14,4 0,5 0,0 0,0 191,1 19,6 4,4 
Fate Sees_214 1,42 43,77 7,6 7,9 12,8 1,9 4,0 6 4,9 26,3 11,3 0,0 4,4 2,2 34,6 3,2 0,0 
Fate Sees_226 4,35 17,62 8,9 8,5 17,7 5,0 1,6 0,0 18,1 16,0 1,7 0,0 0,0 0,0 0,0 0,0 55,6 
Fate Sees_227 0,47 0,75 0,0 3,8 3,6 0,7 0,0 14 0,0 0,0 34,6 17,4 0,0 0,0 0,0 0,0 0,0 
Fate Sees_228 1,06 6,14 5,7 3,0 10,1 2,0 4,1 59 0,0 4,1 166,3 394,8 10,4 109,8 83,6 10,7 131,0 
Fate Sees_229 0,56 3,03 0,0 3,4 4,7 1,3 2,2 33 0,0 4,3 106,4 494,8 13,1 26,7 0,0 6,7 87,1 
Fate Sees_233 6,57 35,31 7,8 7,6 29,7 4,0 6,4 14 34,6 32,2 34,1 323,0 106,8 86,2 0,0 7,8 35,6 
Fate Sees_235 5,47 13,45 24,9 12,7 33,6 3,6 4,2 132 770,1 738,0 23,3 157,5 209,4 14,3 0,0 0,0 0,0 
Fate Sees_236 7,09 31,12 10,7 13,8 39,7 3,9 1,8 18 36,3 42,0 50,5 31,4 89,4 2,3 0,0 27,7 29,4 
Fate Sees_239 3,11 18,01 4,9 4,2 12,4 2,9 4,1 21 21,1 54,7 30,1 310,3 530,2 80,7 0,0 6,8 3,5 
Fate Sees_242 5,13 13,73 0,0 5,2 15,6 3,4 3,4 0,0 3,2 8,1 37,2 96,5 513,4 0,0 0,0 12,5 16,6 
Fate Sees_243 6,13 34,37 11,6 8,1 26,1 2,4 5,7 0,0 10,5 26,3 41,0 783,8 278,0 70,8 0,0 7,8 0,0 
Fate Sees_245 2,10 100,3 11,4 2,7 11,1 0,0 2,2 0,0 1,0 4,5 15,4 61,1 172,9 12,1 0,0 2,8 0,0 
Fate Sees_247 9,84 45,29 17,4 8,1 26,9 3,9 7,4 62 21,0 28,5 59,4 100,5 100,6 0,0 0,0 18,9 25,5 
Fate Sees_248 8,55 25,83 13,5 10,6 61,7 4,9 15,7 47 8,2 9,8 38,3 103,2 188,8 50,3 0,0 8,6 22,6 
Fate Sees_250 1,59 6,25 5,7 0,0 12,9 2,2 4,2 28 6,6 13,5 138,0 125,9 261,2 18,2 0,0 14,8 77,2 
Fate Sees_252  0,00                
Fate Sees_253 12,88 4,89 0,0 2,1 2,0 0,0 1,7 0,0 0,0 1,7 59,6 0,0 0,0 0,0 0,0 27,2 205,0 
Fate Sees_254 3,88 40,55 0,0 3,7 7,0 1,4 2,9 0,0 1,2 13,1 82,9 19,0 8,5 12,3 93,6 15,6 1889,5 
Fate Sees_256 1,69 19,27 7,8 3,8 22,3 3,3 1,9 65 2,2 5,4 133,5 74,4 6,0 0,0 0,0 0,0 53,0 
Fate Sees_257 5,26 13,33 0,0 3,4 9,5 2,5 3,2 0,0 1,6 3,6 33,2 648,8 1057,5 70,8 0,0 4,5 0,0 
Fate Sees_258 6,10 22,87 9,3 6,1 30,1 6,0 18,6 9 7,4 26,0 24,6 265,9 354,0 0,0 0,0 0,0 0,0 
Fate Sees_259 5,56 6,73 0,0 4,6 3,6 0,9 0,0 0,0 0,0 1,4 102,5 9,0 0,0 6,8 385,9 55,4 29,9 
Fate Sees_260 1,11 41,50 6,1 7,9 10,2 1,2 5,4 0,0 2,5 8,6 0,0 1,1 0,0 13,6 130,8 29,8 75,1 
Fate Sees_261 0,53 28,04 3,2 6,9 11,7 1,1 3,9 0,0 1,3 5,3 19,4 1,1 47,5 1,3 239,7 63,2 311,1 
Fate Sees_262 0,50 21,77 14,4 20,1 35,9 8,1 7,2 3 10,1 44,5 13,1 3,9 10,2 7,1 77,2 5,3 0,0 
Fate Sees_263 0,33 24,55 4,5 4,6 8,3 0,0 2,6 0,0 2,0 4,2 7,8 14,1 3,8 4,5 133,1 0,0 6,9 
Fate Sees_264 0,61 36,60 4,2 4,8 7,5 1,4 1,0 0,0 3,2 15,3 18,7 1,5 10,4 2,5 221,9 17,5 0,0 
Fate Sees_265 1,35 51,19 0,0 2,4 7,3 1,3 2,0 0,0 0,9 3,0 40,6 1,3 0,0 1,0 147,1 27,9 41,3 
Fate Sees_266 0,87 61,25 0,0 5,7 5,7 1,1 1,2 0,0 10,1 14,9 20,6 1,9 0,0 0,0 52,2 0,0 0,0 
Fate Sees_267 0,65 27,19 6,6 3,6 13,8 1,9 2,3 0,0 4,1 19,9 0,0 0,0 7,7 0,0 71,8 13,3 93,0 
Fate Sees_268 0,91 38,29 7,8 9,7 17,2 2,0 6,0 3 4,2 18,1 43,7 0,0 12,3 2,1 156,3 0,0 0,0 
 

















































































































































































LOQ [ng/l] 1 1 1 4 5 5 2 5 2 0.05 g/L 0.05 g/L 0.05 g/L 0.05 g/L 0.05 g/L 1.9 1.05 5 
Fate Sees_136 9,6 112,1 0,0 46,5 0,0 104,2 0,0 50,0 0,0 0,55 0,75         < 0,05         < 0,05 0,19 58,35 33,5 97% 
Fate Sees_137 44,6 272,3 0,0 0,0 0,0 57,9 0,0 0,0 0,0 1,6 0,28         < 0,05         < 0,05 1,2 41,05 51,4 98% 
Fate Sees_138 0,0 3,1 0,0 0,0 0,0 27,7 0,0 0,0 0,0         
Fate Sees_139 0,9 0,0 0,0 33,4 0,0 41,4 0,0 10,8 0,0         
Fate Sees_140 5,6 0,0 0,0 0,0 0,0 63,9 0,0 23,9 0,0         
Fate Sees_141 343,5 17,9 3,7 176,8 4,0 114,9 0,0 25,7 0,0         
Fate Sees_142 124,6 12,8 0,0 163,5 0,0 167,2 127,0 13,3 0,0         
Fate Sees_143 0,0 0,0 5,4 0,0 8,9 31,8 16,3 68,9 0,0         < 0,05         < 0,05 0,1         < 0,05         < 0,05 2,30 1,5 32% 
Fate Sees_144 38,4 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 43,90 52,5 98% 
Fate Sees_145 0,0 0,0 1,4 97,5 0,0 14,5 0,0 59,9 0,0         < 0,05         < 0,05         < 0,05         < 0,05 0,72 1,80 2,0 51% 
Fate Sees_146 0,0 1,2 12,2 0,0 0,0 0,0 0,0 38,6 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 5,65 9,4 89% 
Fate Sees_147 1,5 1,1 0,0 0,0 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05 0,9         < 0,05 0,35 82,15 3,5 71% 
Fate Sees_148 0,0 0,0 220,0 16,7 186,3 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 56,35 20,6 95% 
Fate Sees_149 2,8 17,3 0,0 84,9 0,0 82,4 0,0 79,6 0,0         < 0,05 0,44 9,6         < 0,05 5,8 115,00 70,5 99% 
Fate Sees_150 196,9 0,0 104,0 0,0 107,2 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 102,90 4,9 80% 
Fate Sees_151 0,0 0,0 28,9 0,0 9,5 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 83,55 3,9 74% 
Fate Sees_152 0,0 0,0 22,3 18,5 97,9 0,0 8,9 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 125,10 1,5 34% 
Fate Sees_153 0,0 0,0 0,0 4258,6 0,0 599,6 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 46,05 1,0 < 5% 
Fate Sees_155 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 54,15 1,5 33% 
Fate Sees_156 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 58,50 8,1 88% 
Fate Sees_157 3,1 4,9 20,4 0,0 57,3 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 35,00 1,3 24% 
Fate Sees_158 0,0 4,1 0,0 0,0 0,0 20,1 4,6 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 17,35 18,5 95% 
Fate Sees_159 0,0 0,0 0,0 0,0 0,0 132,8 0,0 473,5 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 34,45 1,9 46% 
Fate Sees_160 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 16,90 2,4 58% 
Fate Sees_161 0,0 0,0 7,2 0,0 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 15,70 185,8 99% 
Fate Sees_162 0,0 0,0 22,0 0,0 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 15,90 4,7 79% 
Fate Sees_163 0,0 0,0 2,5 0,0 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 17,45 21,5 95% 
Fate Sees_164 19,8 0,0 17,0 23,9 0,0 0,0 0,0 0,0 0,0 5,2         < 0,05         < 0,05         < 0,05         < 0,05 218,75 23,6 96% 
Fate Sees_165 0,0 0,0 12,0 0,0 15,8 0,0 0,0 0,0 0,0 1,7         < 0,05         < 0,05         < 0,05         < 0,05 154,05 95,5 99% 
Fate Sees_166 2,6 2,1 0,0 26,2 0,0 0,0 11,6 0,0 0,0 0,31         < 0,05 0,11         < 0,05 0,44 418,90 87,9 99% 
Fate Sees_167 0,0 5,0 2,5 16,7 18,1 0,0 3,0 0,0 0,0 3,7         < 0,05         < 0,05         < 0,05 0,09 389,45 18,0 94% 
Fate Sees_168 2,2 0,0 3,4 0,0 0,0 576,3 0,0 0,0 0,0 0,64         < 0,05         < 0,05         < 0,05         < 0,05 154,75 9,0 89% 
Fate Sees_169 0,0 102,2 16,9 0,0 0,0 0,0 0,0 0,0 0,0         < 0,05 0,25 1,1 0,65 1,3 49,60 60,5 98% 
Fate Sees_170 6,8 12,0 0,0 0,0 0,0 37,2 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 710,50 107,5 99% 
Fate Sees_171 9,9 0,0 0,0 0,0 0,0 14,1 0,0 0,0 0,0 0,5         < 0,05 0,25         < 0,05         < 0,05 23,55 7,6 87% 
Fate Sees_175 0,0 0,0 0,0 10,4 0,0 68,6 0,0 0,0 0,0 5,8         < 0,05 0,84         < 0,05         < 0,05 65,10 1,0 < 5% 
Fate Sees_177 0,0 0,0 0,0 4,2 0,0 1300,8 0,0 227,8 0,0 0,6         < 0,05 0,24         < 0,05         < 0,05 55,60 1,0 < 5% 
Fate Sees_179 77,6 0,0 0,0 0,0 0,0 12,3 0,0 0,0 0,0 0,15         < 0,05         < 0,05         < 0,05         < 0,05 100,45 98,2 99% 
Fate Sees_180 34,5 33,9 3,5 0,0 124,3 0,0 9,1 0,0 0,0 0,23         < 0,05         < 0,05         < 0,05         < 0,05 95,00 36,1 97% 
Fate Sees_181 30,4 84,3 0,0 9,7 8,2 0,0 0,0 0,0 0,0 0,3         < 0,05         < 0,05         < 0,05         < 0,05 232,40 33,5 97% 
Fate Sees_182 18,4 51,1 0,0 0,0 19,1 13,4 28,7 0,0 0,0 0,15         < 0,05         < 0,05         < 0,05         < 0,05 207,55 21,3 95% 
Fate Sees_183 0,0 6,6 0,0 30,7 0,0 0,0 0,0 0,0 0,0 1,1         < 0,05 0,39 0,16 0,36 789,40 78,8 99% 
Fate Sees_184 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 2,6         < 0,05         < 0,05 0,09         < 0,05 204,20 175,9 99% 
Fate Sees_189 0,0 0,0 6,3 0,0 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 2,50 1,6 39% 
Fate Sees_190 8,2 0,0 0,0 22,7 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05 0,06         < 0,05 0,17 92,00 47,6 98% 
Fate Sees_191 9,0 7,1 0,0 0,0 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 33,90 18,8 95% 
Fate Sees_193 0,0 3,2 0,0 0,0 0,0 0,0 0,0 57,7 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 10,65 13,8 93% 
Fate Sees_194 35,3 11,9 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,38 0,07         < 0,05         < 0,05 14 66,40 83,3 99% 
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Fate Sees_195 0,0 123,1 0,0 227,8 17,0 0,0 0,0 0,0 0,0 0,87 0,65         < 0,05 0,31 0,22 32,55 3,6 72% 
Fate Sees_196 0,0 33,7 0,0 99,5 6,5 0,0 0,0 0,0 0,0 0,77         < 0,05         < 0,05         < 0,05 0,72 3,00 2,0 49% 
Fate Sees_198 32,8 0,0 0,0 57,7 0,0 0,0 61,7 0,0 0,0 0,17         < 0,05 0,09 0,1         < 0,05 20,95 12,9 92% 
Fate Sees_199 34,0 14,1 0,0 25,1 30,1 0,0 0,0 0,0 0,0 1,7         < 0,05 0,55 1,2         < 0,05 118,20 70,0 99% 
Fate Sees_202 81,3 29,1 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,29         < 0,05         < 0,05         < 0,05 0,3 58,15 274,7 100% 
Fate Sees_203 56,5 0,0 4,2 0,0 37,5 56,1 0,0 41,6 10,2 0,06         < 0,05 12 6,1         < 0,05 24,70 21,7 95% 
Fate Sees_204 153,0 7,2 3,5 26,9 15,0 0,0 0,0 0,0 0,0 0,42 7,7         < 0,05 0,63         < 0,05 274,65 418,3 100% 
Fate Sees_205 127,8 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,1         < 0,05         < 0,05 0,8         < 0,05 25,05 4,9 79% 
Fate Sees_208 1,0 286,0 0,0 0,0 0,0 0,0 7,6 0,0 0,0 8,4         < 0,05         < 0,05         < 0,05 5,9 19,25 22,3 96% 
Fate Sees_209 10,0 3618,5 0,0 238,2 0,0 0,0 30,7 0,0 0,0         < 0,05         < 0,05         < 0,05 0,15 0,23 33,60 12,2 92% 
Fate Sees_210 92,6 657,0 0,0 0,0 0,0 72,0 36,3 110,6 4,7         < 0,05         < 0,05         < 0,05         < 0,05 2 3,50 1,2 17% 
Fate Sees_211 9,0 74,2 1,1 0,0 9,1 34,1 0,0 98,6 0,0         
Fate Sees_214 4,3 1,1 2,3 0,0 28,3 36,6 7,6 11,7 0,0         
Fate Sees_226 2,2 1091,7 4,0 0,0 0,0 44,9 3,3 0,0 0,0 0,08 0,33 0,33 0,33 0,45 230,85 1,2 15% 
Fate Sees_227 0,0 0,0 5,4 20,5 0,0 0,0 0,0 0,0 0,0 0,11         < 0,05         < 0,05         < 0,05         < 0,05 16,10 6,3 84% 
Fate Sees_228 0,0 0,0 23,7 18,4 0,0 74,6 5,8 0,0 0,0         < 0,05 0,29         < 0,05         < 0,05 6,6 16,75 14,7 93% 
Fate Sees_229 0,0 0,0 1,3 0,0 0,0 0,0 0,0 0,0 0,0 0,64 0,22         < 0,05         < 0,05 1,4 46,55 15,7 94% 
Fate Sees_233 10,8 94,9 0,0 71,7 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05 0,09         < 0,05 0,09 121,95 14,5 93% 
Fate Sees_235 3,3 222,2 0,0 0,0 0,0 11,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05 0,09 43,65 16,0 94% 
Fate Sees_236 23,2 507,9 2,4 0,0 0,0 0,0 0,0 0,0 0,0 0,64 0,23         < 0,05         < 0,05 1,3 210,65 76,5 99% 
Fate Sees_239 11,5 45,3 109,5 50,5 0,0 0,0 0,0 0,0 0,0         < 0,05 0,26         < 0,05         < 0,05         < 0,05 90,05 9,0 89% 
Fate Sees_242 2,8 148,1 20,5 61,1 0,0 0,0 21,7 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05 1 222,95 25,6 96% 
Fate Sees_243 4,8 60,3 5,5 30,1 10,5 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 237,40 178,4 99% 
Fate Sees_245 0,0 0,0 36,2 0,0 0,0 71,1 0,0 11,2 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 227,20 54,9 98% 
Fate Sees_247 30,3 956,4 0,0 109,3 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 84,10 34,2 97% 
Fate Sees_248 2,5 67,7 3,4 0,0 3,8 0,0 0,0 0,0 0,0 0,18         < 0,05         < 0,05         < 0,05 0,64 114,65 59,6 98% 
Fate Sees_250 97,6 31,5 0,0 29,1 19,0 14,8 44,8 0,0 0,0 0,74 0,08 0,81         < 0,05         < 0,05 441,05 77,4 99% 
Fate Sees_252                  
Fate Sees_253 0,0 0,0 0,0 197,2 20,1 21,9 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 15,70 1,0 < 5% 
Fate Sees_254 103,0 500,0 0,0 117,8 0,0 54,8 26,2 0,0 0,0         
Fate Sees_256 27,9 0,0 0,0 13,2 0,0 0,0 0,0 0,0 0,0 1,6         < 0,05         < 0,05         < 0,05         < 0,05 58,70 5,6 82% 
Fate Sees_257 9,7 805,8 0,0 67,1 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 145,60 6,5 85% 
Fate Sees_258 3,7 429,4 3,4 0,0 0,0 0,0 0,0 0,0 0,0         < 0,05         < 0,05         < 0,05         < 0,05         < 0,05 304,45 48,5 98% 
Fate Sees_259 78,6 975,9 5,7 208,4 0,0 0,0 10,5 0,0 0,0 2,9         < 0,05         < 0,05         < 0,05 150 49,50 1,0 < 5% 
Fate Sees_260 87,6 79,9 7,4 0,0 0,0 25,9 0,0 7,3 8,9         
Fate Sees_261 9,6 58,1 12,8 0,0 0,0 139,3 5,2 54,4 0,0         
Fate Sees_262 7,0 46,4 3,8 0,0 3,6 30,2 0,0 0,0 0,0         
Fate Sees_263 2,5 50,9 16,1 0,0 0,0 27,5 0,0 121,9 0,0         
Fate Sees_264 40,6 67,6 8,8 0,0 3,1 5,4 2,1 0,0 0,0         
Fate Sees_265 0,0 1,4 0,0 17,3 0,0 192,8 0,0 13,2 0,0         
Fate Sees_266 10,9 276,7 11,9 0,0 0,0 0,0 0,0 0,0 0,0         
Fate Sees_267 15,7 107,1 2,4 0,0 0,0 0,0 5,6 63,4 0,0         
























































































































































































LOQ [ng/l] 0.04 0.04 1 5 1 1 1 1 3 1 1 1 3 5 3 3 5 2 3 3 
Fate Sees_136 0,85 1,76 88 2541 275 115 22 4 0,0 0,0 0,0 5 0,0 0,0 6 0,0 0,0 0,0 0,0 0,0 
Fate Sees_137 1,49 1,37 629 169 1443 94 12 0,0 0,0 2 0,0 366 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_138 0,60 1,64 67 111 487 41 3 0,0 0,0 2 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_139 4,22 4,43 199 3002 1656 174 368 7 0,0 4 270 16 0,0 0,0 8 0,0 0,0 0,0 0,0 0,0 
Fate Sees_140 1,97 1,46 44 93 1136 131 10 75 126 2 1 2 0,0 5 73 0,0 0,0 0,0 0,0 0,0 
Fate Sees_141 0,16 0,27 478 73 2177 4 0,0 0,0 0,0 2 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_142 0,19 0,31 12 14 4609 0,0 0,0 0,0 0,0 1 0,0 0,0 0,0 0,0 27 0,0 0,0 0,0 0,0 0,0 
Fate Sees_143 3,92 2,56 1050 9 538 119 107 38 194 8 1 2 45 0,0 0,0 14 0,0 0,0 0,0 0,0 
Fate Sees_144 1,10 2,90 148 8 1021 82 7 63 0,0 2 1 5 55 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_145 2,91 1,50 275 27 1481 180 49 13 59 5 3 3 0,0 0,0 0,0 0,0 49 0,0 0,0 0,0 
Fate Sees_146 2,62 1,69 257 7 979 257 44 8 87 9 12 5 0,0 0,0 0,0 8 0,0 0,0 0,0 0,0 
Fate Sees_147 4,99 2,21 58 19 906 623 26 51 125 21 10 4 75 36 0,0 3 0,0 0,0 0,0 0,0 
Fate Sees_148 2,77 3,04 265 0,0 1051 100 11 39 17 14 55 4 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_149 6,53 3,91 959 28 879 453 346 59 302 6 6 4 54 0,0 55 14 0,0 0,0 0,0 0,0 
Fate Sees_150 0,52 1,38 355 0,0 81 0,0 0,0 0,0 0,0 21 2 5 0,0 0,0 0,0 0,0 0,0 42 0,0 0,0 
Fate Sees_151 0,17 7,26 23 66 0,0 0,0 0,0 127 0,0 37 3 3 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_152 1,04 18,48 11 1518 0,0 0,0 1077 29 0,0 19 2 4 0,0 0,0 15 0,0 0,0 0,0 184 0,0 
Fate Sees_153 0,00 0,74 8 85 0,0 0,0 22 0,0 28 4 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_155 0,38 0,00 55 0,0 281 0,0 0,0 10 88 0,0 0,0 0,0 0,0 0,0 21 0,0 0,0 0,0 0,0 0,0 
Fate Sees_156 0,23 1,96 26 30 0,0 0,0 0,0 53 54 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_157 0,00 0,01 8 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_158 2,18 14,49 158 126 373 0,0 60 115 78 11 35 6 0,0 0,0 112 0,0 59 0,0 0,0 0,0 
Fate Sees_159 0,65 24,32 12 123 0,0 0,0 0,0 25 0,0 0,0 4 0,0 0,0 0,0 17 0,0 0,0 0,0 0,0 0,0 
Fate Sees_160 3,80 3,83 8 838 26 0,0 0,0 3 121 0,0 0,0 0,0 89 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_161 221,17 0,29 25 760 0,0 0,0 0,0 10 0,0 8 0,0 0,0 155 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_162 0,04 0,29 15 0,0 0,0 0,0 0,0 13 0,0 0,0 0,0 3 0,0 0,0 0,0 0,0 0,0 0,0 0,0 3 
Fate Sees_163 0,00 0,70 17 11 29 8 0,0 122 0,0 2 1 2 21 141 0,0 0,0 17 0,0 27 3 
Fate Sees_164 0,05 0,04 5 11 0,0 0,0 3 5 28 2 0,0 0,0 68 0,0 0,0 0,0 0,0 0,0 0,0 18 
Fate Sees_165 3,17 0,78 1346 144 1146 46 47 55 0,0 7 0,0 2 0,0 0,0 19 0,0 0,0 0,0 0,0 0,0 
Fate Sees_166 2,45 1,32 187 112 1282 288 82 38 32 6 2 17 0,0 28 49 0,0 0,0 0,0 0,0 0,0 
Fate Sees_167 7,52 2,55 74 692 1624 86 53 0,0 67 3 0,0 30 0,0 48 0,0 0,0 0,0 6 0,0 0,0 
Fate Sees_168 2,55 2,52 393 32 2209 87 49 33 0,0 3 4 3 0,0 0,0 37 0,0 19 5 9 0,0 
Fate Sees_169 14,06 9,85 1858 112 1323 66 39 19 58 5 3 3 0,0 60 11 0,0 0,0 0,0 0,0 0,0 
Fate Sees_170 4,54 2,81 331 35 692 328 10 1 6 7 18 7 45 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_171 3,39 2,05 15791 387 891 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 6 0,0 0,0 
Fate Sees_175 3,77 2,82 3932 22 709 28 0,0 23 48 20 0,0 0,0 0,0 37 0,0 0,0 0,0 4 0,0 0,0 
Fate Sees_177 2,35 2,39 104 100 815 105 0,0 0,0 0,0 4 2 8 0,0 13 0,0 0,0 0,0 2 5 0,0 
Fate Sees_179 14,81 1,80 52 13 541 113 4 0,0 0,0 4 2 4 94 0,0 10 0,0 0,0 0,0 11 0,0 
Fate Sees_180 4,22 4,57 2913 26 1144 21 14 0,0 0,0 0,0 0,0 0,0 58 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_181 2,54 1,88 1058 53 718 86 8 0,0 48 0,0 0,0 2 22 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_182 5,33 3,76 1091 75 666 33 0,0 0,0 143 0,0 0,0 0,0 0,0 80 0,0 0,0 0,0 4 0,0 0,0 
Fate Sees_183 2,96 3,18 243 13 690 46 10 0,0 13 0,0 2 0,0 25 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_184 0,96 1,14 953 0,0 419 70 7 0,0 422 5 0,0 4 0,0 113 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_189 0,19 0,06 374 6 0,0 0,0 0,0 0,0 98 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_190 4,05 1,39 650 46 84 884 17 6 0,0 2 39 391 0,0 0,0 0,0 0,0 0,0 0,0 34 0,0 
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Fate Sees_191 9,00 2,32 73 7 230 591 46 19 0,0 11 50 23 59 0,0 14 0,0 0,0 0,0 0,0 0,0 
Fate Sees_193 6,18 3,19 111 34 604 210 21 4 56 6 19 58 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_194 7,46 1,53 2 53 340 218 8 7 0,0 4 14 22 30 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_195 12,94 3,59 510 67 648 433 16 38 21 5 6 40 0,0 16 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_196 2,55 3,23 1098 45 837 65 66 0,0 0,0 4 0,0 11 0,0 106 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_198 7,18 5,51 949 196 1378 90 97 0,0 4 0,0 0,0 9 0,0 33 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_199 9,05 3,23 237 12 856 22 22 14 101 0,0 11 25 35 0,0 9 0,0 0,0 0,0 0,0 0,0 
Fate Sees_202 14,67 3,34 285 12 606 35 21 19 0,0 2 4 9 0,0 0,0 25 0,0 0,0 0,0 0,0 0,0 
Fate Sees_203 16,11 2,39 502 14 734 22 19 11 20 2 21 5 0,0 0,0 50 7 3265 0,0 0,0 0,0 
Fate Sees_204 6,08 1,97 120 25 578 60 23 14 88 3 23 5 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_205 11,07 4,17 167 518 969 44 17 7 0,0 4 14 12 0,0 0,0 0,0 0,0 0,0 0,0 13 0,0 
Fate Sees_208 14,31 3,06 117 12 2678 15 33 3 0,0 26 4 13 0,0 0,0 0,0 10 0,0 0,0 0,0 0,0 
Fate Sees_209 2,68 2,10 253 14 303 141 192 994 493 3 1 12 0,0 142 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_210 4,62 7,85 192 30 317 38 1426 733 535 0,0 4 33 0,0 30 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_211 3,88 2,46 88 18 161 645 517 2411 1531 0,0 2 14 0,0 689 0,0 81 0,0 0,0 0,0 0,0 
Fate Sees_214 0,75 1,35 49 64 1142 59 13 0,0 0,0 18 0 5 131 26 55 0,0 0,0 0,0 3 0,0 
Fate Sees_226 0,87 0,43 34 9 155 52 2 2 79 1 0,0 3 51 15 5 5 0,0 0,0 0,0 0,0 
Fate Sees_227 1,15 0,70 358 162 425 30 5 0,0 314 2 0,0 366 0,0 107 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_228 0,58 0,38 19 20 236 194 0,0 0,0 122 0,0 0,0 5 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_229 1,90 2,13 1798 82 1233 223 4 2 11 3 2 28 29 40 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_233 0,43 0,47 3 20 781 106 38 1 0,0 0,0 0,0 16 0,0 151 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_235 4,20 2,85 567 32 1254 152 7 2 119 0,0 0,0 6 0,0 18 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_236 2,98 2,06 139 37 747 70 6 5 11 0,0 0,0 18 0,0 353 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_239 9,71 2,60 409 65 1392 398 4 2 0,0 0,0 3 5 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_242 5,19 3,32 490 47 965 187 13 299 48 0,0 1 6 15 12 289 0,0 199 0,0 0,0 16 
Fate Sees_243 4,99 2,64 560 152 1774 190 39 85 130 0,0 15 15 0,0 0,0 53 0,0 0,0 0,0 0,0 0,0 
Fate Sees_245 6,60 3,96 518 34 1176 152 30 95 15 2 27 16 0,0 0,0 28 0,0 0,0 0,0 0,0 0,0 
Fate Sees_247 0,98 0,34 76 54 690 3 0,0 0,0 0,0 4 0,0 1 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_248 10,86 6,48 1575 42 1549 405 43 17 0,0 0,0 0,0 30 41 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_250 3,71 2,37 289 19 1620 167 11 0,0 47 2 0,0 5 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_252 18,43 8,65 491 0,0 1979 242 22 520 63 0,0 201 4 40 0,0 18 0,0 0,0 0,0 0,0 0,0 
Fate Sees_253                     
Fate Sees_254 0,10 0,82 9658 254 13 0,0 0,0 2 174 2 0,0 0,0 0,0 66 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_256 0,88 1,04 1 1148 972 62 0,0 0,0 0,0 0,0 0 0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_257 6,59 2,14 765 144 1539 1147 0,0 67 18 3 0,0 3 0,0 0,0 113 0,0 0,0 0,0 0,0 0,0 
Fate Sees_258 4,23 2,46 544 18 1318 170 17 1704 0,0 0,0 0,0 105 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_259 4,81 1,94 410 21 1119 229 18 22 0,0 3 2 13 0,0 0,0 0,0 0,0 0,0 0,0 0,0 3 
Fate Sees_260 4,64 2,63 248 28 885 756 120 20 0,0 0,0 0,0 70 0,0 0,0 20 0,0 0,0 0,0 0,0 0,0 
Fate Sees_261 0,90 0,85 100 16 856 34 3 1 0,0 2 0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_262 0,31 1,06 58 71 767 46 14 0,0 0,0 3 0,0 1 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_263 1,04 1,48 276 99 1046 180 75 0,0 0,0 1 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_264 0,27 1,44 9 12 508 0,0 14 1 0,0 1 0,0 0,0 0,0 0,0 0,0 0,0 0,0 6 0,0 0,0 
Fate Sees_265 0,50 0,83 39 77 444 42 5 1 24 3 1 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_266 0,68 0,86 67 12 757 21 2 0 0,0 2 0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 
Fate Sees_267 0,64 1,24 99 1588 900 68 6 0,0 14 2 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0 

























































































































































































30 50 50 50 25 25 50 10 15 20 20 30 50 10 20 20 15 15 
Fate Sees_136 <30 <50 <50 <50 <25 <25 <50 <10 <15 44 <20 <30 <50 <10 <20 <20 62 24 
Fate Sees_137 <30 <50 <50 <50 <30 <25 <50 <10 <15 <20 164 <30 <50 37 <20 <20 52 <15 
Fate Sees_138 <30 <50 <50 <50 <25 <25 <50 <15 <50  <20 <30 <50 <10 <20 <20 <15 <15 
Fate Sees_139                   
Fate Sees_140 <30 <50 <50 <50 <25 <25 <50 <15 <50  32 <30 <50 24 <20 <20 <15 <15 
Fate Sees_141                   
Fate Sees_142 <30 <50 <50 -- <25 <25 <50 <15 <50  <20 <30 <50 11 <20 <20 <15 <15 
Fate Sees_143 <30 <50 95 <50 <25 <25 <50 53 <15 <20 301 <30 <50 436 <20 <20 55 <15 
Fate Sees_144 <30 <50 101 <50 <25 <25 <50 133 <15 <20 171 <30 <50 313 <20 <20 58 <15 
Fate Sees_145 <30 <50 59 -- <25 <25 <50 134 53 <20 343 <30 <50 375 <20 <20 95 <15 
Fate Sees_146 <30 <50 79 <50 <25 <25 <50 89 21 <20 434 <30 <50 244 <20 <20 60 109 
Fate Sees_147 <30 <50 <50 <50 <25 <25 <50 53 317 <20 1690 <30 <50 233 <20 <20 74 <15 
Fate Sees_148 <30 <50 <50 <50 <25 <25 <50 132 198 <20 47 <30 <50 25 <20 <20 96 <15 
Fate Sees_149 <30 <50 <50 <50 <25 <25 <50 211 <15 <20 616 <30 <50 552 <20 <20 61 <15 
Fate Sees_150                   
Fate Sees_151                   
Fate Sees_152                   
Fate Sees_153                   
Fate Sees_155                   
Fate Sees_156                   
Fate Sees_157                   
Fate Sees_158                   
Fate Sees_159                   
Fate Sees_160                   
Fate Sees_161                   
Fate Sees_162                   
Fate Sees_163                   
Fate Sees_164                   
Fate Sees_165                   
Fate Sees_166                   
Fate Sees_167                   
Fate Sees_168                   
Fate Sees_169 <30 <50 101 <50 <25 <25 <50 19 <15 <20 633 105 <50 723 <20 <20 235 92 
Fate Sees_170                   
Fate Sees_171                   
Fate Sees_175                   
Fate Sees_177                   
Fate Sees_179                   
Fate Sees_180                   
Fate Sees_181                   
Fate Sees_182                   
Fate Sees_183                   
Fate Sees_184                   
Fate Sees_189                   
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Fate Sees_190                   
Fate Sees_191                   
Fate Sees_193                   
Fate Sees_194 <30 <50 62 <50 <25 <25 <50 125 <15 <20 448 <30 <50 310 <20 <20 195 112 
Fate Sees_195 <30 <50 <50 <50 <25 <25 <50 37 <15 <20 96 <30 <50 561 <20 <20 124 19 
Fate Sees_196 <30 <50 <50 <50 <25 <25 <50 39 <15 <20 81 <30 <50 440 <20 <20 217 57 
Fate Sees_198                   
Fate Sees_199                   
Fate Sees_202                   
Fate Sees_203 <30 <50 <50 <50 <25 <25 <50 129 104 <20 109 <30 <50 176 <20 <20 104 <15 
Fate Sees_204 <30 <50 <50 <50 <25 <25 <50 277 <15 <20 60 <30 <50 180 <20 <20 117 <15 
Fate Sees_205 <30 <50 <50 <50 <25 <25 <50 147 22 <20 31 <30 <50 208 <20 <20 115 <15 
Fate Sees_208 <30 <50 97 -- <25 <25 <50 10 <15 <20 195 <30 <50 75 <20 <20 96 77 
Fate Sees_209 <30 <50 86 <50 <25 <25 <50 79 <15 29 <20 <30 <50 47 <20 <20 265 149 
Fate Sees_210 <30 <50 122 <50 <25 <25 <50 187 29 <20 1183 <30 <50 800 <20 <20 189 <15 
Fate Sees_211                   
Fate Sees_214                   
Fate Sees_226 <30 <50 59 <50 <25 <25 <50 17 28 24 101 <30 <50 76 <20 <20 59 <15 
Fate Sees_227 <30 <50 <50 <50 <25 <25 <50 17 17 <20 388 <30 <50 149 <20 <20 91 <15 
Fate Sees_228 <30 <50 <50 <50 <25 <25 93 26 128 <20 228 <30 <50 141 <20 <20 87 <15 
Fate Sees_229 <30 <50 <50 <50 <25 <25 <50 <10 <15 <20 164 <30 <50 120 26 <20 49 42 
Fate Sees_233                   
Fate Sees_235                   
Fate Sees_236 <30 <50 <50 <50 <25 <25 <50 91 <15 <20 564 <30 <50 207 <20 <20 71 199 
Fate Sees_239                   
Fate Sees_242                   
Fate Sees_243                   
Fate Sees_245                   
Fate Sees_247                   
Fate Sees_248 <30 <50 <50 <50 <25 <25 <50 109 18 <20 202 <30 <50 204 <20 <20 77 340 
Fate Sees_250                   
Fate Sees_252                   
Fate Sees_253                   
Fate Sees_254 <30 <50 <50 <50 <25 <25 <50 <15 <50  122 <30 <50 104 <20 <20 119 <15 
Fate Sees_256                   
Fate Sees_257                   
Fate Sees_258                   
Fate Sees_259 <30 <50 <50 <50 <25 <25 <50 <15 <50  <20 <30 <50 99 <20 <20 66 <15 
Fate Sees_260                   
Fate Sees_261                   
Fate Sees_262                   
Fate Sees_263                   
Fate Sees_264                   
Fate Sees_265                   
Fate Sees_266                   
Fate Sees_267                   



































































































































































































0,055 0,01 0,035 0,01 0,02 0,005 0,005 0,015 0,015 0,005 0,015 0,005 
Fate Sees_136             
Fate Sees_137 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   < 0,030  n.n.   n.n.   n.n.   
Fate Sees_138 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,013 n.n.   0,038 n.n.   n.n.   n.n.   
Fate Sees_139             
Fate Sees_140 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,13 n.n.   0,19 n.n.   < 0,030  n.n.   
Fate Sees_141             
Fate Sees_142 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,19 n.n.   0,26 n.n.   n.n.   < 0,010  
Fate Sees_143 n.n.   n.n.   n.n.   n.n.   < 0,040  n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_144 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_145 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,016 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_146 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_147 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_148 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_149 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_150 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   < 0,010  n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_151 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   < 0,010  n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_152 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,017 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_153 0,28 n.n.   0,68 n.n.   0,11 n.n.   0,062 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_155 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_156 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_157 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_158 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   < 0,030  n.n.   
Fate Sees_159 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_160 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_161 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   < 0,030  n.n.   
Fate Sees_162 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   < 0,010  n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_163 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_164 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,073 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_165 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,035 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_166 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,046 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_167 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,025 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_168 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,021 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_169 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_170 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,075 n.n.   < 0,030  n.n.   n.n.   n.n.   
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Fate Sees_171 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,031 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_175 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,018 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_177 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_179 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,055 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_180 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,024 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_181 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.a.   n.a.   n.a.   n.a.   n.a.   n.a.   
Fate Sees_182 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,033 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_183 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,06 n.n.   0,036 n.n.   n.n.   n.n.   
Fate Sees_184 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,022 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_189 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_190 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,084 n.n.   < 0,030  n.n.   n.n.   n.n.   
Fate Sees_191 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,036 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_193 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,02 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_194 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,014 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_195 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,22 n.n.   0,16 n.n.   < 0,030  n.n.   
Fate Sees_196 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,18 n.n.   0,1 n.n.   n.n.   n.n.   
Fate Sees_198 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_199 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,031 n.n.   0,032 n.n.   n.n.   n.n.   
Fate Sees_202 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_203 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   < 0,030  n.n.   n.n.   n.n.   
Fate Sees_204 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_205 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   < 0,010  n.n.   < 0,030  n.n.   n.n.   n.n.   
Fate Sees_208 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   < 0,010  n.n.   < 0,030  n.n.   n.n.   n.n.   
Fate Sees_209 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,021 n.n.   0,091 n.n.   n.n.   n.n.   
Fate Sees_210 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,03 n.n.   n.n.   n.n.   
Fate Sees_211             
Fate Sees_214             
Fate Sees_226 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,048 n.n.   n.n.   n.n.   
Fate Sees_227 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   < 0,030  n.n.   n.n.   n.n.   
Fate Sees_228 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_229 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   < 0,030  n.n.   n.n.   n.n.   
Fate Sees_233 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,48 n.n.   0,14 n.n.   n.n.   n.n.   
Fate Sees_235 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,11 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_236 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,053 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_239 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,07 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_242 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,071 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_243 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,098 n.n.   n.n.   n.n.   n.n.   < 0,010  
Fate Sees_245 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,074 n.n.   0,099 n.n.   n.n.   n.n.   
Fate Sees_247 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,095 n.n.   < 0,030  n.n.   n.n.   n.n.   
Fate Sees_248 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,13 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_250 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,017 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_252 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,056 n.n.   0,072 n.n.   n.n.   n.n.   
Fate Sees_253 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,018 n.n.   0,032 n.n.   n.n.   n.n.   
Fate Sees_254 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,2 n.n.   0,13 n.n.   0,077 n.n.   
Fate Sees_256 n.n.   n.n.   n.n.   n.n.   < 0,040  n.n.   0,012 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_257 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,11 n.n.   n.n.   n.n.   n.n.   n.n.   
Fate Sees_258 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,067 n.n.   0,032 n.n.   n.n.   n.n.   
Fate Sees_259 n.n.   n.n.   n.n.   n.n.   n.n.   n.n.   0,095 n.n.   0,088 n.n.   n.n.   n.n.   
Fate Sees_260             
Fate Sees_261             
Fate Sees_262             
Fate Sees_263             
Fate Sees_264             
Fate Sees_265             
Fate Sees_266             
Fate Sees_267             















































































































































































































1 1 1 1 1 1 1 1 1 1 
Fate Sees_136 110 330 140 970 73 56 8,7 2,4 <LOQ <LOQ 
Fate Sees_137 150 190 200 1600 190 190 12 2,7 <LOQ <LOQ 
Fate Sees_138 130 89 120 810 420 78 11 3,4 <LOQ <LOQ 
Fate Sees_139            
Fate Sees_140 170 140 2400 1600 610 89 53 9,4 <LOQ <LOQ 
Fate Sees_141            
Fate Sees_142 160 250 400 4300 860 470 180 44 <LOQ <LOQ 
Fate Sees_143 120 260 75 1000 470 20 130 3,7 <LOQ <LOQ 
Fate Sees_144 85 140 270 1400 170 47 34 6,3 <LOQ <LOQ 
Fate Sees_145 110 110 62 700 120 110 18 11 <LOQ <LOQ 
Fate Sees_146 54 64 33 400 120 130 4,3 5,6 <LOQ <LOQ 
Fate Sees_147 76 73 66 940 210 54 21 5,4 <LOQ <LOQ 
Fate Sees_148 75 420 21 900 5,0 230 3,2 13 <LOQ <LOQ 
Fate Sees_149 170 220 90 890 260 230 34 6,6 <LOQ <LOQ 
Fate Sees_150 82 61 58 21000 2,8 9300 11 <LOQ <LOQ <LOQ 
Fate Sees_151 130 910 160 710 21 670 17 7,7 <LOQ <LOQ 
Fate Sees_152 130 68 22 360 24 490 12 9,8 <LOQ <LOQ 
Fate Sees_153 280 760 36 60 10 1400 610 <LOQ <LOQ <LOQ 
Fate Sees_155 130 100 120 5800 9,9 190 71 <LOQ <LOQ <LOQ 
Fate Sees_156 78 83 5,6 40 16 18 12 9,7 <LOQ <LOQ 
Fate Sees_157 87 52 27 170 46 340 7,6 10 <LOQ <LOQ 
Fate Sees_158 79 100 120 450 17 29 51 20 <LOQ <LOQ 
Fate Sees_159 93 58 21 60 22 190 19 7,7 <LOQ <LOQ 
Fate Sees_160 130 140 37 160 15 52 37 21 <LOQ <LOQ 
Fate Sees_161 160 360 200 310 5,6 11 20 6,5 <LOQ <LOQ 
Fate Sees_162 140 74 17 500 16 14 12 5,7 <LOQ <LOQ 
Fate Sees_163 110 480 18 530 210 23 20 5,4 <LOQ <LOQ 
Fate Sees_164 140 210 270 4400 430 650 75 35 <LOQ <LOQ 
Fate Sees_165 64 89 90 410 480 92 10 <LOQ <LOQ <LOQ 
Fate Sees_166 100 66 200 2400 360 70 21 5,2 <LOQ <LOQ 
Fate Sees_167 78 48 310 1900 790 29 150 42 <LOQ <LOQ 
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Fate Sees_168 110 50 47 1200 26 60 19 4,3 <LOQ <LOQ 
Fate Sees_169 150 390 63 1300 330 410 16 5,5 <LOQ <LOQ 
Fate Sees_170 160 290 90 970 150 7900 49 3,2 <LOQ <LOQ 
Fate Sees_171 72 510 18 120 96 7500 16 7,2 <LOQ <LOQ 
Fate Sees_175 110 120 47 490 68 27 17 7,5 <LOQ <LOQ 
Fate Sees_177 100 200 36 400 46 33 6,5 2,3 <LOQ <LOQ 
Fate Sees_179 130 190 75 320 170 89 16 1,8 <LOQ <LOQ 
Fate Sees_180 88 310 110 2000 170 200 6,2 1,0 <LOQ <LOQ 
Fate Sees_181 170 400 85 400 190 4600 15 7,7 <LOQ <LOQ 
Fate Sees_182 170 200 73 370 130 1200 13 5,8 <LOQ <LOQ 
Fate Sees_183 230 890 97 690 90 75 14 32 <LOQ <LOQ 
Fate Sees_184 100 440 120 630 63 10 6,4 6,0 <LOQ <LOQ 
Fate Sees_189 83 110 50 380 28 340 8,4 9,3 <LOQ <LOQ 
Fate Sees_190 120 110 48 610 50 37 24 6,5 <LOQ <LOQ 
Fate Sees_191 120 81 33 510 58 240 17 9,2 <LOQ <LOQ 
Fate Sees_193 100 91 71 1200 57 270 27 4,9 <LOQ <LOQ 
Fate Sees_194 56 310 43 1200 110 1700 51 20 <LOQ <LOQ 
Fate Sees_195 150 180 310 10000 450 84 46 11 <LOQ <LOQ 
Fate Sees_196 140 81 110 990 83 8,5 31 4,3 <LOQ <LOQ 
Fate Sees_198 92 440 200 1100 580 43000 120 1000 <LOQ <LOQ 
Fate Sees_199 340 860 56 320 100 2700 84 5400 <LOQ <LOQ 
Fate Sees_202 260 370 190 270 86 62 16 26 <LOQ <LOQ 
Fate Sees_203 57 120 21 360 58 110 32 11 <LOQ <LOQ 
Fate Sees_204 77 390 50 290 140 230 6,9 43 <LOQ <LOQ 
Fate Sees_205 200 590 200 1100 300 20 33 12 <LOQ <LOQ 
Fate Sees_208 46 230 52 950 120 410 7,4 5,0 <LOQ <LOQ 
Fate Sees_209 580 1100 790 3300 480 1300 110 210 <LOQ <LOQ 
Fate Sees_210 320 330 240 2100 120 42 19 3,3 <LOQ <LOQ 
Fate Sees_211 8,3 8,5 11 150 35 12000 9,2 5,5 <LOQ <LOQ 
Fate Sees_214 8,2 3,7 23 220 46 5400 1,6 2,0 <LOQ <LOQ 
Fate Sees_226 130 260 17 130 52 77 8,5 2,2 <LOQ <LOQ 
Fate Sees_227 73 140 47 200 47 31 10 3,3 <LOQ <LOQ 
Fate Sees_228 220 220 32 440 6,0 72 51 16 <LOQ <LOQ 
Fate Sees_229 110 370 210 470 120 1700 16 3,6 <LOQ <LOQ 
Fate Sees_233 180 230 140 1400 130 180 66 8,6 <LOQ <LOQ 
Fate Sees_235 130 430 71 600 170 100 35 710 <LOQ <LOQ 
Fate Sees_236 140 570 88 1400 200 2100 16 11 <LOQ <LOQ 
Fate Sees_239 94 86 58 620 180 46 6,4 1,0 <LOQ <LOQ 
Fate Sees_242 260 730 170 1600 500 770 38 37 <LOQ <LOQ 
Fate Sees_243 130 750 180 1300 560 250 41 62 <LOQ <LOQ 
Fate Sees_245 140 140 270 2200 290 150 36 16 <LOQ <LOQ 
Fate Sees_247 240 560 120 1100 240 2000 31 46 <LOQ <LOQ 
Fate Sees_248 73 120 180 2100 370 1200 19 4,1 <LOQ <LOQ 
Fate Sees_250 290 1700 160 1100 620 130 45 64 <LOQ <LOQ 
Fate Sees_252 110 150 160 780 71 270 44 8,6 <LOQ <LOQ 
Fate Sees_253 150 340 7,3 54 150 46 15 19 <LOQ <LOQ 
Fate Sees_254 870 330 330 1600 500 13000 95 23 <LOQ <LOQ 
Fate Sees_256 61 130 70 420 26 29 3,2 1,2 <LOQ <LOQ 
Fate Sees_257 130 140 62 470 44 53 7,3 2,5 <LOQ <LOQ 
Fate Sees_258 190 160 110 710 190 56 12 <LOQ <LOQ <LOQ 
Fate Sees_259 310 160 84 940 300 18 29 3,5 <LOQ <LOQ 
Fate Sees_260 5,0 6,2 11 92 28 13000 7,1 6,7 <LOQ <LOQ 
Fate Sees_261 6,0 7,4 23 370 190 9900 5,3 2,2 <LOQ 1,1 
Fate Sees_262 11 10 1,5 25 9,5 2600 2,2 3,0 <LOQ <LOQ 
Fate Sees_263 5,8 3,4 17 98 50 1400 2,1 4,0 <LOQ <LOQ 
Fate Sees_264 1,7 10 4,5 38 12 6700 2,6 2,3 <LOQ <LOQ 
Fate Sees_265 5,1 7,5 27 170 83 19000 7,4 12 <LOQ <LOQ 
Fate Sees_266 7,2 5,5 26 200 64 3100 4,9 1,8 <LOQ 1,3 
Fate Sees_267 6,4 7,5 16 150 35 10000 1,3 3,0 <LOQ <LOQ 






































































































































































0,1 10 5 59 5 0,1 0,1 5 10 0,1 10 5 1 5 0,5 0,5 5 1 
Fate Sees_136 0,3 <LOQ <LOQ <LOQ <LOQ 0,1 2,2 <LOQ <LOQ 0,1 <LOQ <LOQ <LOQ 7,3 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_137 0,6 <LOQ <LOQ <LOQ <LOQ 0,1 11,1 <LOQ <LOQ 0,6 <LOQ <LOQ <LOQ 5,8 <LOQ <LOQ <LOQ 1,7 
Fate Sees_138 0,2 <LOQ <LOQ <LOQ <LOQ <LOQ 12,3 <LOQ <LOQ 0,2 <LOQ <LOQ <LOQ <LOQ <LOQ 0,9 <LOQ <LOQ 
Fate Sees_139                                     
Fate Sees_140 4,0 <LOQ <LOQ <LOQ <LOQ <LOQ 54,3 <LOQ <LOQ 0,1 <LOQ <LOQ <LOQ 28,0 <LOQ 0,7 <LOQ <LOQ 
Fate Sees_141                                     
Fate Sees_142 3,4 <LOQ <LOQ <LOQ <LOQ <LOQ 15,0 <LOQ <LOQ 0,2 <LOQ <LOQ <LOQ 8,4 <LOQ 0,8 <LOQ 1,3 
Fate Sees_143 3,6 <LOQ <LOQ <LOQ <LOQ <LOQ 17,1 <LOQ <LOQ 0,7 <LOQ <LOQ <LOQ 44,4 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_144 3,9 <LOQ <LOQ <LOQ <LOQ <LOQ 18,1 <LOQ <LOQ 1,4 <LOQ <LOQ <LOQ 74,4 <LOQ <LOQ <LOQ 2,6 
Fate Sees_145 0,9 <LOQ <LOQ <LOQ <LOQ <LOQ 3,9 <LOQ <LOQ 0,5 <LOQ <LOQ <LOQ 65,9 <LOQ <LOQ <LOQ 1,5 
Fate Sees_146 0,8 <LOQ <LOQ <LOQ <LOQ <LOQ 8,2 <LOQ <LOQ 0,2 <LOQ <LOQ <LOQ 21,1 <LOQ <LOQ <LOQ 2,2 
Fate Sees_147 0,7 <LOQ <LOQ <LOQ <LOQ <LOQ 23,3 <LOQ <LOQ 0,5 <LOQ <LOQ <LOQ 36,7 <LOQ <LOQ <LOQ 2,5 
Fate Sees_148 0,5 <LOQ <LOQ <LOQ <LOQ 0,1 9,5 <LOQ <LOQ 0,6 <LOQ <LOQ <LOQ 19,1 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_149 1,2 <LOQ <LOQ <LOQ <LOQ <LOQ 36,4 <LOQ <LOQ 1,9 <LOQ <LOQ 1,3 48,9 <LOQ <LOQ <LOQ 1,1 
Fate Sees_150 0,8 25,4 <LOQ <LOQ <LOQ 0,8 0,9 <LOQ 28,6 1,1 <LOQ <LOQ <LOQ 8,5 <LOQ 1,3 40,7 5,3 
Fate Sees_151 <LOQ <LOQ <LOQ <LOQ <LOQ 0,3 0,5 <LOQ <LOQ 0,7 <LOQ <LOQ <LOQ 9,8 <LOQ 0,9 12,2 <LOQ 
Fate Sees_152 0,5 10,6 8,8 <LOQ <LOQ <LOQ 0,7 <LOQ 31,2 1,2 <LOQ 10,4 <LOQ 5,5 <LOQ 3,0 15,8 2,3 
Fate Sees_153 <LOQ 20,5 <LOQ <LOQ <LOQ 2,3 0,2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 10,9 <LOQ 2,6 <LOQ <LOQ 
Fate Sees_155 0,7 <LOQ <LOQ <LOQ <LOQ 0,2 0,5 <LOQ <LOQ 0,8 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_156 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,1 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_157 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 1,4 <LOQ <LOQ 0,2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_158 0,4 <LOQ <LOQ <LOQ <LOQ 0,2 0,7 <LOQ <LOQ 0,2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_159 0,1 <LOQ <LOQ <LOQ <LOQ 0,1 0,9 <LOQ <LOQ 0,4 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 7,7 <LOQ 
Fate Sees_160 0,3 11,4 <LOQ <LOQ <LOQ <LOQ 0,8 <LOQ 259,1 0,2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_161 0,1 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_162 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_163 0,1 <LOQ <LOQ <LOQ <LOQ <LOQ 0,1 <LOQ <LOQ 0,1 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_164 0,1 <LOQ <LOQ <LOQ <LOQ 0,2 15,1 <LOQ 15,1 0,2 <LOQ <LOQ <LOQ 10,7 <LOQ 1,0 <LOQ <LOQ 
Fate Sees_165 0,1 <LOQ <LOQ <LOQ <LOQ <LOQ 13,3 <LOQ <LOQ 0,5 <LOQ <LOQ <LOQ <LOQ <LOQ 1,3 <LOQ 1,3 
Fate Sees_166 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 64,3 <LOQ <LOQ 0,9 <LOQ <LOQ <LOQ 14,7 <LOQ <LOQ <LOQ 1,2 
Fate Sees_167 0,3 <LOQ <LOQ <LOQ <LOQ 0,3 133,8 <LOQ <LOQ 4,2 <LOQ <LOQ <LOQ 33,9 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_168 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 32,6 <LOQ <LOQ 0,7 <LOQ <LOQ <LOQ 14,8 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_169 0,2 <LOQ <LOQ <LOQ <LOQ <LOQ 20,1 <LOQ <LOQ 4,9 <LOQ <LOQ <LOQ 49,1 <LOQ <LOQ <LOQ 1,2 
Fate Sees_170 13,1 10,8 <LOQ 72,9 <LOQ <LOQ 423,4 <LOQ 12,6 0,3 <LOQ <LOQ <LOQ 188,6 <LOQ <LOQ <LOQ 2,0 
Fate Sees_171 9,2 <LOQ <LOQ <LOQ <LOQ <LOQ 271,0 <LOQ <LOQ 0,1 <LOQ <LOQ <LOQ 155,9 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_175 0,4 <LOQ <LOQ <LOQ <LOQ <LOQ 6,9 <LOQ <LOQ 0,4 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_177 2,6 <LOQ <LOQ <LOQ <LOQ <LOQ 21,5 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 4,9 
Fate Sees_179 8,3 <LOQ <LOQ <LOQ <LOQ 0,1 257,6 <LOQ <LOQ 0,4 <LOQ <LOQ <LOQ 87,3 <LOQ <LOQ <LOQ 1,4 
Fate Sees_180 8,5 <LOQ <LOQ <LOQ <LOQ <LOQ 195,9 <LOQ <LOQ 0,4 <LOQ <LOQ <LOQ 153,8 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_181 3,1 <LOQ <LOQ <LOQ <LOQ <LOQ 163,7 <LOQ <LOQ 0,4 <LOQ <LOQ <LOQ 63,4 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_182 4,5 <LOQ <LOQ <LOQ <LOQ 0,1 186,2 <LOQ <LOQ 0,5 <LOQ <LOQ <LOQ 60,7 <LOQ <LOQ 7,3 1,1 
 114 
 
Fate Sees_183 20,5 <LOQ <LOQ <LOQ <LOQ 0,3 6,7 <LOQ <LOQ 0,9 <LOQ <LOQ <LOQ 48,1 <LOQ 0,5 <LOQ 1,4 
Fate Sees_184 0,2 <LOQ <LOQ <LOQ <LOQ 0,2 0,5 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_189 0,2 <LOQ <LOQ <LOQ <LOQ <LOQ 14,9 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 28,3 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_190 1,2 <LOQ <LOQ <LOQ <LOQ <LOQ 10,4 <LOQ <LOQ 0,2 <LOQ <LOQ <LOQ 20,6 <LOQ 0,8 <LOQ <LOQ 
Fate Sees_191 1,7 <LOQ <LOQ <LOQ <LOQ <LOQ 9,8 <LOQ <LOQ 0,1 <LOQ <LOQ <LOQ 32,0 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_193 0,5 <LOQ <LOQ <LOQ <LOQ 0,2 25,2 <LOQ <LOQ 0,1 <LOQ <LOQ <LOQ 21,6 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_194 3,4 <LOQ 14,6 <LOQ <LOQ 0,1 47,3 <LOQ <LOQ 2,7 <LOQ <LOQ <LOQ 56,2 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_195 1,7 <LOQ <LOQ <LOQ <LOQ <LOQ 4,8 <LOQ <LOQ 0,4 <LOQ <LOQ <LOQ 34,4 <LOQ <LOQ <LOQ 1,2 
Fate Sees_196 2,5 <LOQ <LOQ <LOQ <LOQ <LOQ 12,8 <LOQ <LOQ 0,2 <LOQ <LOQ <LOQ 29,7 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_198 0,8 <LOQ <LOQ <LOQ <LOQ 0,1 34,7 <LOQ <LOQ 1,9 <LOQ <LOQ <LOQ 39,6 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_199 1,5 <LOQ <LOQ <LOQ <LOQ <LOQ 38,3 <LOQ <LOQ 2,0 <LOQ <LOQ <LOQ 61,0 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_202 1,3 <LOQ <LOQ <LOQ <LOQ <LOQ 51,2 <LOQ <LOQ 4,3 <LOQ <LOQ <LOQ 75,2 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_203 0,8 <LOQ <LOQ <LOQ <LOQ <LOQ 15,3 <LOQ <LOQ 0,4 <LOQ <LOQ <LOQ 14,6 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_204 0,5 <LOQ <LOQ <LOQ <LOQ <LOQ 74,5 <LOQ <LOQ 0,7 <LOQ <LOQ <LOQ 35,9 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_205 0,8 <LOQ <LOQ <LOQ <LOQ <LOQ 67,5 <LOQ <LOQ 3,0 <LOQ <LOQ <LOQ 27,2 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_208 7,5 <LOQ <LOQ <LOQ <LOQ <LOQ 29,9 <LOQ <LOQ 1,6 <LOQ <LOQ <LOQ 38,7 <LOQ <LOQ 7,1 1,2 
Fate Sees_209 0,9 <LOQ <LOQ <LOQ <LOQ 0,3 35,5 <LOQ <LOQ 1,0 <LOQ <LOQ <LOQ 93,7 <LOQ 1,8 <LOQ 1,1 
Fate Sees_210 3,7 <LOQ <LOQ <LOQ <LOQ <LOQ 10,6 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 32,4 <LOQ <LOQ <LOQ 1,7 
Fate Sees_211 2,6 <LOQ <LOQ <LOQ <LOQ 2,4 20,9 <LOQ <LOQ 4,6 <LOQ <LOQ 1,5 18,2 <LOQ 2,5 <LOQ <LOQ 
Fate Sees_214 5,0 <LOQ <LOQ <LOQ <LOQ 0,3 15,7 <LOQ <LOQ 3,0 <LOQ <LOQ <LOQ 36,0 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_226 2,1 <LOQ <LOQ <LOQ <LOQ <LOQ 7,8 <LOQ <LOQ 1,9 <LOQ <LOQ <LOQ 8,3 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_227 0,2 <LOQ <LOQ <LOQ <LOQ 0,1 0,3 <LOQ <LOQ 0,4 <LOQ <LOQ <LOQ 6,3 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_228 0,3 <LOQ <LOQ <LOQ <LOQ <LOQ 0,4 <LOQ <LOQ 0,9 <LOQ <LOQ <LOQ 10,2 <LOQ <LOQ <LOQ 1,3 
Fate Sees_229 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,7 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_233 3,8 <LOQ <LOQ <LOQ <LOQ <LOQ 9,7 <LOQ <LOQ 1,5 <LOQ <LOQ <LOQ 18,2 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_235 5,7 <LOQ <LOQ <LOQ <LOQ 0,1 1,8 <LOQ <LOQ 0,5 <LOQ <LOQ <LOQ 15,7 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_236 2,7 <LOQ <LOQ <LOQ <LOQ <LOQ 24,5 <LOQ <LOQ 1,0 <LOQ <LOQ <LOQ 9,4 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_239 1,8 <LOQ <LOQ <LOQ <LOQ <LOQ 20,9 <LOQ <LOQ 1,1 <LOQ <LOQ <LOQ 21,0 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_242 2,1 <LOQ <LOQ <LOQ <LOQ <LOQ 10,1 <LOQ <LOQ 0,2 <LOQ <LOQ <LOQ 12,9 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_243 3,1 <LOQ <LOQ <LOQ <LOQ 0,2 10,7 <LOQ <LOQ 1,9 <LOQ <LOQ <LOQ 46,0 <LOQ 1,6 <LOQ <LOQ 
Fate Sees_245 1,1 <LOQ <LOQ <LOQ <LOQ <LOQ 22,5 <LOQ <LOQ 3,5 <LOQ <LOQ <LOQ 16,8 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_247 2,8 <LOQ <LOQ <LOQ <LOQ <LOQ 13,1 <LOQ <LOQ 0,6 <LOQ <LOQ <LOQ 14,1 <LOQ <LOQ <LOQ 1,2 
Fate Sees_248 3,5 <LOQ <LOQ <LOQ <LOQ 0,1 23,6 <LOQ <LOQ 0,9 <LOQ <LOQ <LOQ 39,1 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_250 1,9 <LOQ <LOQ <LOQ <LOQ <LOQ 151,7 <LOQ <LOQ 0,4 <LOQ <LOQ <LOQ 20,9 <LOQ <LOQ <LOQ 2,5 
Fate Sees_252 4,4 <LOQ <LOQ <LOQ <LOQ <LOQ 178,0 <LOQ <LOQ 1,5 <LOQ <LOQ <LOQ 61,1 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_253 0,8 <LOQ <LOQ <LOQ <LOQ <LOQ 86,2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 18,6 <LOQ 0,5 <LOQ 1,7 
Fate Sees_254 9,4 33,0 <LOQ <LOQ <LOQ 0,4 143,0 <LOQ <LOQ 4,7 <LOQ <LOQ 2,2 47,8 <LOQ 0,7 6,6 2,0 
Fate Sees_256 0,4 <LOQ <LOQ <LOQ <LOQ <LOQ 43,5 <LOQ <LOQ 0,5 <LOQ <LOQ <LOQ 39,5 <LOQ <LOQ <LOQ 2,8 
Fate Sees_257 1,9 <LOQ <LOQ <LOQ <LOQ <LOQ 15,1 <LOQ <LOQ 2,6 <LOQ <LOQ <LOQ 16,0 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_258 1,8 <LOQ <LOQ <LOQ <LOQ <LOQ 24,9 <LOQ <LOQ 1,4 <LOQ <LOQ <LOQ 21,1 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_259 8,3 <LOQ <LOQ <LOQ <LOQ 0,2 108,2 <LOQ <LOQ 2,9 <LOQ <LOQ 1,7 16,9 <LOQ 1,0 <LOQ 1,3 
Fate Sees_260 7,6 <LOQ <LOQ <LOQ <LOQ <LOQ 25,0 <LOQ <LOQ 1,8 <LOQ <LOQ <LOQ 57,0 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_261 4,6 <LOQ <LOQ <LOQ <LOQ <LOQ 19,5 <LOQ <LOQ 0,8 <LOQ <LOQ <LOQ 60,9 <LOQ <LOQ 5,5 <LOQ 
Fate Sees_262 4,5 <LOQ <LOQ <LOQ <LOQ <LOQ 28,4 <LOQ <LOQ 1,5 <LOQ <LOQ <LOQ 31,8 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_263 4,8 <LOQ <LOQ <LOQ <LOQ <LOQ 6,5 <LOQ <LOQ 1,0 <LOQ <LOQ <LOQ 56,0 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_264 4,3 <LOQ <LOQ <LOQ <LOQ 0,3 8,7 <LOQ <LOQ 1,1 <LOQ <LOQ <LOQ 29,7 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_265 13,5 <LOQ <LOQ <LOQ <LOQ 0,1 105,5 <LOQ <LOQ 0,3 <LOQ <LOQ <LOQ 133,5 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_266 3,6 <LOQ <LOQ <LOQ <LOQ <LOQ 20,6 <LOQ <LOQ 0,2 <LOQ <LOQ <LOQ 79,8 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_267 8,3 <LOQ <LOQ <LOQ <LOQ 0,4 19,0 <LOQ <LOQ 1,0 <LOQ <LOQ <LOQ 43,6 <LOQ 0,6 <LOQ <LOQ 












































































































































































0,5 5 5 0,5 0,05 1 5 0,5 10 0,5 5 0,1 0,5 5 5 10 5 10 
Fate Sees_136 2,4 <LOQ <LOQ <LOQ 10,5 <LOQ 16,2 <LOQ <LOQ <LOQ 66,6 5,0 161,1 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_137 43,9 <LOQ <LOQ 3,6 9,5 <LOQ 207,3 <LOQ <LOQ <LOQ 121,8 9,2 227,8 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_138 1,3 <LOQ <LOQ <LOQ 1,3 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 552,6 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_139                                     
Fate Sees_140 161,6 <LOQ <LOQ 57,9 5,3 <LOQ 55,5 <LOQ <LOQ <LOQ 250,8 303,8 36,9 11,9 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_141                                     
Fate Sees_142 137,2 <LOQ <LOQ 22,8 4,1 <LOQ 83,0 <LOQ <LOQ <LOQ 293,8 66,1 107,2 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_143 11,4 <LOQ <LOQ 1,2 2,0 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,2 2,6 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_144 5,6 <LOQ <LOQ <LOQ 22,5 <LOQ 29,4 <LOQ <LOQ <LOQ 277,7 <LOQ 5,5 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_145 20,9 <LOQ <LOQ 6,8 9,0 <LOQ 11,0 <LOQ <LOQ <LOQ <LOQ <LOQ 120,4 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_146 14,2 <LOQ <LOQ 8,0 2,9 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,7 89,8 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_147 5,8 <LOQ <LOQ 5,1 4,9 <LOQ <LOQ <LOQ <LOQ <LOQ 23,0 0,6 181,1 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_148 2,9 <LOQ <LOQ 5,0 0,9 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,8 46,9 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_149 48,6 <LOQ <LOQ 7,2 7,6 <LOQ <LOQ <LOQ <LOQ <LOQ 52,6 4,9 188,1 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_150 7,6 <LOQ <LOQ 0,7 0,5 6,3 22,3 <LOQ 16,9 <LOQ 11,9 2,4 20,4 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_151 7,7 <LOQ <LOQ <LOQ 0,9 <LOQ <LOQ <LOQ 14,0 <LOQ <LOQ 0,7 7,0 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_152 188,9 <LOQ <LOQ <LOQ 1,3 <LOQ <LOQ <LOQ 14,0 <LOQ 14,5 3,7 7,5 <LOQ <LOQ <LOQ <LOQ 28,0 
Fate Sees_153 13,0 <LOQ <LOQ <LOQ 11,4 1,0 <LOQ <LOQ <LOQ <LOQ <LOQ 0,5 0,7 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_155 2,1 <LOQ <LOQ 0,6 0,3 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 5,3 0,9 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_156 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,6 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_157 5,0 <LOQ <LOQ 0,6 6,2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 14,7 20,2 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_158 36,8 <LOQ <LOQ <LOQ 0,5 <LOQ <LOQ <LOQ <LOQ <LOQ 5,8 1,0 0,6 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_159 9,5 <LOQ <LOQ <LOQ 0,3 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,4 6,4 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_160 14,1 325,1 <LOQ 0,6 0,3 <LOQ <LOQ <LOQ <LOQ 1,1 <LOQ 3,0 25,6 5,2 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_161 1,8 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,4 0,7 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_162 0,6 <LOQ <LOQ <LOQ 0,1 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,6 4,5 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_163 1,4 <LOQ <LOQ <LOQ 0,1 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 1,4 0,6 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_164 1,6 <LOQ <LOQ 4,3 1,8 <LOQ 206,8 <LOQ <LOQ <LOQ 26,2 31,6 203,9 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_165 12,3 <LOQ <LOQ 1,4 2,6 <LOQ 32,7 <LOQ <LOQ <LOQ 32,9 27,9 379,0 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_166 11,9 <LOQ <LOQ 13,8 12,1 <LOQ 12,5 <LOQ <LOQ <LOQ 68,2 113,4 412,8 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_167 6,1 <LOQ <LOQ 22,5 16,9 <LOQ <LOQ <LOQ <LOQ <LOQ 173,1 398,8 413,9 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_168 6,0 18,3 <LOQ 7,1 5,6 <LOQ 28,0 <LOQ <LOQ 0,6 18,8 36,1 198,4 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_169 21,6 <LOQ <LOQ 6,1 5,6 <LOQ <LOQ <LOQ <LOQ <LOQ 402,4 1,1 237,0 18,5 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_170 826,4 <LOQ <LOQ 20,1 17,4 <LOQ 6810,2 <LOQ <LOQ 0,5 497,1 95,2 437,2 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_171 78,0 <LOQ <LOQ 7,8 9,1 <LOQ 441,8 <LOQ <LOQ <LOQ 422,6 168,6 117,1 5,9 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_175 1,6 <LOQ <LOQ <LOQ 0,2 <LOQ 10,4 <LOQ <LOQ <LOQ 256,7 <LOQ 11,7 <LOQ <LOQ <LOQ <LOQ 10,8 
Fate Sees_177 0,8 <LOQ <LOQ <LOQ 1,0 <LOQ <LOQ <LOQ <LOQ <LOQ 353,0 0,6 67,5 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_179 651,8 <LOQ <LOQ 19,4 8,2 <LOQ 4236,0 <LOQ <LOQ <LOQ 428,3 95,1 332,9 9,8 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_180 20,0 <LOQ <LOQ 17,8 10,4 <LOQ 290,1 <LOQ <LOQ <LOQ 231,2 106,0 139,7 10,9 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_181 233,2 <LOQ <LOQ 11,9 6,6 <LOQ 796,8 <LOQ <LOQ <LOQ 423,5 79,3 191,2 8,4 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_182 33,2 <LOQ <LOQ 13,1 7,0 <LOQ 800,5 <LOQ <LOQ <LOQ 443,0 121,0 122,4 7,7 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_183 22,3 <LOQ <LOQ 64,4 41,4 <LOQ 261,7 <LOQ <LOQ <LOQ <LOQ 7,8 299,4 5,8 7,9 <LOQ <LOQ <LOQ 
Fate Sees_184 <LOQ <LOQ <LOQ <LOQ 0,2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,8 283,6 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_189 3,3 <LOQ <LOQ <LOQ 9,9 <LOQ <LOQ <LOQ <LOQ <LOQ 129,0 0,2 0,7 <LOQ <LOQ <LOQ <LOQ <LOQ 
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Fate Sees_190 0,7 <LOQ <LOQ <LOQ 6,3 <LOQ <LOQ <LOQ <LOQ <LOQ 40,3 0,9 30,7 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_191 33,6 <LOQ <LOQ <LOQ 10,9 <LOQ <LOQ <LOQ <LOQ <LOQ 80,9 3,8 19,5 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_193 4,6 <LOQ <LOQ 1,3 2,5 <LOQ <LOQ <LOQ <LOQ <LOQ 34,5 10,8 18,2 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_194 45,9 <LOQ <LOQ 6,0 25,6 <LOQ 23,7 <LOQ <LOQ <LOQ 129,8 13,1 65,7 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_195 310,0 <LOQ <LOQ 8,2 22,8 <LOQ 421,0 <LOQ <LOQ <LOQ 191,9 10,1 97,8 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_196 312,3 <LOQ <LOQ 12,0 15,3 <LOQ 14,6 <LOQ <LOQ <LOQ 140,6 11,1 69,8 5,9 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_198 6,0 <LOQ <LOQ 2,5 16,8 <LOQ <LOQ <LOQ <LOQ <LOQ 15,4 8,5 12,0 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_199 15,0 <LOQ <LOQ 5,8 16,8 <LOQ 105,1 <LOQ 25,7 <LOQ 18,9 6,3 20,3 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_202 11,3 <LOQ <LOQ 8,2 91,4 <LOQ 37,4 <LOQ <LOQ <LOQ 35,8 7,4 64,6 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_203 5,0 <LOQ <LOQ 1,9 4,9 <LOQ 44,5 <LOQ <LOQ <LOQ 19,2 5,0 87,0 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_204 18,3 <LOQ <LOQ 6,0 18,2 <LOQ 115,7 <LOQ <LOQ <LOQ 21,4 5,3 50,0 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_205 25,0 <LOQ <LOQ 2,2 39,6 <LOQ 168,1 <LOQ <LOQ <LOQ 31,9 5,4 17,6 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_208 85,1 <LOQ <LOQ 12,5 20,1 <LOQ 369,3 <LOQ <LOQ <LOQ 64,9 100,7 103,9 7,2 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_209 70,2 <LOQ <LOQ 9,0 44,2 <LOQ 115,2 <LOQ <LOQ <LOQ 48,9 74,4 111,8 8,7 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_210 46,1 <LOQ <LOQ 42,0 6,6 <LOQ <LOQ <LOQ <LOQ 0,8 <LOQ 0,6 13,1 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_211 199,3 <LOQ <LOQ 4,9 3,5 <LOQ 92,8 <LOQ 11,9 <LOQ 78,7 14,5 99,4 5,7 <LOQ <LOQ 5,8 <LOQ 
Fate Sees_214 13,8 <LOQ <LOQ 7,4 6,7 <LOQ 43,3 <LOQ <LOQ <LOQ 58,0 25,1 116,0 6,0 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_226 13,7 <LOQ <LOQ 12,0 0,6 <LOQ 83,2 <LOQ <LOQ <LOQ 59,7 46,3 138,6 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_227 4,0 <LOQ <LOQ 17,1 13,8 <LOQ 6,4 <LOQ <LOQ <LOQ 45,8 0,5 53,3 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_228 5,5 <LOQ <LOQ 32,0 12,2 <LOQ <LOQ <LOQ <LOQ <LOQ 57,1 1,9 31,9 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_229 2,3 <LOQ <LOQ 8,5 4,0 <LOQ 111,6 <LOQ <LOQ <LOQ 55,5 0,3 40,4 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_233 23,6 <LOQ <LOQ 14,5 3,7 <LOQ 5,8 <LOQ <LOQ <LOQ 384,2 108,3 63,0 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_235 50,3 <LOQ <LOQ 12,5 1,6 <LOQ <LOQ <LOQ 13,4 <LOQ 427,2 93,8 35,6 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_236 46,3 <LOQ <LOQ 25,4 1,7 <LOQ 147,5 <LOQ <LOQ 1,6 321,8 41,0 184,3 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_239 58,8 <LOQ <LOQ 19,5 1,9 <LOQ <LOQ <LOQ <LOQ <LOQ 598,3 61,8 45,3 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_242 28,0 <LOQ <LOQ 6,4 1,7 <LOQ 11,8 <LOQ <LOQ <LOQ 291,9 72,5 36,8 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_243 58,4 <LOQ <LOQ 45,9 3,0 <LOQ <LOQ <LOQ <LOQ <LOQ 545,6 109,8 33,1 6,1 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_245 4,5 <LOQ <LOQ 54,8 3,8 <LOQ 18,8 <LOQ <LOQ <LOQ 816,4 90,7 85,4 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_247 29,7 <LOQ <LOQ 16,1 7,4 <LOQ 13,7 <LOQ <LOQ <LOQ 587,5 126,1 61,3 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_248 12,2 <LOQ <LOQ 14,6 4,4 <LOQ 5,4 <LOQ <LOQ <LOQ 859,1 64,4 92,1 7,9 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_250 63,2 <LOQ <LOQ 3,0 26,0 <LOQ 447,5 <LOQ <LOQ <LOQ 245,7 59,1 125,9 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_252 21,5 <LOQ <LOQ 4,5 57,3 <LOQ 31,4 <LOQ <LOQ <LOQ 144,3 54,9 70,5 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_253 1,9 <LOQ <LOQ <LOQ 141,5 <LOQ 8,8 <LOQ <LOQ <LOQ 1287,1 8,7 2,2 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_254 98,1 <LOQ <LOQ 32,5 41,6 <LOQ 684,4 <LOQ <LOQ <LOQ 59,5 28,4 344,1 21,5 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_256 2,6 <LOQ <LOQ 0,6 12,2 <LOQ 62,2 <LOQ <LOQ <LOQ 128,5 47,0 38,6 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_257 55,5 <LOQ <LOQ 25,5 0,6 <LOQ <LOQ <LOQ <LOQ <LOQ 421,5 127,0 104,7 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_258 70,1 <LOQ <LOQ 26,5 2,0 <LOQ 11,2 <LOQ <LOQ <LOQ 484,9 107,7 138,1 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_259 43,4 <LOQ <LOQ 12,8 37,5 <LOQ 469,2 <LOQ <LOQ <LOQ 211,8 29,3 598,1 16,6 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_260 143,0 <LOQ <LOQ 10,7 3,9 <LOQ 184,0 <LOQ <LOQ <LOQ 39,5 13,3 268,4 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_261 134,6 <LOQ <LOQ 7,0 2,1 <LOQ 29,3 <LOQ <LOQ <LOQ 58,8 9,2 92,7 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_262 52,1 <LOQ <LOQ 2,0 4,3 <LOQ 82,5 <LOQ <LOQ <LOQ 27,6 14,7 77,2 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_263 79,0 <LOQ <LOQ 5,4 2,8 <LOQ 10,1 <LOQ <LOQ <LOQ 40,4 9,8 48,4 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_264 150,0 <LOQ <LOQ 12,5 0,7 <LOQ 93,8 <LOQ <LOQ <LOQ 66,9 15,4 39,5 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_265 684,6 <LOQ <LOQ 9,2 26,3 <LOQ 1250,2 <LOQ <LOQ <LOQ 213,2 61,9 420,6 7,6 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_266 159,1 <LOQ <LOQ 6,1 1,6 <LOQ <LOQ <LOQ <LOQ <LOQ 86,6 5,9 46,4 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_267 102,3 <LOQ <LOQ 16,2 2,6 <LOQ 83,0 <LOQ <LOQ <LOQ 25,9 49,8 74,2 <LOQ <LOQ <LOQ <LOQ <LOQ 
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Fate Sees_136 <LOQ <LOQ 0,8 6,8 <LOQ <LOQ <LOQ 4,1 <LOQ <LOQ <LOQ 3,6 21,5 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_137 <LOQ 0,3 <LOQ 55,3 <LOQ <LOQ <LOQ 6,0 <LOQ <LOQ <LOQ 1,4 16,5 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_138 <LOQ <LOQ <LOQ 663,7 <LOQ <LOQ <LOQ 0,9 5,4 <LOQ <LOQ <LOQ 1765,8 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_139                                     
Fate Sees_140 <LOQ 0,2 0,6 2184,8 <LOQ <LOQ <LOQ 15,4 1,2 <LOQ <LOQ 0,1 427,8 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_141                                     
Fate Sees_142 <LOQ <LOQ 2,0 1262,5 <LOQ <LOQ <LOQ 15,2 1,3 <LOQ <LOQ 0,3 467,6 <LOQ <LOQ <LOQ <LOQ 7,8 
Fate Sees_143 <LOQ 0,2 <LOQ 2,2 <LOQ <LOQ <LOQ 12,8 <LOQ <LOQ <LOQ 0,4 44,7 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_144 <LOQ <LOQ <LOQ 6,6 <LOQ <LOQ <LOQ 12,8 <LOQ <LOQ <LOQ 0,9 42,1 <LOQ <LOQ <LOQ <LOQ 6,1 
Fate Sees_145 <LOQ <LOQ <LOQ 1,8 <LOQ <LOQ <LOQ 7,2 <LOQ <LOQ <LOQ 0,8 33,6 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_146 <LOQ 0,1 0,6 4,8 <LOQ <LOQ <LOQ 2,5 <LOQ <LOQ <LOQ 1,0 64,7 <LOQ <LOQ <LOQ <LOQ 10,7 
Fate Sees_147 <LOQ 0,4 <LOQ 20,4 <LOQ <LOQ <LOQ 3,7 <LOQ <LOQ <LOQ 0,7 72,3 <LOQ <LOQ <LOQ <LOQ 19,4 
Fate Sees_148 <LOQ 0,3 <LOQ 2,2 <LOQ <LOQ <LOQ 28,7 <LOQ <LOQ <LOQ 0,5 25,4 <LOQ <LOQ 0,6 <LOQ <LOQ 
Fate Sees_149 <LOQ 0,1 1,1 16,4 <LOQ <LOQ <LOQ 4,0 <LOQ <LOQ <LOQ 1,3 47,3 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_150 <LOQ 0,7 5,3 7,3 <LOQ 9,1 <LOQ 1312,1 5,8 <LOQ 0,9 0,3 34,9 <LOQ <LOQ 1,4 <LOQ <LOQ 
Fate Sees_151 <LOQ 0,3 2,5 4,2 <LOQ <LOQ <LOQ 1,7 3,8 <LOQ <LOQ 0,2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_152 <LOQ 2,1 9,6 7,9 <LOQ 16,5 <LOQ 40,0 1,1 <LOQ 2,4 3,4 13,8 <LOQ <LOQ 1,2 <LOQ 18,6 
Fate Sees_153 <LOQ 0,4 <LOQ 3,9 <LOQ <LOQ <LOQ 0,6 <LOQ 14,8 0,6 <LOQ <LOQ <LOQ <LOQ 0,5 <LOQ <LOQ 
Fate Sees_155 <LOQ 0,8 <LOQ 4,5 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_156 <LOQ <LOQ <LOQ 3,0 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_157 <LOQ 0,1 <LOQ 13,3 <LOQ <LOQ <LOQ 0,9 5,2 <LOQ <LOQ 0,2 20,3 <LOQ <LOQ <LOQ <LOQ 17,0 
Fate Sees_158 <LOQ 30,8 0,7 17884,0 24,3 <LOQ <LOQ <LOQ 1,3 <LOQ <LOQ 0,2 <LOQ <LOQ <LOQ 1,9 <LOQ <LOQ 
Fate Sees_159 <LOQ 0,5 <LOQ 3,2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,8 0,2 5,4 <LOQ <LOQ <LOQ <LOQ 32,2 
Fate Sees_160 <LOQ 2691,5 <LOQ 5,9 2409,1 <LOQ <LOQ 0,6 62,3 <LOQ <LOQ 0,1 62,7 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_161 <LOQ <LOQ <LOQ 2,4 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_162 <LOQ 0,1 <LOQ 4,4 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_163 <LOQ 0,1 <LOQ 7,0 <LOQ <LOQ <LOQ 0,9 <LOQ <LOQ <LOQ 0,2 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_164 <LOQ 1,3 0,5 57,4 <LOQ <LOQ <LOQ 1,5 <LOQ <LOQ 0,5 0,2 58,6 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_165 <LOQ 0,2 2,3 318,9 <LOQ <LOQ <LOQ 5,3 <LOQ <LOQ <LOQ 0,2 55,1 <LOQ <LOQ <LOQ <LOQ 20,9 
Fate Sees_166 <LOQ 0,1 0,6 192,1 <LOQ <LOQ <LOQ 4,6 <LOQ <LOQ <LOQ 0,6 62,4 <LOQ <LOQ <LOQ <LOQ 29,6 
Fate Sees_167 <LOQ 0,2 <LOQ 704,0 <LOQ <LOQ <LOQ 5,0 <LOQ <LOQ <LOQ 1,1 69,6 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_168 <LOQ 113,5 <LOQ 266,1 169,2 <LOQ <LOQ 1,2 11,0 <LOQ <LOQ 0,4 29,7 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_169 <LOQ 0,7 <LOQ 287,7 <LOQ <LOQ <LOQ 10,9 <LOQ <LOQ <LOQ 0,5 43,9 <LOQ <LOQ <LOQ <LOQ 11,4 
Fate Sees_170 <LOQ 1,7 2,2 6,0 <LOQ <LOQ <LOQ 45,8 1,5 <LOQ <LOQ 27,0 280,3 <LOQ <LOQ <LOQ <LOQ 9,2 
Fate Sees_171 <LOQ 0,5 1,2 1,7 <LOQ <LOQ <LOQ 43,4 1,7 <LOQ <LOQ 37,0 242,0 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_175 <LOQ 0,7 <LOQ 80,9 <LOQ <LOQ <LOQ 2,7 <LOQ <LOQ <LOQ <LOQ 26,0 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_177 <LOQ <LOQ <LOQ 121,7 <LOQ <LOQ <LOQ 2,4 <LOQ <LOQ <LOQ <LOQ 37,6 <LOQ <LOQ <LOQ <LOQ 5,6 
Fate Sees_179 <LOQ 0,1 2,4 1,7 <LOQ <LOQ <LOQ 12,8 1,5 <LOQ <LOQ 45,8 529,5 <LOQ <LOQ <LOQ <LOQ 10,2 
Fate Sees_180 <LOQ 0,4 1,5 2,7 <LOQ <LOQ <LOQ 18,9 4,5 <LOQ <LOQ 46,7 368,9 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_181 <LOQ 0,2 2,4 12,4 <LOQ <LOQ <LOQ 20,4 1,5 <LOQ <LOQ 39,0 471,3 <LOQ <LOQ <LOQ <LOQ 6,4 
Fate Sees_182 <LOQ 0,9 0,9 5,2 <LOQ <LOQ <LOQ 22,2 <LOQ <LOQ <LOQ 23,5 378,9 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_183 <LOQ 2,2 2,2 916,4 <LOQ <LOQ <LOQ 10,0 <LOQ <LOQ <LOQ 38,9 20,2 <LOQ <LOQ <LOQ <LOQ 43,6 
Fate Sees_184 <LOQ <LOQ <LOQ 265,4 <LOQ <LOQ <LOQ 2,2 <LOQ <LOQ <LOQ 1,1 7,9 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_189 <LOQ 0,1 <LOQ 334,4 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,5 95,2 <LOQ <LOQ <LOQ <LOQ <LOQ 
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Fate Sees_190 <LOQ <LOQ <LOQ 50,9 <LOQ <LOQ <LOQ 1,6 <LOQ <LOQ <LOQ 0,2 77,0 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_191 <LOQ 0,1 <LOQ 179,9 <LOQ <LOQ <LOQ 0,7 <LOQ <LOQ <LOQ 0,6 14,4 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_193 <LOQ <LOQ <LOQ 129,0 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,2 50,6 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_194 <LOQ 0,2 1,2 221,8 0,5 14,3 <LOQ 2,3 <LOQ <LOQ <LOQ 0,2 179,3 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_195 <LOQ 0,1 <LOQ 231,6 <LOQ <LOQ <LOQ 6,7 <LOQ <LOQ <LOQ 1,0 64,3 <LOQ <LOQ <LOQ <LOQ 18,0 
Fate Sees_196 <LOQ 0,8 <LOQ 49,5 <LOQ <LOQ <LOQ 4,3 <LOQ <LOQ <LOQ 0,2 17,2 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_198 <LOQ 0,2 2,8 16,1 <LOQ <LOQ <LOQ 1,7 <LOQ <LOQ <LOQ 0,8 77,7 <LOQ <LOQ <LOQ <LOQ 5,1 
Fate Sees_199 <LOQ 0,6 <LOQ 17,9 <LOQ <LOQ <LOQ 3,8 <LOQ <LOQ <LOQ 0,5 53,6 <LOQ <LOQ <LOQ <LOQ 6,8 
Fate Sees_202 <LOQ 0,5 <LOQ 14,3 <LOQ <LOQ <LOQ 11,9 <LOQ <LOQ <LOQ 0,8 219,9 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_203 <LOQ 0,1 <LOQ 4,1 <LOQ <LOQ <LOQ 3,6 <LOQ <LOQ <LOQ 0,9 98,0 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_204 <LOQ <LOQ 0,6 9,0 <LOQ <LOQ <LOQ 3,3 <LOQ <LOQ <LOQ 1,0 206,5 <LOQ <LOQ <LOQ <LOQ 8,7 
Fate Sees_205 <LOQ 0,2 0,9 32,2 <LOQ <LOQ <LOQ 7,0 <LOQ <LOQ <LOQ 1,8 190,1 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_208 <LOQ 0,3 <LOQ 291,7 <LOQ <LOQ <LOQ 22,4 <LOQ <LOQ <LOQ <LOQ 61,3 <LOQ <LOQ <LOQ <LOQ 9,7 
Fate Sees_209 <LOQ <LOQ 2,9 1203,2 <LOQ <LOQ <LOQ 19,3 <LOQ <LOQ 0,6 0,1 51,1 <LOQ <LOQ 0,7 <LOQ <LOQ 
Fate Sees_210 <LOQ 0,2 <LOQ 423,6 <LOQ <LOQ <LOQ 23,1 1,7 <LOQ <LOQ <LOQ 60,9 <LOQ <LOQ <LOQ <LOQ 21,1 
Fate Sees_211 <LOQ 1,3 5,5 247,0 2,2 <LOQ <LOQ 7,1 <LOQ <LOQ <LOQ 10,4 229,3 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_214 <LOQ 0,2 1,3 221,6 <LOQ <LOQ <LOQ 3,4 <LOQ <LOQ <LOQ 6,1 224,6 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_226 <LOQ 1,2 <LOQ 393,5 <LOQ <LOQ <LOQ 2,9 <LOQ <LOQ <LOQ 1,5 18,3 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_227 <LOQ 0,3 <LOQ 10,2 <LOQ <LOQ <LOQ 5,5 <LOQ <LOQ <LOQ <LOQ 25,2 <LOQ <LOQ <LOQ <LOQ 14,6 
Fate Sees_228 <LOQ 0,5 <LOQ 23,8 <LOQ <LOQ <LOQ 3,7 <LOQ <LOQ <LOQ 0,2 60,8 <LOQ <LOQ <LOQ <LOQ 30,8 
Fate Sees_229 <LOQ 0,2 <LOQ 8,0 <LOQ <LOQ <LOQ 1,4 <LOQ <LOQ <LOQ <LOQ 62,2 <LOQ <LOQ <LOQ <LOQ 25,2 
Fate Sees_233 <LOQ 1,1 <LOQ 817,8 2,2 <LOQ <LOQ 0,9 <LOQ <LOQ <LOQ 0,9 433,8 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_235 <LOQ 0,4 2,0 640,7 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,8 27,8 <LOQ <LOQ <LOQ <LOQ 8,5 
Fate Sees_236 <LOQ 0,3 3,8 405,6 <LOQ <LOQ <LOQ 1,4 <LOQ <LOQ <LOQ 0,4 198,2 <LOQ <LOQ <LOQ <LOQ 16,7 
Fate Sees_239 <LOQ 0,1 <LOQ 859,5 <LOQ <LOQ <LOQ 1,1 1,2 <LOQ <LOQ 0,6 287,8 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_242 <LOQ 0,3 <LOQ 493,4 <LOQ <LOQ <LOQ 0,8 <LOQ <LOQ <LOQ 0,6 468,1 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_243 <LOQ 0,6 2,1 567,4 <LOQ <LOQ <LOQ 1,6 <LOQ <LOQ <LOQ 0,2 565,0 <LOQ <LOQ <LOQ <LOQ 9,7 
Fate Sees_245 <LOQ <LOQ <LOQ 1145,6 <LOQ <LOQ <LOQ 1,8 <LOQ <LOQ <LOQ <LOQ 325,3 <LOQ <LOQ <LOQ <LOQ 11,3 
Fate Sees_247 <LOQ 0,2 1,4 861,1 <LOQ <LOQ <LOQ 0,7 <LOQ <LOQ <LOQ 0,5 256,5 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_248 <LOQ 0,2 2,9 483,8 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 0,8 621,2 <LOQ <LOQ <LOQ <LOQ 23,0 
Fate Sees_250 <LOQ 0,5 0,8 341,3 <LOQ <LOQ <LOQ 4,4 <LOQ <LOQ <LOQ 0,4 74,4 <LOQ <LOQ <LOQ <LOQ 21,0 
Fate Sees_252 <LOQ 1,2 <LOQ 236,8 1,5 <LOQ <LOQ 10,5 <LOQ <LOQ <LOQ 0,3 49,0 <LOQ <LOQ <LOQ <LOQ 6,5 
Fate Sees_253 <LOQ 0,4 0,6 3,4 <LOQ <LOQ <LOQ 0,9 <LOQ <LOQ <LOQ 0,6 <LOQ <LOQ <LOQ 0,7 <LOQ <LOQ 
Fate Sees_254 <LOQ 1,0 3,3 1372,3 <LOQ <LOQ <LOQ 33,6 4,6 <LOQ <LOQ 0,9 149,9 <LOQ <LOQ <LOQ <LOQ 37,9 
Fate Sees_256 <LOQ <LOQ <LOQ 653,1 <LOQ <LOQ <LOQ 10,9 <LOQ <LOQ <LOQ 0,2 51,4 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_257 <LOQ 0,2 <LOQ 799,8 <LOQ <LOQ <LOQ 0,7 <LOQ <LOQ <LOQ 0,2 484,3 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_258 <LOQ 0,4 1,2 588,8 <LOQ <LOQ <LOQ <LOQ 1,0 <LOQ <LOQ 1,0 388,0 <LOQ <LOQ <LOQ <LOQ 9,7 
Fate Sees_259 <LOQ 0,3 0,7 1259,0 <LOQ <LOQ <LOQ 50,6 1,5 <LOQ <LOQ 0,3 224,0 <LOQ <LOQ <LOQ <LOQ 8,1 
Fate Sees_260 <LOQ 0,5 0,9 88,2 <LOQ <LOQ <LOQ 6,8 4,7 <LOQ <LOQ 3,3 121,9 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_261 <LOQ 0,5 2,5 85,4 <LOQ <LOQ <LOQ 3,6 1,4 <LOQ <LOQ 4,7 192,4 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_262 <LOQ 0,2 1,4 237,4 <LOQ <LOQ <LOQ 3,6 1,4 <LOQ <LOQ 4,3 162,2 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_263 <LOQ 0,3 0,9 45,4 <LOQ <LOQ <LOQ 5,2 <LOQ <LOQ <LOQ 1,6 89,7 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_264 <LOQ 0,4 3,7 239,5 <LOQ <LOQ <LOQ 3,0 <LOQ <LOQ <LOQ 6,6 182,7 <LOQ <LOQ <LOQ <LOQ 5,5 
Fate Sees_265 <LOQ 0,4 3,3 294,0 <LOQ <LOQ <LOQ 9,5 <LOQ <LOQ <LOQ 3,3 157,9 <LOQ <LOQ <LOQ <LOQ 24,7 
Fate Sees_266 <LOQ 0,3 6,1 65,7 <LOQ <LOQ <LOQ 25,6 3,4 <LOQ <LOQ 0,4 348,8 <LOQ <LOQ <LOQ <LOQ <LOQ 
Fate Sees_267 <LOQ 0,2 2,1 71,5 <LOQ <LOQ <LOQ 10,7 <LOQ <LOQ <LOQ 4,6 157,5 <LOQ <LOQ <LOQ <LOQ <LOQ 


















































































































0,5 0,1 10 10 5 50 0,5 0,5 0,1 0,5 10 0,5 
Fate Sees_136 1,7 1,4 <LOQ <LOQ <LOQ 3114,0 0,6 25,0 <LOQ 69,0 <LOQ <LOQ 
Fate Sees_137 2,3 2,1 25,6 <LOQ <LOQ 3426,0 0,9 98,3 0,1 51,4 <LOQ <LOQ 
Fate Sees_138 2,0 1,8 <LOQ <LOQ <LOQ 59,0 <LOQ 1165,7 <LOQ 276,5 <LOQ 0,7 
Fate Sees_139                        
Fate Sees_140 6,6 2,2 <LOQ <LOQ <LOQ 342,9 <LOQ 681,6 0,3 205,2 <LOQ 0,9 
Fate Sees_141                        
Fate Sees_142 12,3 6,8 <LOQ <LOQ <LOQ 64,6 0,6 704,9 0,7 107,6 <LOQ <LOQ 
Fate Sees_143 2,0 1,8 <LOQ <LOQ <LOQ 1010,5 1,5 181,0 <LOQ 54,0 <LOQ 1,7 
Fate Sees_144 1,6 3,4 <LOQ <LOQ <LOQ 1696,1 <LOQ 282,2 <LOQ 104,3 <LOQ 10,0 
Fate Sees_145 <LOQ 5,5 <LOQ <LOQ <LOQ 1229,2 <LOQ 599,5 <LOQ 149,6 <LOQ 1,4 
Fate Sees_146 1,5 29,5 <LOQ <LOQ <LOQ 274,3 <LOQ 593,9 0,2 44,6 <LOQ 1,8 
Fate Sees_147 2,1 1,4 <LOQ <LOQ <LOQ 764,9 1,2 438,1 <LOQ 70,7 <LOQ 2,2 
Fate Sees_148 0,7 4,3 <LOQ <LOQ <LOQ 665,7 0,8 308,0 <LOQ 134,7 <LOQ 18,3 
Fate Sees_149 1,4 2,8 <LOQ <LOQ <LOQ 518,1 1,2 501,9 <LOQ 131,1 <LOQ 6,2 
Fate Sees_150 11,1 9,6 <LOQ 15,9 <LOQ <LOQ 3,9 19,7 <LOQ 54,2 <LOQ 0,5 
Fate Sees_151 3,9 18,9 <LOQ <LOQ <LOQ <LOQ 4,7 5,5 1,1 27,2 <LOQ <LOQ 
Fate Sees_152 9,8 6,4 <LOQ 26,1 9,8 <LOQ 3,1 6,9 1,7 21,0 <LOQ <LOQ 
Fate Sees_153 5,3 1,0 <LOQ 37,5 12,6 <LOQ 2,9 2,3 <LOQ 17,8 <LOQ <LOQ 
Fate Sees_155 3,7 1,6 <LOQ <LOQ <LOQ <LOQ 2,1 2,6 0,2 52,9 <LOQ <LOQ 
Fate Sees_156 2,5 4,4 <LOQ <LOQ <LOQ <LOQ <LOQ 1,7 <LOQ <LOQ <LOQ <LOQ 
Fate Sees_157 4,7 4,0 <LOQ <LOQ <LOQ <LOQ 4,6 22,3 0,3 16,6 <LOQ 0,9 
Fate Sees_158 1,8 2,2 978,9 18,3 <LOQ <LOQ 1,2 0,7 0,2 11,4 16,5 0,6 
Fate Sees_159 8,6 2,3 <LOQ 18,6 <LOQ <LOQ <LOQ 86,0 <LOQ 10,1 <LOQ <LOQ 
Fate Sees_160 4,4 4,8 <LOQ <LOQ <LOQ <LOQ 1,0 3,0 0,2 16,3 <LOQ 2,8 
Fate Sees_161 3,4 2,4 <LOQ <LOQ <LOQ <LOQ <LOQ 0,5 <LOQ 2,9 <LOQ <LOQ 
Fate Sees_162 8,4 1,8 <LOQ <LOQ <LOQ <LOQ 1,3 1,7 <LOQ 5,4 <LOQ <LOQ 
Fate Sees_163 7,7 3,4 <LOQ <LOQ <LOQ <LOQ 2,2 43,9 0,3 6,9 <LOQ <LOQ 
Fate Sees_164 7,6 28,2 19,6 <LOQ <LOQ 113,3 2,6 170,9 0,3 64,3 <LOQ 0,9 
Fate Sees_165 9,0 8,8 <LOQ 15,5 <LOQ 283,2 0,7 250,7 0,9 123,1 <LOQ 0,9 
Fate Sees_166 4,0 4,3 <LOQ <LOQ <LOQ 73,0 <LOQ 432,9 0,1 150,3 <LOQ 1,5 
Fate Sees_167 4,0 2,1 <LOQ <LOQ <LOQ 309,2 0,8 1160,0 <LOQ 374,5 <LOQ 2,5 
Fate Sees_168 1,5 2,6 <LOQ <LOQ <LOQ 169,6 <LOQ 169,0 <LOQ 77,6 <LOQ 1,3 
Fate Sees_169 3,3 2,7 134,4 <LOQ <LOQ 452,1 2,0 402,2 <LOQ 198,7 <LOQ 42,6 
Fate Sees_170 2,2 3,7 175,6 <LOQ <LOQ 1936,7 2,8 278,4 0,4 548,3 <LOQ 0,7 
Fate Sees_171 2,0 15,2 81,4 <LOQ <LOQ 662,3 1,6 251,7 <LOQ 125,3 <LOQ 0,6 
Fate Sees_175 6,8 2,9 17,5 <LOQ <LOQ <LOQ <LOQ 242,9 <LOQ 8,3 <LOQ <LOQ 
Fate Sees_177 5,4 2,3 <LOQ <LOQ <LOQ <LOQ 0,5 186,9 <LOQ 31,2 <LOQ <LOQ 
Fate Sees_179 0,9 1,9 110,6 <LOQ <LOQ 600,7 1,4 507,2 <LOQ 302,8 <LOQ 1,2 
Fate Sees_180 1,4 3,4 23,1 <LOQ <LOQ 248,3 1,2 287,7 0,4 271,3 <LOQ 0,7 
Fate Sees_181 2,3 2,1 41,2 <LOQ <LOQ 540,0 1,4 214,7 <LOQ 186,0 <LOQ 0,8 
Fate Sees_182 1,7 2,7 43,0 <LOQ <LOQ 375,3 2,2 213,3 0,1 233,9 <LOQ 1,3 
Fate Sees_183 1,1 85,8 <LOQ <LOQ <LOQ 378,3 <LOQ 18,4 0,1 65,4 <LOQ 1,6 
Fate Sees_184 1,2 10,2 <LOQ <LOQ <LOQ 66,6 1,3 1,5 0,2 1,4 <LOQ <LOQ 
Fate Sees_189 1,1 6,1 <LOQ <LOQ <LOQ 307,0 0,6 61,5 <LOQ 66,7 <LOQ <LOQ 
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Fate Sees_190 1,2 2,0 <LOQ <LOQ <LOQ <LOQ <LOQ 127,7 <LOQ 57,8 <LOQ <LOQ 
Fate Sees_191 0,9 6,8 <LOQ <LOQ <LOQ <LOQ <LOQ 53,6 <LOQ 52,0 <LOQ 1,3 
Fate Sees_193 1,3 1,9 <LOQ <LOQ <LOQ <LOQ <LOQ 61,9 <LOQ 71,7 <LOQ <LOQ 
Fate Sees_194 1,1 5,0 18,2 <LOQ <LOQ 115,3 0,7 179,7 <LOQ 171,4 <LOQ 1,2 
Fate Sees_195 2,5 1,7 36,4 <LOQ <LOQ 131,6 0,9 228,6 0,2 133,7 <LOQ <LOQ 
Fate Sees_196 1,4 1,8 11,3 <LOQ <LOQ 114,6 0,8 166,1 <LOQ 128,6 <LOQ 0,8 
Fate Sees_198 1,5 43,1 11,3 <LOQ <LOQ 83,8 0,9 137,3 0,1 61,1 <LOQ 0,9 
Fate Sees_199 1,2 36,3 <LOQ <LOQ <LOQ 106,2 1,5 133,5 0,2 97,0 <LOQ 1,7 
Fate Sees_202 1,9 2,5 <LOQ <LOQ <LOQ 87,0 2,1 211,5 <LOQ 169,7 <LOQ 1,7 
Fate Sees_203 <LOQ 5,9 <LOQ <LOQ <LOQ <LOQ <LOQ 126,5 <LOQ 31,4 <LOQ <LOQ 
Fate Sees_204 2,4 3,7 <LOQ <LOQ <LOQ 155,6 0,7 244,5 0,1 77,2 <LOQ 0,9 
Fate Sees_205 3,5 3,2 10,3 <LOQ <LOQ 248,9 0,7 410,2 <LOQ 146,5 <LOQ 0,7 
Fate Sees_208 1,2 4,3 <LOQ <LOQ <LOQ 531,9 1,0 257,1 <LOQ 168,0 <LOQ 1,1 
Fate Sees_209 3,3 3,9 <LOQ 10,9 <LOQ 4344,8 3,0 398,5 0,8 184,1 <LOQ <LOQ 
Fate Sees_210 3,1 2,0 <LOQ <LOQ <LOQ 1058,0 0,6 222,7 <LOQ 149,0 <LOQ 1,4 
Fate Sees_211 5,9 9,9 17,2 <LOQ <LOQ <LOQ <LOQ 361,8 <LOQ 132,7 <LOQ 0,9 
Fate Sees_214 2,1 3,3 <LOQ <LOQ <LOQ <LOQ 1,0 309,7 0,3 102,5 <LOQ 1,6 
Fate Sees_226 1,6 2,5 15,8 <LOQ <LOQ 418,0 0,7 31,7 <LOQ 56,8 <LOQ <LOQ 
Fate Sees_227 0,7 2,5 <LOQ <LOQ <LOQ <LOQ 0,8 55,9 0,5 22,9 <LOQ <LOQ 
Fate Sees_228 1,9 3,3 <LOQ <LOQ <LOQ <LOQ <LOQ 60,5 0,8 30,3 <LOQ 0,5 
Fate Sees_229 2,0 2,1 <LOQ <LOQ <LOQ <LOQ 1,1 41,0 0,3 18,1 <LOQ <LOQ 
Fate Sees_233 1,7 2,3 <LOQ <LOQ <LOQ 258,3 0,7 235,9 0,1 189,5 <LOQ <LOQ 
Fate Sees_235 1,4 23,4 33,0 <LOQ <LOQ 230,5 0,7 249,6 <LOQ 125,1 <LOQ <LOQ 
Fate Sees_236 1,8 5,7 33,1 <LOQ <LOQ 148,1 0,9 199,3 <LOQ 67,6 <LOQ 0,7 
Fate Sees_239 1,6 2,6 <LOQ <LOQ <LOQ 153,3 <LOQ 186,4 <LOQ 156,2 <LOQ <LOQ 
Fate Sees_242 1,6 20,4 19,7 <LOQ <LOQ 323,8 0,6 211,2 <LOQ 88,7 <LOQ 0,5 
Fate Sees_243 1,6 11,9 <LOQ <LOQ <LOQ 288,3 1,2 252,5 0,2 121,8 <LOQ <LOQ 
Fate Sees_245 3,1 5,3 11,4 <LOQ <LOQ 232,3 1,0 305,5 0,2 206,2 <LOQ <LOQ 
Fate Sees_247 1,2 12,3 11,5 <LOQ <LOQ 73,5 0,7 218,4 <LOQ 71,5 <LOQ <LOQ 
Fate Sees_248 1,8 5,4 <LOQ <LOQ <LOQ 120,1 1,6 380,4 <LOQ 153,1 <LOQ <LOQ 
Fate Sees_250 2,3 17,1 <LOQ <LOQ <LOQ 413,0 1,8 456,3 0,5 70,6 <LOQ <LOQ 
Fate Sees_252 3,1 2,4 <LOQ <LOQ <LOQ 250,2 0,6 196,3 <LOQ 113,9 <LOQ 0,5 
Fate Sees_253 5,7 3,3 <LOQ <LOQ <LOQ 417,7 2,7 0,8 0,3 65,8 <LOQ <LOQ 
Fate Sees_254 2,5 2,4 432,2 <LOQ <LOQ 927,4 1,7 271,1 0,5 329,6 <LOQ 0,8 
Fate Sees_256 1,5 3,7 <LOQ <LOQ <LOQ 313,6 <LOQ 84,6 0,1 72,5 <LOQ <LOQ 
Fate Sees_257 2,0 2,7 99,9 <LOQ <LOQ 333,7 <LOQ 183,1 0,1 256,3 <LOQ <LOQ 
Fate Sees_258 2,1 3,2 <LOQ <LOQ <LOQ 267,9 1,0 221,9 <LOQ 228,9 <LOQ <LOQ 
Fate Sees_259 2,9 3,9 217,9 <LOQ <LOQ 878,8 0,9 443,6 0,4 275,1 <LOQ 0,5 
Fate Sees_260 3,4 3,4 39,2 <LOQ <LOQ <LOQ 0,8 502,6 0,3 118,2 <LOQ 1,4 
Fate Sees_261 1,9 2,5 23,1 <LOQ <LOQ <LOQ 0,9 487,3 <LOQ 177,4 <LOQ 1,1 
Fate Sees_262 3,5 2,5 <LOQ 13,3 <LOQ <LOQ 0,8 358,5 0,1 138,2 <LOQ 0,9 
Fate Sees_263 1,5 3,4 <LOQ <LOQ <LOQ <LOQ 1,4 318,1 0,3 92,5 <LOQ <LOQ 
Fate Sees_264 3,3 7,6 15,3 <LOQ <LOQ <LOQ 0,8 307,9 <LOQ 87,1 <LOQ 0,5 
Fate Sees_265 4,4 2,6 17,8 12,7 <LOQ <LOQ 3,0 471,3 <LOQ 386,4 <LOQ 2,5 
Fate Sees_266 4,2 2,4 <LOQ 11,6 <LOQ <LOQ 2,4 834,2 0,2 239,1 <LOQ 1,6 
Fate Sees_267 6,0 4,3 22,8 <LOQ <LOQ <LOQ 0,9 346,1 0,2 88,6 <LOQ 1,0 






Annex 9: Estrogenicity and dioxin-like toxicity by in vitro reporter gene bioassays; Lab: RECETOX, Masaryk University, Brno, Czech Republic. 







Fate Sees_136 3,56 0,12 
Fate Sees_137  <0,5  0,11 
Fate Sees_138   
Fate Sees_139   
Fate Sees_140   
Fate Sees_141   
Fate Sees_142   
Fate Sees_143  <0,5  <0,1 
Fate Sees_144 1,95 <0,1 
Fate Sees_145 1,2 0,20 
Fate Sees_146  <0,5  0,24 
Fate Sees_147 1,26 0,18 
Fate Sees_148 1,70 0,12 
Fate Sees_149 2,12 0,16 
Fate Sees_150 1,8 n.a. 
Fate Sees_151 <0,5 n.a. 
Fate Sees_152  <0,5  n.a. 
Fate Sees_153  <0,5  n.a. 
Fate Sees_155 <0,5 n.a. 
Fate Sees_156 0,8 n.a. 
Fate Sees_157  <0,5  n.a. 
Fate Sees_158  <0,5  n.a. 
Fate Sees_159 1,2 n.a. 
Fate Sees_160 0,6 n.a. 
Fate Sees_161 <0,5 n.a. 
Fate Sees_162 <0,5 n.a. 
Fate Sees_163 3,40 n.a. 
Fate Sees_164 <0,5 n.a. 
Fate Sees_165  <0,5  n.a. 
Fate Sees_166 <0,5 n.a. 
Fate Sees_167 <0,5 n.a. 
Fate Sees_168 <0,5 n.a. 
Fate Sees_169 4,15 0,28 
Fate Sees_170 <0,5 n.a. 
Fate Sees_171 <0,5 n.a. 
Fate Sees_175 0,80 n.a. 
Fate Sees_177 17,9 n.a. 
Fate Sees_179 <0,5 n.a. 
Fate Sees_180 <0,5 n.a. 
Fate Sees_181 <0,5 n.a. 
Fate Sees_182 <0,5 n.a. 
Fate Sees_183 0,74 n.a. 
Fate Sees_184 <0,5 n.a. 
Fate Sees_189 0,6 n.a. 
Fate Sees_190  <0,5  n.a. 
Fate Sees_191 <0,5 n.a. 
Fate Sees_193 <0,5 n.a. 
Fate Sees_194  <0,5  0,12 
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Fate Sees_195  <0,5  0,32 
Fate Sees_196  <0,5  0,20 
Fate Sees_198 <0,5 n.a. 
Fate Sees_199 1,23 n.a. 
Fate Sees_202 <0,5 n.a. 
Fate Sees_203  <0,5  0,10 
Fate Sees_204 0,53 0,10 
Fate Sees_205  <0,5  0,11 
Fate Sees_208 <0,5 0,26 
Fate Sees_209 3,27 0,21 
Fate Sees_210  <0,5  0,44 
Fate Sees_211   
Fate Sees_214   
Fate Sees_226 12,21 <0,1 
Fate Sees_227  <0,5  <0,1 
Fate Sees_228 0,97 0,15 
Fate Sees_229  <0,5  0,12 
Fate Sees_233 <0,5 n.a. 
Fate Sees_235 <0,5 n.a. 
Fate Sees_236  <0,5  0,14 
Fate Sees_239 0,94 n.a. 
Fate Sees_242 <0,5 n.a. 
Fate Sees_243 <0,5 n.a. 
Fate Sees_245 <0,5 n.a. 
Fate Sees_247 <0,5 n.a. 
Fate Sees_248 0,59 0,16 
Fate Sees_250 <0,5 n.a. 
Fate Sees_252 <0,5 n.a. 
Fate Sees_253 0,6 n.a. 
Fate Sees_254 6,0 n.a. 
Fate Sees_256 0,84 n.a. 
Fate Sees_257  <0,5  n.a. 
Fate Sees_258 <0,5 n.a. 
Fate Sees_259 0,67 n.a. 
Fate Sees_260   
Fate Sees_261   
Fate Sees_262   
Fate Sees_263   
Fate Sees_264   
Fate Sees_265   
Fate Sees_266   
Fate Sees_267   






Annex 10: Analytical results for inorganic elements in WWTP effluents [mg/l]. Lab: JRC-IES. Be and Cr were in all cases below the LOD (0.001 mg/l). 
n.d. means below LOD.  
Sample Hg Ag Al As Ba Cd Co Cu Mg Mn Mo Ni Pb Sb Se Tl Zn 
LOD [mg/l] 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 
Fate Sees_136 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 89,2 0,10 n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_137 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 69,2 0,03 n.d. n.d. n.d. n.d. n.d. n.d. 0,04 
Fate Sees_138 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 8,2 0,03 n.d. n.d. n.d. n.d. n.d. n.d. 0,04 
Fate Sees_139 n.d. n.d. n.d. n.d. 0,04 n.d. n.d. n.d. 6,1 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.a. 
Fate Sees_140 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 9,1 0,01 n.d. n.d. n.d. n.d. n.d. n.d. 0,10 
Fate Sees_141 n.d. n.d. n.d. n.d. 0,01 n.d. n.d. n.d. 7,6 0,08 n.d. n.d. n.d. n.d. n.d. n.d. n.a. 
Fate Sees_142 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 9,1 0,04 n.d. n.d. n.d. n.d. n.d. n.d. 0,06 
Fate Sees_143 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 23,4 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,05 
Fate Sees_144 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 7,9 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,05 
Fate Sees_145 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 16,7 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,05 
Fate Sees_146 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 28,1 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_147 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 19,8 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,03 
Fate Sees_148 n.d. n.d. n.d. n.d. 0,03 n.d. n.d. n.d. 21,2 0,32 n.d. n.d. n.d. n.d. n.d. n.d. 0,03 
Fate Sees_149 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 15,3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,05 
Fate Sees_150 n.d. n.d. 0,11 n.d. n.d. n.d. n.d. n.d. 25,4 0,08 0,27 0,16 n.d. n.d. n.d. n.d. 0,02 
Fate Sees_151 n.d. n.d. n.d. n.d. 0,05 n.d. n.d. n.d. 55,4 0,35 0,50 0,05 n.d. n.d. n.d. n.d. 0,03 
Fate Sees_152 n.d. n.d. 0,58 n.d. n.d. n.d. 0,06 n.d. 10,2 0,13 0,09 0,42 n.d. 0,90 n.d. n.d. 0,24 
Fate Sees_153 n.d. n.d. 0,13 n.d. n.d. n.d. n.d. 0,03 15,1 0,07 n.d. n.d. n.d. n.d. n.d. n.d. 0,15 
Fate Sees_155 n.d. n.d. n.d. n.d. 0,04 n.d. n.d. n.d. 36,5 0,49 n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_156 n.d. n.d. 0,13 n.d. 0,03 n.d. n.d. n.d. 0,1 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Fate Sees_157 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 61,5 0,15 0,18 n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_158 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 20,5 0,07 n.d. n.d. n.d. n.d. n.d. n.d. 0,06 
Fate Sees_159 n.d. n.d. 0,20 n.d. 0,04 n.d. n.d. n.d. 10,7 0,03 n.d. n.d. n.d. n.d. n.d. n.d. 0,03 
Fate Sees_160 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 7,5 0,04 0,03 n.d. n.d. n.d. n.d. n.d. 0,01 
Fate Sees_161 n.d. n.d. 0,30 n.d. n.d. n.d. n.d. n.d. 57,0 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,009 
Fate Sees_162 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 33,4 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,007 
Fate Sees_163 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 67,4 0,04 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Fate Sees_164 n.d. n.d. n.d. n.d. 0,02 n.d. n.d. n.d. 30,3 0,09 n.d. n.d. n.d. n.d. n.d. n.d. 0,04 
Fate Sees_165 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 19,9 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,03 
Fate Sees_166 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 8,3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,05 
Fate Sees_167 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 12,8 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,03 
Fate Sees_168 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 6,3 0,03 0,10 n.d. n.d. n.d. n.d. n.d. 0,09 
Fate Sees_169 n.d. n.d. n.d. n.d. 0,01 n.d. n.d. n.d. 19,5 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,09 
Fate Sees_170 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 9,2 0,19 n.d. n.d. n.d. n.d. n.d. n.d. 0,04 
Fate Sees_171 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 10,7 0,14 n.d. n.d. n.d. n.d. n.d. n.d. 0,03 
Fate Sees_175 n.d. n.d. n.d. n.d. 0,05 n.d. n.d. n.d. 83,0 0,07 0,01 n.d. n.d. n.d. n.d. n.d. 0,01 
Fate Sees_177 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 53,1 0,01 n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_179 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 11,2 0,18 n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_180 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 11,2 0,34 n.d. n.d. n.d. n.d. n.d. n.d. 0,05 
Fate Sees_181 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 7,0 0,05 n.d. n.d. n.d. n.d. n.d. n.d. 0,04 
Fate Sees_182 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 6,4 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_183 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 144,0 0,03 n.d. n.d. n.d. n.d. n.d. n.d. 0,05 
Fate Sees_184 n.d. n.d. n.d. n.d. 0,02 n.d. n.d. n.d. 87,3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,04 
Fate Sees_189 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 9,9 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,04 
Fate Sees_190 n.d. n.d. n.d. n.d. 0,02 n.d. n.d. n.d. 24,6 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_191 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 14,0 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,01 
Fate Sees_193 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 14,8 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_194 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 15,2 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_195 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 23,8 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,06 
Fate Sees_196 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 7,0 0,02 n.d. n.d. n.d. n.d. n.d. n.d. 0,03 
Fate Sees_198 n.d. n.d. n.d. n.d. 0,02 n.d. n.d. n.d. 11,7 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,03 
Fate Sees_199 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 13,6 0,08 n.d. n.d. n.d. n.d. n.d. n.d. 0,01 
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Fate Sees_202 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 17,2 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,06 
Fate Sees_203 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 28,6 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_204 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 19,8 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,03 
Fate Sees_205 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,03 12,5 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,03 
Fate Sees_208 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 24,5 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,04 
Fate Sees_209 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 29,0 0,02 n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_210 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 15,0 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,05 
Fate Sees_211 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 5,1 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.a. 
Fate Sees_214 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 7,2 0,006 n.d. n.d. n.d. n.d. n.d. n.d. n.a. 
Fate Sees_226 n.d. n.d. n.d. n.d. 0,04 n.d. n.d. n.d. 16,0 0,05 n.d. n.d. n.d. n.d. n.d. n.d. 0,03 
Fate Sees_227 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 13,7 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_228 n.d. n.d. n.d. n.d. 0,01 n.d. n.d. n.d. 14,4 0,02 n.d. n.d. n.d. n.d. n.d. n.d. 0,14 
Fate Sees_229 n.d. n.d. n.d. n.d. 0,02 n.d. n.d. n.d. 30,0 0,01 n.d. n.d. n.d. n.d. n.d. n.d. 0,01 
Fate Sees_233 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 10,8 0,13 n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_235 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 14,9 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_236 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 12,2 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_239 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 12,1 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,07 
Fate Sees_242 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 8,9 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_243 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 5,5 0,13 n.d. n.d. n.d. n.d. n.d. n.d. 0,04 
Fate Sees_245 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 7,8 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,03 
Fate Sees_247 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 13,6 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_248 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 5,2 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,01 
Fate Sees_250 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 10,3 0,05 n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_252 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 18,4 0,03 n.d. n.d. n.d. n.d. n.d. n.d. 0,04 
Fate Sees_253 n.d. n.d. 0,12 n.d. n.d. n.d. n.d. n.d. 8,3 0,03 n.d. n.d. n.d. n.d. n.d. n.d. 0,09 
Fate Sees_254 n.d. n.d. 0,05 n.d. n.d. n.d. n.d. n.d. 8,2 0,04 n.d. n.d. n.d. n.d. n.d. n.d. 0,04 
Fate Sees_256 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 30,4 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_257 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 6,3 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_258 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 14,9 n.d. n.d. n.d. n.d. n.d. n.d. n.d. 0,02 
Fate Sees_259 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 6,4 0,03 n.d. n.d. n.d. n.d. n.d. n.d. 0,01 
Fate Sees_260 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 5,4 0,20 n.d. n.d. n.d. n.d. n.d. n.d. n.a. 
Fate Sees_261 n.d. n.d. n.d. n.d. 0,009 n.d. n.d. n.d. 4,9 0,08 n.d. n.d. n.d. n.d. n.d. n.d. n.a. 
Fate Sees_262 n.d. n.d. n.d. n.d. 0,02 n.d. n.d. n.d. 3,6 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.a. 
Fate Sees_263 n.d. n.d. n.d. n.d. 0,01 n.d. n.d. n.d. 6,5 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.a. 
Fate Sees_264 n.d. n.d. n.d. n.d. 0,02 n.d. n.d. n.d. 7,9 0,11 n.d. n.d. n.d. n.d. n.d. n.d. n.a. 
Fate Sees_265 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 5,0 0,14 n.d. n.d. n.d. n.d. n.d. n.d. n.a. 
Fate Sees_266 n.d. n.d. n.d. n.d. 0,02 n.d. n.d. n.d. 10,6 0,03 n.d. n.d. n.d. n.d. n.d. n.d. n.a. 
Fate Sees_267 n.d. n.d. n.d. n.d. 0,008 n.d. n.d. n.d. 6,8 0,005 n.d. n.d. n.d. n.d. n.d. n.d. n.a. 















































Annex Fig. 7: LC-MS2 chromatograms of Diclofenac in Fate Sees samples 226 (Italy), 209 (Spain), 

















Annex Fig. 10: Fate Sees sample 204 (AWV Wiener Neustadt-Sud). Diclofenac and Ibuprofen 






Annex Fig. 11: Fate Sees sample 205 (Wasserverband Ossiacher See). Diclofenac and Ibuprofen 



















































Annex Fig. 19: LC-MS2 chromatograms of PFHxS in Fate-Sees samples 151 (Belgium), 235 (NL), and 






Annex Fig. 20 : LC-MS2 chromatograms of small-chain PFASs in a standard solution and Fate Sees 






Annex Fig. 21: LC-MS2 chromatograms of PFBS in Fate Sees samples 166 (Belgium) and 168 






Annex Fig. 22: LC-MS2 chromatograms of different Fate Sees samples for PFBS and PFHxS. No 






Annex Fig. 23: LC-MS2 chromatograms of different Fate Sees samples for PFBS. No retention time 






EUR 25563 – Joint Research Centre – Institute for Environment and Sustainability 
Title: EU Wide Monitoring Survey on Waste Water Treatment Plant Effluents 
Authors: Robert Loos, Raquel Carvalho, Diana C. António, Ludek Blaha, Barbora Jarosova, Stefan Voorspoels, David 
Schwesig, Peter Haglund, Jerker Fick, Oliver Gans, Sara Comero, Michela Ghiani, Teresa Lettieri, Giovanni Locoro, 
Bruno Paracchini, Simona Tavazzi, Bernd M. Gawlik  
 
Luxembourg: Publications Office of the European Union 
2012 – 136 pp. – 21.0 x 29.7 cm 
EUR – Scientific and Technical Research series – ISSN 1831-9424 (online), ISSN 1018-5593 (print)  
ISBN 978-92-79-26784-0 (pdf) 




In the year 2010, effluents from 90 European waste water treatment plants (WWTPs) were collected and analysed in total for 160 organic 
chemicals and 20 inorganic trace elements. The analyses were complemented by applying also effect-based monitoring approaches aiming at 
estrogenicity and dioxin-like toxicity analysed by in vitro reporter gene bioassays, and yeast and diatom culture acute toxicity optical bioassays. 
The analytical work was performed in six European expert laboratories.  
Analyses of organic substances were performed by solid-phase extraction (SPE) or liquid-liquid extraction (LLE) followed by high performance 
liquid chromatography tandem mass spectrometry (HPLC-MS-MS) or gas chromatography high-resolution mass spectrometry (GC-HRMS). 
Inorganic compounds were analysed by inductively coupled plasma – mass spectrometry (ICP-MS) or ICP atomic emission spectrometry (ICP-AES).  
This European-wide monitoring study on the occurrence of micropollutants in WWTP effluents represents the largest EU wide monitoring survey 
on WWTP effluents ever performed. It produced a comprehensive data set on many so far only locally investigated “emerging” compound classes 
including pharmaceuticals and personal care products (PPCPs), veterinary (antibiotic) drugs, perfluoroalkyl substances (PFASs), organophosphate 
ester flame retardants, pesticides (and some metabolites) or industrial chemicals such as benzotriazoles (corrosion inhibitors), polycyclic musk 
fragrances, x-ray contrast agents, Gadolinium compounds, and siloxanes.  
The obtained results show the presence of 131 target organic compounds in European wastewater effluents, in concentrations ranging from low 
nanograms to milligrams per liter. These results obtained from 90 different European WWTPs allow the calculation of a European median level for 
the chemicals investigated. The most relevant compounds identified in the effluent water samples in terms of frecquency of detection, maximum, 
average and medium concentration levels were Sucralose, Acesulfame K (artificial sweeteners), PFOA, PFHxA, PFHpA, PFOS (perfluoroalkyl 
substances), DEET (insect repellent), Benzotriazoles (corrosion inhibitors), the pharmaceuticals Bisoprolol, Carbamazepine, Ciprofloxacine, 
Citaprolam, Clindamycine, Codeine, Diltiazem, Diphenhydramin, Eprosartan, Fexofenadine, Flecainide, Gemfibrozil, Fluconazole, Haloperidol, 
Ibersartan, Ibuprofen, Ketoprofen, Oxazepam, Risperidone, Sulfamethoxazole, Telmisartan, Tramadol, Trimethoprim, Venlafaxin, the organo-
phosphate ester flame retardants Tri-iso-butylphosphate (TIBP), Tributylphosphate (TBP), Tris(2-chloroethyl)phosphate (TCEP), Tris(2-
chloroisopropyl)phosphate (TCPP), Tris(2-butoxyethyl)phosphate (TDCP), Tris(2-butoxyethyl)phosphate (TBEP), Triphenyl-phosphate (TPP), 2-
Ethylhexyldiphenyl-phosphate (EHDPP), the x-ray contrast media Amidotrizoic acid, Iohexol, Iopromid, Iomeprol, Iopamidol, the pesticides 
Terbutylazine, Terbutylazine-desethyl (metabolite), MCPA, Mecoprop, Diuron, Triclosan (antibacterial), and Gadolinium (from magnetic 
resonance imaging contrast media used in hospitals).  
The toxicity tests applied showed some toxicity. From the total number of 75 WWTP effluents analyzed for estrogenicity, 27 sample extracts 
showed estrogenic activity higher than the detection limit > 0.5 ng/l estrogen equivalents (EEQ). Twenty five effluent sample extracts we 
screened for dioxin-like activity, and twenty one out of these 25 tested sample extracts exceeded the detection limit (0.1 ng/l TEQbiotest) but the 
maximal detected dioxin-like activity was only 0.4 ng/l TEqbiotest. Finally, three out of 13 effluent samples tested on acute toxicity revealed 
themselves harmful for the growth of yeast and diatom organisms.  
Finally, the results were compared with other published local, national, or smaller international studies on WWTPs. This comparison showed that 
lower median effluent concentrations were found in our large-scale European-wide study (n=90) compared to local studies of single WWTPs. It is 
difficult to compare results of median concentrations of one WWTP (or a small number) with the median of this study (n=90) because many 
different plants around Europe were included. In contrast, maximum and average concentrations are in relatively good agreement to other 
studies.  
What is clear is that the elimination of most of the anthrophogenic substances in conventional WWTPs with secondary biological treatment is 
incomplete and improvements of wastewater treatment and subsequent treatments of the produced sludge are required to prevent the 
introduction of these micropollutants in the environment. It must be considered that today’s conventional waste water treatment technology 
(mechanical and biological steps) is from the 1970s; it was designed to remove nitrogen and phosphorus, and some non-polar chemicals which 
are removed with the sewage sludge.  
It is being discussed in Europe to upgrade WWTPs with additional tertiary treatment steps such as ozonation and/or powdered activated carbon 
adsorption to remove micropollutants from WWTP effluents. In the Swiss “Micropoll Strategy” project complementary treatment steps have been 
evaluated and it has been shown that water quality can be significantly improved using processes such as powdered activated carbon adsorption 
or ozonation. 
Under the view of escalating population growth, and increased water stress in many regions of the world, reuse of treated water and waste water 
recycling are becoming more important options for water supply. The increasing worldwide contamination of freshwater systems with thousands 
of industrial and natural chemical compounds is one of the key environmental problems facing humanity. Although most of these compounds are 
present at low concentrations, many of them raise considerable toxicological concerns, particularly when present as components of complex 





























































As the Commission’s in-house science service, the Joint Research Centre’s mission is to provide 
EU policies with independent, evidence-based scientific and technical support throughout the 
whole policy cycle. 
 
Working in close cooperation with policy Directorates-General, the JRC addresses key societal 
challenges while stimulating innovation through developing new standards, methods and tools, 
and sharing and transferring its know-how to the Member States and international community. 
 
Key policy areas include: environment and climate change; energy and transport; agriculture 
and food security; health and consumer protection; information society and digital agenda; 
safety and security including nuclear; all supported through a cross-cutting and multi-
disciplinary approach. 
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